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Chapter 1
General Introduction 
1. Pathogenesis of atherosclerosis
Atherosclerosis is the underlying pathology responsible for most cardiovascular 
disease (CVD)-related deaths and as such a leading cause of death worldwide. 
This chronic, lipid-driven autoimmune-like disease starts already during early 
adolescence and persists throughout a lifetime. The disease affects primarily 
the medium and large-sized arteries and through the combination of vascular 
damage, lipid accumulation and inflammation, atherosclerotic lesions develop. 
In time these initial lesions progress and may eventually rupture and give rise to 
clinical manifestations such as myocardial infarction or stroke (Figure 1).1
  
Figure 1. Atherosclerosis development. Lesion initation starts already during adolescence and can pro-
gress over the following decades into stable or vulnerable plaques. Subsequent rupture or erosion of the 
fibrous cap covering the vulnerable plaque can cause thrombus formation, resulting in an acute myocar-
dial infarction or stroke. Libby et al. Nature 2002; 420, 868-874 
High-fat intake, sedentary lifestyle, hypertension, smoking and stress are a few of 
the risk factors for atherosclerosis and reflect the high incidence of CVD in Western 
society.2 Nowadays, CVD is one of the leading causes of death globally, with an 
estimated 17.3 million deaths (30% of all reported deaths) in 2008.3 With the 
increasing prevalence of traditional risk factors for atherosclerotic cardiovascular 
diseases (e.g. high cholesterol diet, diabetes, stress)  in the developing world, 
this number is predicted to increase to 23.3 million deaths annually by 2030.4,5 
Current therapies are aimed at modifying these risk factors via pharmacological 
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interventions and behavioral changes. At later stages of the disease surgical 
interventions may be necessary such as percutaneous transluminal angioplasty 
(PTA), stenting and bypass surgery. The most successful interventional therapy 
so far has been plasma lipid lowering (low-density lipoprotein cholesterol) by 
means of statin treatment.6 However, despite an astonishing 30% reduction in 
symptomatic cardiovascular disease risk in patients receiving statins, a clear 
residual risk remains and indicates the urgent need for new therapeutic strategies 
based on a thorough understanding of the disease process and all of its risk 
factors.
1.1 Lesion initiation
A healthy functional artery is composed of three layers. In direct contact with 
the blood is the intima, which consists of a monolayer of endothelial cells and 
subendothelial connective tissue (forming the basement membrane) which 
covers the second, medial layer of vascular smooth muscle cells. This medial 
layer is flanked by the internal and external elastic lamina. Outside the external 
lamina resides the collagen-rich adventitial tissue composed of fibroblasts, 
connective tissue and perivascular nerves (Figure 2). A healthy endothelium is 
important to maintain vascular homeostasis, as it mediates vasoconstriction and 
vasodilation, has anticoagulant properties and affects vascular smooth muscle 
cell proliferation.7 The primary arteries affected by atherosclerosis are the 
coronary arteries, the branching points of the aorta and the carotid arteries at 
the height of the bifurcations. This observation and the patchy distribution of the 
early atheroma, made Caro et al. already in 1969, suggests an important role 
for blood hemodynamic forces (e.g. oscillatory and low shear stress) in lesion 
initiation.8,9 Over the years, lesion initiation has been a fiercely debated topic 
and led to several hypotheses. Currently the general consensus is a response-
to-injury model in which endothelial damage induced by hemodynamic stresses 
and atherogenic factors such as high plasma levels of cholesterol-containing 
low-density lipoprotein (LDL), hypertension and smoking play a central role.10,11 
Activation of the endothelium changes the endothelial permeability resulting in 
the entry and retention of lipoproteins. Within the vessel wall, these LDL particles 
undergo modifications (oxidation, glycation and association with proteoglycans), 
which change the particle’s size, charge and lipid content.12 In parallel, increased 
endothelial expression of adhesion molecules including vascular cell adhesion 
molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1)13, E- and 
P-selectin14 and chemokines such as monocyte chemoattractant protein-1 (MCP-1) 
results in attraction and attachment of circulating leukocytes to the endothelium 
and subsequent infiltration into the intima. The recruited monocytes differentiate 
into macrophages under the influence of local inflammatory cytokines (such as 
tumor necrosis factor-α (TNF-α), macrophage colony stimulating factor (M-CSF), 
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interleukin-2 (IL-2) and interferon-γ (INF-γ)) and take up the modified LDL via 
scavenger receptors.15 Modified LDL is readily taken up by macrophages but the 
massive amount of cholesterol cannot be secreted effectively, resulting in the 
formation lipid-rich foam cells, characteristic of the atherosclerotic lesion.16,17 The 
expanding inflammatory response at the site of initial injury results in a further 
increase in endothelial adhesion molecule expression and chemokine secretion 
(e.g. MCP-1, CCL5, CXCL10 and CXCL11), which attracts additional monocytes 
and T lymphocytes (T cells) to the initial lesion, called the ‘fatty streak’. Such fatty 
streaks can already be detected in the arteries of children and young adolescents 
and while usually asymptomatic these initial lesions may progress in time into 
more advanced stages of the disease.
Figure 2.The different layers and players. A characteristic atherosclerotic lesion, with an inflamed intimal 
layer consisting of a lipid-rich necrotic core covered by a fibrous cap and endothelial monolayer. Multiple 
cellular players infiltrate the intimal layer and contribute to plaque progression, including cells of the innate 
and adaptive immune system as well as vascular smooth muscle cells. The internal and external elastic 
lamina form the boundaries of the tunica media, which consists primarily of vascular smooth muscle cells 
and extracellular matrix. This layer is immuneprivileged and can facilitate outward remodeling to initially 
compensate for the decrease in lumen size due to plaque growth. Outside the external elastic lamina 
resides the adventitia which harbors a network of small blood vessels (the vasa vasorum), lymphatic 
vessels and nerve fibers, providing nutrients and inflammatory stimuli which contributes to plaque 
formation and progression. Libby & Hansson Circ Res. 2015 ;116(2):307-311.
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1.2 Lesion progression and destabilization
The next stage of atherosclerotic lesion development is characterized by the 
proliferation and migration of  vascular smooth muscle cells (VSMC) from the media 
into the intima. Here they accumulate subendothelially and produce extracellular 
matrix components such as collagen and proteoglycans, which form a fibrous cap 
covering the subendothelial pool of lipids, cholesterol crystals and cellular debris. 
This so called lipid-rich necrotic core is primarily formed due to apoptosis/necrosis 
of the lipid-laden macrophages and retention of lipoprotein particles. While the 
content of the necrotic core is highly thrombogenic, initially the fibrous cap forms 
an adequate barrier and when thick enough the plaque can remain stable and 
asymptomatic for years.18 However, the majority of clinical manifestations such as 
a myocardial infarction (MI) or a stroke arise upon rupture or erosion of the fibrous 
cap. In over 70% of the cases, acute MI is attributable to the thrombotic occlusion 
of a coronary artery caused by the exposure of the thrombogenic content of the 
necrotic core to the coagulation system of the blood.19 Changes in the integrity 
of the fibrous cap occur through a combination of exposure to stressors from the 
luminal side (e.g. mechanical shear stress from the blood flow) and from within 
the intima (e.g. inflammation, vascular smooth muscle cell apoptosis and collagen 
degradation).20,21 Initially, the reduction in cross-sectional area of the lumen by 
the growing lesion is compensated by outward remodeling of the artery wall, 
which normalizes the shear stress.22 However, as lesion development progresses 
this compensation is not sufficient and the plaque starts to protrude into the 
lumen, resulting in local regions of disturbed flow.23 Pro-inflammatory cytokines 
and enzymes produced and released within the advanced atherosclerotic lesion 
have been shown to affect both collagen synthesis by the intimal VSMCs and 
induce breakdown of collagen. In particular matrix metallo-proteinases (MMPs) 
locally released from recruited and infiltrated macrophages, T cells, neutrophils 
and mast cells play an important role in plaque and fibrous cap destabilization.
Although the intima is the centre stage of the disease, accumulating evidence 
demonstrates the importance of the media24 and adventitial tissue25 in atherosclerotic 
plaque development and progression. In addition to the extracellular matrix and 
fibroblasts, the perivascular tissue contains a large capillary blood vessel network, 
the vasa vasorum, sympathetic and autonomic nerves as well as lymphatic vessels, 
which provide nourishment and facilitate communication and trafficking routes 
throughout the different layers. Furthermore, populations of macrophages, mast 
cells, dendritic cells, T- and B-lymphocytes and vascular progenitor cells reside in 
the adventitia26 and increased perivascular inflammation strongly correlates with 
plaque progression and destabilization.27,28 The adventitial vasa vasorum is the 
major source of neovessels, which are formed during disease progression due to 
intimal hypoxia and the local release of angiogenic factors (vascular endothelial 
growth factor (VEGF) and basic fibroblast growth factor (bFGF)) from endothelial 
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cells and infiltrated immune cells. Increased neovascularization and a high vasa 
vasorum density has been associated with increased inflammation and reduced 
stability of the plaque. Leakiness of these newly developed intimal capillaries may 
result in intraplaque hemorrhage (IPH), which further fuels the inflammatory 
response and increases the stress on the fibrous cap.
2. Risk factors for cardiovascular disease
2.1 Established risk factors and current interventions
Until the late 60’s, risk factors for coronary heart disease entailed the patient’s age 
and family history. Large-scale epidemiological studies such as the Framingham 
Heart Study have added many more risk factors, which are now widely used for risk 
prediction calculations and therapeutic strategies. Current risk prediction algorithms 
for developing symptomatic cardiovascular disease (e.g. the Framingham Risk 
Score or Systematic Coronary Risk Evaluation) take into account gender, age, 
hypertension, blood cholesterol levels (low and high density lipoprotein (LDL and 
HDL) levels), smoking and diabetes mellitus.29,30 While the original Framingham 
Risk Score could only be applied to predict the risk of coronary heart disease, 
extensions of this study and others have led to new prediction models, which also 
include other cardiovascular diseases, such as cerebrovascular disease (stroke), 
peripheral arterial disease and deep vein thrombosis. Based on these predictions 
patients are classified in low, intermediate or high risk categories of developing 
CVD within 10 years and offered cholesterol and blood pressure lowering drugs 
and urged to change behavioral risk factors, such as an unhealthy diet, smoking, 
physical inactivity. An alternate means of representing and communicating an 
individual’s cardiovascular risk is vascular age, which represents an individual’s 
risk matched with the age at which the risk is equivalent but all other risk factors 
are at ideal levels (Figure 3). Especially in young- and middle-aged individuals in 
which the 10-year risk of CVD is generally low, vascular age may have a bigger 
impact and result in better compliance with medication schemes and suggested 
lifestyle changes. However, the precise definition of vascular age is still ambiguous 
and needs further application and validation.31 
The initial knowledge of (modifiable) risk factors for CVD were mainly based on 
Caucasian study results. As cardiovascular disease is a leading cause of death 
globally the INTERHEART study was set up as a first step to assess the worldwide 
association of risk factors for myocardial infarction. This case-control study in over 
15.000 cases and almost 15.000 control subjects confirmed the strong associations 
for the major risk factors (e.g. smoking, abnormal lipid levels, hypertension, 
diabetes, abdominal obesity) and importantly these were consistently adverse in 
all countries and ethnic groups included in the investigation.32 The INTERHEART 
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study also evaluated additional factors such as socioeconomic status (education 
and income) and psychosocial factors (depression, locus of control, perceived 
stress, and life events) and their association with risk of myocardial infarction.2 
The results of this study corroborated results from previous prospective studies 
demonstrating positive associations between levels of work stress33,34, marital 
stress35 and perceived mental stress36 and the incidence of coronary heart 
disease. Importantly, this stress-induced excess risk of acute MI was shown to be 
consistent across geographic location, age and gender and remained significant 
when adjusting for other cardiovascular risk factors. 
2.2 Psychological stress as risk factor for CVD
The stress response is aimed at readying an organism to fight or flight. Therefore, 
two major pathways are activated, the limbic hypothalamus-pituitary-adrenal 
(HPA-axis) and the sympathetic adrenomedullary (SAM) axis. The first primarily 
leads to the production and secretion of corticosteroids and the second to 
catecholamine release, an increased heart rate and peripheral vasoconstriction. 
Figure 3. An example of a vascular age determination. Vascular age represents an individual’s risk 
matched with the age at which the risk is equivalent but all other risk factors are at ideal levels. This 
concept may improve risk communication with the patient, especially for patients with a low 10-year risk 
of CVD, and may prove valuable as a tool to improve cardiovascular risk prediction. Groenewegen et al. 
European Journal of Preventive Cardiology 2015
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Together these systems are aimed at accessing and mobilizing the bodies energy’s 
stores and enhance the immune system in anticipation and response to a threat. 
Chronic exposure to stress and / or its main hormones has been shown affect the 
development and progression of many diseases, including atherosclerosis.37 On 
the acute timescale, (severe) stress exposure has been demonstrated to act as a 
trigger for acute cardiovascular events, such as myocardial infarction or stroke. The 
many facets of the stress response and its implications for cardiovascular disease 
are covered in more detail in Chapter 2.  With atherosclerosis being a chronic 
inflammatory disease, special interest goes out to the immune modulatory actions 
of the various hormones and neuropeptides released upon stress exposure.38 In 
addition to the well-known immunosuppressive effects of glucocorticoids, pituitary 
hormones and neuropeptides released from peripheral nerve endings, such as 
prolactin, corticotrophin releasing hormone (CRH), adrenocorticotrophic hormone 
(ACTH), neuropeptide Y (NPY), substance P (SP) and opioids can affect cellular 
and humoral immune responses implicated in atherosclerosis development and 
progression.
3. Plaque inflammation the immune cells involved and their responses 
to stress
The immune responses in all layers of the vessel wall play an important role in the 
development and progression of atherosclerosis. In general the immune system 
can be divided into innate and adaptive immunity. The innate immune response is 
mediated by monocytes and macrophages, neutrophils and mast cells as well as 
dendritic cells, basophils, eosinophils, natural killer (NK) cells and NK T cells, which 
provide a general, non-specific, first line of defense against infection and tissue 
damage. The adaptive immune response, facilitated by T- and B-lymphocytes 
on the other hand is antigen-specific and initiated by antigen presentation by 
specialized antigen presenting cells (APCs), such as  dendritic cells (figure 4).
3.1 Innate immunity
In order to respond quickly to invading pathogens and tissue damage, cells of the 
innate immune system are either highly abundant in the circulation or, in the case 
of the mast cell, reside in tissues in close contact with the outside environment. 
Recognition of pathogens and danger signals (e.g. extracellular nucleic acids) 
occurs primarily via membrane bound pattern recognition receptors, such as the 
Toll-like receptor (TLR) family, NOD-like receptors and C-type lectin and scavenger 
receptors. Upon activation these cells produce and secrete pro-inflammatory 
cytokines and chemokines to kill the pathogen and attract other immune cells to 
the site of inflammation. Phagocytes, such as monocytes, macrophages, dendritic 
cells and neutrophils efficiently internalize  pathogens and cellular debris, which is 
subsequently degraded in the lysosomal and endosomal compartment.            
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Small antigenic parts can be subsequently presented on the outside of the 
cell by MHC molecules and initiate an antigen-specific immune response. The 
psychological stress response is aimed at preparing an individual for possible 
injury and thus has potent immunomodulatory properties on both innate and 
adaptive immune function.
3.1.1 Monocytes and macrophages 
The most abundant immune cell type within the atherosclerotic lesion is the 
monocyte/macrophage. Derived from hematopoietic stem and progenitor 
cells (HSPC) in the bone marrow and residing outside the bone marrow in the 
splenic reservoir, two distinct populations of monocytes have been identified.39,40 
The non-classical monocyte population, characterized by surface expression 
of CD14lowCD16+ in humans and Ly6C-CX3CR1highCCR2- in mice, have been 
demonstrated to patrol and crawl along the endothelium. Upon PAMP or DAMP 
Figure 4. Immune responses in the atherosclerotic plaque. In general (ox)LDL and other atherosclerotic 
risk factors activate the endothelium, increasing its permeability and adhesion molecule expression level. 
Monocytes subsequently adhere to the endothelium and transmigrate to the subendothelial space, where 
they differentiate into macrophages, take up oxLDL, and become foam cells. Self or foreign antigen 
processing and presentation by macrophages and dendritic cells in the plaque and draining lympnodes, 
combined with co-stimulatory and cytokine signals result in the differentiation of naïve T cells into the 
different pro- and anti-atherosclerotic T cell subsets observed in the atherosclerotic lesion. Yamashita et 
al.  J Cardiol. 2015.
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recognition, these cells secrete pro-inflammatory cytokines and chemokines to 
recruit other immune cells.41 The classical monocyte subset (CD14highCD16- in 
human and Ly6C+CX3CR1lowCCR2+ in mice) is subsequently among the first to be 
recruited to the site of inflammation, in a  chemokine receptor (CCR2, CCR5 and 
CX3CR1) -dependent manner.42  There they produce large amounts of inflammatory 
mediators such as TNFα, IL-6, IL-1β, IL-12 and infiltrate in the vessel wall. Under 
the influence of differentiation factors like macrophage-colony stimulating factor 
(M-CSF), infiltrated monocytes mature into macrophages and monocyte-derived 
dendritic cells. Via a scavenger receptor-mediated process plaque macrophages 
and dendritic cells take up the oxidized LDL, become foam cells and present 
specific antigens which further fuel the ongoing inflammatory response.43 Similar 
to monocytes, different  functional subpopulations of tissue macrophages have 
been identified. Under the influence of local concentrations of cytokines, bacterial 
moieties (e.g. LPS) but also lipid mediators, macrophages can differentiate 
into a classically activated M1 or alternatively activated M2 phenotype.44 M1 
macrophages induced by LPS, INFγ, IL-1β, TNFα, and oxLDL are considered pro-
inflammatory and have increased phagocytic and bacterial killing capacity via pro-
inflammatory cytokine release and the production of nitric oxide and reactive 
oxygen species (ROS). Alternative activation, resulting in an anti-inflammatory 
macrophage type, occurs via PPARγ receptor activation and by stimulation with 
the anti-inflammatory cytokines IL-4 and IL-13.45 Atherosclerosis severity has 
clearly been linked to the presence and amount of lesional M1 macrophagesref! 
and polarization of the macrophage phenotype to M2 macrophages, for example 
by IL-13 or thioredoxin-1 administration, results in reduced macrophage numbers 
in the atherosclerotic lesion, a less vulnerable lesion type or even a reduction in 
lesion development.46,47
The effects of stress mediators on monocyte and macrophage functioning 
has primarily focused on monocyte progenitor release into the circulation and 
subsequent trafficking to the atherosclerotic plaque. Chronic stress exposure in 
mice and humans was recently shown to enhance HSPC release from the bone 
marrow via sympathetic nervous system-induced reduction of the retention 
factor CXCL12. The resulting increase in circulating leukocytes and inflammatory 
monocytes significantly enhances atherosclerotic lesion development.48 On 
the other hand, in wound healing models, stress seems to increase neutrophil 
recruitment without affecting macrophage infiltration, while decreasing both 
macrophage and neutrophil pro-inflammatory mediator release and microbicidal 
capacity.49
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3.1.2 Mast cells
Another important effector cell of the innate immune system is the mast cell. 
Equipped with various damage- and pathogen-associated molecular pattern 
recognition receptors, such as TLRs and immunoglobulin receptors, mast cells 
are involved in the first line of defense against bacteria, viruses and parasites. 
To fulfill this function these relatively long-lived cells reside in tissues which are 
in close proximity to the outside world, such as various mucosal tissues, the skin 
and perivascular tissue. Bone marrow-derived mast cell precursor cells migrate to 
these tissues by chemotactic gradients, for instance CCL11, and maturate under 
the influence of locally produced stem cell factor (SCF) and IL-3. Mast cell activation 
occurs via multiple pathways. In allergy and asthma, antigen-induced crosslinking 
of IgE molecules bound to membrane FcεR results in massive degranulation 
of preformed mast cell granules in the surrounding tissue. Mast cell granules 
contain a plethora of pro-inflammatory cytokines, mast cell specific proteases, 
such as tryptases, chymases and carboxypeptidase A3 and vasoactive amines like 
histamine. Although mast cells had been discovered in the atherosclerotic plaque 
in the 1990s50,51, their participation in lesion progression and destabilization was 
conclusively demonstrated only a few years ago.52,53 In human atherosclerotic 
lesions mast cells are found both in the intima and adventitia54, while murine mast 
cells reside only in the perivascular tissue. In both species however, mast cells have 
been shown to accumulate during disease progression and actively contribute to 
the severity and vulnerability of the plaque.55  Mast cell derived TNFα and IL-6 was 
sufficient to enhance lesion development in apoE-/- mice52 and mast cell-derived 
chymase and tryptase induced neovessel leakiness, increased the incidence of 
intraplaque hemorrhages and decreased the overall stability of atherosclerotic 
lesions.56,57 Mast cells express various receptors, including TRLs, complement 
receptors, scavenger receptors and different neuropeptide receptors. Mast cell 
activation by complement factors (e.g. C5a)58, plaque-derived phospholipids (e.g. 
LPA)59 and TLR ligands60 results in selective release of different pro-inflammatory 
mediators and as such can have different effects on the atherosclerotic plaque. 
Within the perivascular tissue mast cell reside in close proximity to peripheral 
nerves61, which via the local release of neuropeptides may contribute to mast cell 
activation. For example, the sensory neuropeptide substance P (SP) is a potent 
mast cell activator and local administration of this peptide caused intraplaque 
hemorrhaging in a SP-receptor (NK1R) -dependent manner.62 
The abundance of mast cells in the skin and lungs makes this cell type a key 
player in allergic skin conditions and asthma. Interestingly, stress has been shown 
to contribute to sudden exacerbations of asthma and allergic responses63,64 as 
well as impair intestinal barrier function in inflammatory bowel disease65 in a mast 
cell-dependent manner. In contrast to atopic disease, limited literature exist on 
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stress-induced mast cell activation in cardiovascular disease.66 Outside the HPA-
axis, peripherally released corticotrophin releasing hormone (CRH) may be an 
important factor involved in stress-induced cardiac mast cell activation.67 However, 
various other factors released upon chronic and acute stress exposure, including 
corticosteroids, catecholamines,  neurotensin and neuropeptide Y are capable of 
modifying mast cell responses and require additional research.
3.1.3 Neutrophils
In the circulation, the neutrophil is the most abundant white blood cell type. 
However, due to their short life  span and rare and difficult detection in the 
atherosclerotic lesion, they have received little attention with respect to their 
role in lesion initiation and progression. Recent technical advances in imaging 
and tracing techniques however have shown neutrophils to be recruited to the 
atherosclerotic lesion and, like mast cells, contribute to local inflammation by 
the release of preformed granules containing ROS, myeloperoxidase (MPO), 
multiple pro-inflammatory cytokines and matrix degrading enzymes.68 Ly6G 
staining (expressed by murine neutrophils) localizes the neutrophil primarily to 
highly inflammatory and vulnerable shoulder regions of the plaque and depletion 
of neutrophils by Ly6G antibody injections reduced lesion development in 
apoE-/- mice.69 Neutrophils attach and are captured at the site of lesion initiation in 
a similar way as monocytes. E- and P-selectin are involved in the initial retention 
of circulating neutrophils. Chemokine-chemokine receptor interactions, such as 
CCL5, binding to CCR1 and CCR5 and the CXCL1-CXCR2 and CXCL12-CXCR4 
axis facilitate neutrophil recruitment and attachment to the endothelium.46,70,71 
Macrophage-derived CCL3, another chemokine binding to CCR1 and CCR5, was 
also demonstrated to be a potent chemotactic factor for neutrophils and to reduce 
their turnover, both contributing to atherosclerosis. 
Chronic stress induced hematopoietic progenitor proliferation in the bone marrow 
and the observed reduction in CXCL12 expression significantly increased neutrophil 
numbers in the circulation and the atherosclerotic plaque.48 Stress, via epinephrine 
and norepinephrine release, rapidly increases circulating levels of all leukocyte 
populations. Driven mainly by corticosterone these cells subsequently traffic to 
sites of inflammation or return to the bone marrow or lymphoid organs or die. In 
contrast, neutrophil numbers keep increasing during a 2h lasting experimental 
stressor, indicating the need for secondary (inflammatory) cues to contribute to 
the stress-induced exacerbation of inflammation (figure 5).72
3.1.4 Dendritic cells
While plaque macrophages can present antigens and activate antigen-specific 
CD4+ T cells, the most potent antigen presenting cell type is the dendritic cell (DC). 
Different DC subsets are derived from a common monocyte-DC precursor, which 
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subsequently may give rise to a committed DC precursor, however the precise 
branching points in the developmental pathway are still under debate.73 These 
precursors differentiate into plasmacytoid dendritic cells (pDCs) or exit the bone 
marrow as immature or pre-DCs. These immature DCs patrol the circulation and 
pick up antigens at sites of inflammation, like the atherosclerotic lesion, upon which 
they maturate into classical DCs and upregulate antigen-presenting molecules 
(major histocompatibility (MHC) class I and II) and co-stimulatory molecules 
(CD40). Subsequently they either migrate under the influence of pro-inflammatory 
cytokines and chemokines towards lymphoid organs or directly present the 
processed antigens to naive and memory T cells in the adventitia.74,75 Depending 
on the type of antigen presentation and co-stimulatory molecule expression 
both pro- and anti-inflammatory adaptive responses can be induced. DCs have 
been shown to accumulate during atherosclerosis progression and experiments 
with CD11c deficient mice suggest a contributing role for particularly monocyte-
derived DCs in lipid retention in the lesion.76 In contrast, the potent suppressive 
effect of tolerogenic DCs via the induction of anti-inflammatory regulatory T cells 
(Tregs) may prove a promising therapeutic avenue. For instance, both transfer 
of oxLDL-pulsed mature DCs77 and injection of oxLDL-induced apoptotic DCs78 
markedly upregulated the number of splenic and circulating Tregs, which resulted 
in reduced inflammatory monocyte levels and lesion development in LDLr-/- mice.
Similar to its effects on monocyte and macrophage migration stress exposure 
results in increased aortic levels of CD11b+ CD11c+ DCs in apoE-/- mice both under 
normal and hypercholesterolemic conditions.79 Acute stress may actually act as 
an endogenous adjuvant during immunization by enhancing maturation and 
migration of dendritic cells resulting in increased T cell activation in the draining 
lymphodes.80 Similar human results were obtained for antibody titer production 
upon influenza vaccination. Both exercise and mental stress in close temporal 
proximity to the immunization ensued lasting high antibody titers, especially in 
women.81 Chronic stress however seems to inversely correlate with the antibody 
response to influenza vaccination in a strain-dependent manner.82
3.2 Adaptive immunity
In contrast to innate immunity, adaptive immunity is characterized by specific 
recognition of an antigen by membrane B cell receptors and immunoglobulin 
receptors on B cells and T cell receptors (TCR) on T cells. Antigen presentation 
by macrophages and dendritic cells and subsequent recognition by T and B 
cells drives the clonal expansion and differentiation in effector cells with pro-
inflammatory properties directed against the source of the antigen. To protect 
against randomly generated TCRs that recognize self-molecules, additional signals 
in the form of cytokines and costimulatory molecules (e.g. CD40L) produced by 
innate immune cells are necessary for T cell survival. In addition, regulatory T 
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cells are another form of a tolerogenic mechanism to limit autoimmunity.83  In 
atherosclerosis several exogenous and endogenous antigens have been identified, 
resulting in detectable antibody titers against pathogens such as Heliobacter 
pylori and Cytomegalovirus, but also endogenous proteins, including heat-shock 
proteins and modified self-proteins such as oxLDL.
3.2.1 T-lymphocytes
Like the innate immune cells, T cells are recruited  to the atherosclerotic lesion and 
contribute to lesion development. Most T cells in the atherosclerotic plaque are 
CD4+ T cells and adoptive transfer of these cells in immunodeficient apoE-/-scid/
scid mice resulted in accelerated atherosclerosis.84 Priming and clonal expansion 
of naïve T cells occurs primarily in the secondary lymphoid organs where CD8+ 
T cells (cytotoxic T cells) and CD4+ T cells (T helper cells) recognize antigens 
presented by APCs on MHC class I and MHC class II molecules, respectively. 
Further activation occurs upon a secondary encounter with the antigen in 
combination with additional activation signals. Depending on the cytokine milieu 
present CD4+ T cells differentiate further into pro-atherogenic T helper 1 (Th1) 
cells, which secrete IL-1, IL-2, INF-γ, TNF-α, IL-12 and IL-18 and stimulate plaque 
macrophages and other immune cells or anti-inflammatory T helper 2 (Th2) cells, 
producing IL-4, IL-5 and IL-13. Vaccination against IL-12 resulting in reduced Th1-
mediated immunity significantly attenuated experimental atherosclerosis.85 The 
precise involvement of Th2 cells in atherosclerosis remains controversial as both 
pro- and anti-inflammatory effects of the cells have been observed and during 
disease progression a shift toward Th2-mediated immunity occurs.
Stress has been shown to result in mobilization of both cytotoxic T cells and T 
helper cells and increase their migration to target tissues, including the inflamed 
endothelium.72,86 
3.2.2 B-lymphocytes
Although relatively few B cells can be detected in the atherosclerotic lesions 
and originally confined to their role in humoral immunity, recent advances in 
the identification of different B cell subsets indicate both atheroprotective and 
atherogenic responses by these different subsets.87 B cell depletion by means 
of splenectomy in apoE-/- mice aggravates atherosclerotic plaque development 
and this effect is reversed by transfer of educated B cells from older 
apoE-/- mice.88 Interestingly, this atheroprotective effect seems to be attributable 
to the B1a B cell subset, while B2 B cells are highly atherogenic.89,90 Both B cell 
subsets have been shown to produce and secrete different amounts and types of 
immunoglobulins directed against atherosclerosis-related antigens (e.g. oxLDL), 
which may explain their differential effects on lesion progression.91 Limited data 
exist on the effects of stress on B cell function. Chronic restraint stress was shown 
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3.3 Atherothrombosis – Platelets and the coagulation system
In addition to the large lipid and inflammatory content of the plaque, the 
atherosclerotic lesion contains a variety of procoagulant and thrombogenic factors. 
Atherothrombosis, the process of (occlusive) thrombus formation upon rupture or 
erosion of the fibrous cap, is the major cause of acute coronary syndromes. Upon 
disruption of the vessel wall both platelet activation and aggregation and the fibrin-
producing coagulation system generate a clot to restore the vascular integrity.94 
Two major blood coagulation pathways exist, the contact (intrinsic) pathway 
and the tissue factor (extrinsic) pathway, which both converge into a common 
pathway resulting in the conversion of prothrombin to thrombin. In turn thrombin 
facilitates the conversion of fibronectin to soluble fibrin, which becomes stabilized 
and forms the eventual thrombus.94,95 Regulation of coagulation, resolution of the 
clot and restoration of blood flow is normally facilitated by inhibitory factors, such 
as the Tissue Factor Pathway Inhibitors (TFPI-1 and 2), anti-thrombin formation 
Figure 5. Schematic overview of acute stress-induced leukocyte redistribution mediated by the 
major stress hormones norepinephrine, epinephrine and corticosterone. Dhabhar et al. 2012 
Psychoneuroendocrinology Sep; 37(9): 1345–1368
to decrease B cell maturation in response to tetanus toxin in mice and in rats, 
while 2 hours of immobilization stress significantly decreased mitogen-induced B 
cell proliferation.92,93
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and activation of the blood fibrinolytic system. In short, activation of the pro-
enzyme plasminogen into plasmin results in plasmin-mediated degradation of 
the fibrin clot into fibrin degradation products (FDP). Plaque derived tissue factor 
(TF), collagen, fibrinogen and FDPs as well as innate immune cells play a key 
role in atherothrombosis. For instance, direct interactions between neutrophils, 
monocytes, mast cells and platelets have been shown to both potentiate and 
inhibit thrombus formation and platelet activation in atherothrombosis.96,97 
Like its effects on the immune system, aberrant HPA and SAM activity as seen 
with chronic stress results in haemostatic complications. Platelet abnormalities, 
increases in procoagulant molecules (i.e. fibrinogen) and endothelial dysfunction 
together result in a procoagulant status of the blood in depressed patients and 
subjects experiencing chronic work-related stress.98,99 As acute stress activates 
both the coagulation and fibrinolysis system, the observed triggering of acute 
cardiovascular events upon severe stress exposure may reflect a combined action 
of immune cell activation and changed coagulant status of the blood.
Figure 6. Blood coagulation and fibrinolysis pathways in atherothrombosis. Viles-Gonzalez et al. Eur 
Heart J. 2004 ;25(14):1197-207.
4. Research models
Atherosclerosis is a complex multifactorial disease limiting the usefulness of in 
vitro models, in which single cell types can be studied. Although these in vitro 
models are supportive when studying a specific immunological response to 
for example an atherogenic plaque component, the use of animal models is 
indispensable. The ability to generate specific gene knockout mice has been 
and is highly valuable to study the mechanisms underlying atherosclerotic 
disease susceptibility, progression and for preclinical therapeutic screening of 
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(pharmacological) interventions. Unfortunately, unlike humans, wild-type mice 
do not develop atherosclerosis and are highly resistant to atherogenic stimuli. 
Genetic knockout of the LDL receptor, apolipoprotein E or insertion of a transgene 
with the ApoE*3-Leiden mutation, has resulted in three hypercholesterolemic 
and atherosclerosis susceptible mouse strains, which have been extensively used 
for preclinical atherosclerosis research. Still, only apoE-/- mice develop lesions 
on a normal chow (low cholesterol) diet. LDLr-/- mice and ApoE*3-Leiden mice 
develop atherosclerosis when fed a western-type (high cholesterol) diet.100 A new 
strategy inducing hypercholesterolemia by means of adenoviral expression of 
PCSK9 circumvents germline genetic engineering and provides temporal control 
of disease induction, which may be very useful in disease models for which no 
LDLr-/- or apoE-/- strains exist.101
4.1 Mouse models of atherosclerosis and thrombosis
Similar to the human situation, atherosclerotic plaques develop in mice at sites 
of disturbed blood flow, which include the aortic arch and its bifurcations, the 
brachiocephalic artery, innominate artery and the aortic root at the level of the 
tricuspid valve (figure 7A). However, lesion growth at different sites varies greatly 
and is relatively slow.9 To induce rapid site-specific lesion formation several 
strategies have been developed. Semi-constrictive cuff or collar placement around 
the femoral arteries or carotid arteries (figure 7B) considerably accelerates 
atherosclerosis development and progression of the lesions into more advance 
and vulnerable stages.102,103 Endothelial denudation, by means of wire-injury, and 
vein graft (vena cava) placement in the carotid artery, results in a neointima 
like lesion in which vascular smooth muscle proliferation plays an important 
role. An additional benefit of the cuff and collar-induced atherosclerosis and vein 
graft models is the ability to locally manipulate the perivascular environment. 
For instance, pluronic gel placement with cytokines or viral vectors have proven 
useful in elucidating specific effects of atherogenic and atheroprotective agents 
at different stages of the disease.56,58,59,62,104,105 In contrast to the human situation, 
spontaneous plaque rupture and subsequent thrombus formation does not occur 
in mice. To study thrombogenesis and the atherothrombotic responses in mice 
one has to revert to more extreme models such as mechanical disruption of 
established lesions or laser- and FeCl3-induced vascular injury models.106,107 
4.2 Mouse models of acute and chronic stress
Like the pathophysiology of cardiovascular disease, an organisms response to 
stress (both perceived and real) is a complex and multifactorial phenomenon in 
which endocrine, metabolic and immunologic processes are intricately woven. 
The use of laboratory animal models has been indispensable in shedding light 
on the central and peripheral effect of stress and its contribution to various 
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The physiological response to stress is largely dependent on the intensity and 
duration of the stressor. The acute (lasting minutes to hours) and chronic stress 
response (lasting several hours a day for weeks or months) vary, in their respective 
hemodynamic and neurohormonal responses as well as the persistence of these 
eff ects. Chronic stress exposure is generally assumed harmful due to metabolic, 
endocrine and immunologic adaptation, which even last after cessation of the 
stressor. Animal models of chronic stress, mainly rat and mouse models, entail the 
chronic exposure to (combinations of) physical and psychological stressors. Like 
humans, rodents exhibit clear age, sex and even individual diff erences in perception, 
processing and coping mechanisms and as such many diff erent models have been 
developed tailored at mimicking specifi c human conditions, such as depression and 
post-traumatic stress disorder. To prevent habituation to the stressor most chronic 
stress paradigms involve multiple stressors in a random order, causing so called 
chronic unpredictable stress. Although generally immunosuppressive, chronic 
stress exposure results in maladaptation of the neuroendocrine response and a 
shifts in leukocyte distribution, which can aggravate atherosclerosis.108 In contrast 
Figure 7. A) Longitudinal representation of the major arterial vasculature illustrating the distribution of 
atherosclerosis (gray shading) in LDL receptor–defi cient mice fed a high-fat atherogenic diet. Adapted 
and modifi ed from Van der Laan et al. Arterioscler Thromb Vasc Biol. 2004;24:12-22. B) Perivascular 
collar-induced atherosclerosis model in the carotid arteries. Adapted and modifi ed from von der Thusen 
et al. Circulation. 2001 ;102:1164-1170.
diseases, including intestinal and skin diseases as well as autoimmune diseases 
like rheumatoid arthritis and atherosclerosis.
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to the immune dysregulation observed with chronic stress, acute stress primarily 
results in immune enhancement. Depending on the inflammatory or disease status 
of an organism the result can be detrimental or beneficial. For instance, acute 
stress has been causally linked to exacerbations of skin diseases and asthma, but 
also increased immunoprotection during surgery and vaccination.109 Methods to 
induce acute stress include immobilization (restraint), cold or heat stress, forced 
swim, shaking, electric foot shock and the introduction of an (aggressive) intruder. 
Due to both the physical and psychological aspect of restraint stress and the 
relative ease and low cost of this stressor, for example in a well-ventilated 50 ml 
centrifuge tube, restraint stress is most often used in acute stress experiments. 
5. Study aims
Vascular inflammation plays a crucial role in atherosclerotic lesion development and 
progression and the immunemodulatory properties of the (acute) stress response 
is among the most potent known to man. Previous research has demonstrated a 
contributing role for perivascular mast cells in lesion development, progression 
and destabilization. However the precise triggers of mast cell activation in the 
context of atherosclerosis remain elusive. Interestingly, perivascular mast cells 
have been shown to colocalize with nerve fibers innervating the vessel wall, 
suggesting the possibility of neuronal regulation of mast cell activation. In 
this thesis we aimed to investigate the potential of the acute stress response 
and related neurohormonal mediators in activating vascular mast cells and its 
subsequent effects on atherosclerotic lesion progression and atherothrombotic 
complications. 
6. Outline thesis
Acute cardiovascular syndromes such as myocardial infarction and stroke remain 
a leading cause of death world-wide. Atherosclerotic lesion stability and the 
thrombogenic potential of the blood upon plaque rupture are major risk factors. In 
order to reduce the amount of cardiovascular disease-related deaths, a thorough 
understanding of all its risk factors is eminent and the immunological response to 
psychological stress is a underappreciated modifiable risk factors which deserves 
further attention.
The aim of this thesis is to gain insight in the pro-atherogenic effects of acute 
stress exposure and in particular investigate the contribution of stress-induced 
perivascular mast cell activation on atherosclerotic lesion progression and 
destabilization. Chapter 2 encompasses a review which focuses on acute and 
chronic psychological stress as risk factors for atherosclerotic cardiovascular 
disease and its deadly complications, myocardial infarction and stroke. In 
Chapter 3, we show that acute stress, by means of 2 hours immobilization, 
significantly activates cardiac mast cells, resulting in a mast cell-dependent 
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increase in circulating and local pro-inflammatory cytokine release and reduced 
atherosclerotic lesion stability. Chapter 4 describes the effects of the acute 
stressor on the thrombogenic potential of the blood and the contribution of the 
mast cell herein. Previous results have shown a potent pro-atherogenic response 
to neuropeptide induced mast cell activation. In Chapter 5 we investigated 
the differential expression of neuropeptide Y in stable and unstable human 
and mouse atherosclerotic plaques, demonstrating NPY accumulation during 
disease progression. A pro-atherogenic role for NPY was demonstrated by local 
overexpression of NPY near the atherosclerotic plaque, which resulted in increased 
lesion development and perivascular mast cell activation. Chapter 6 provides 
further insight in the contribution of NPY signaling via its different receptors, Y1, 
Y2 or Y5. In Chapter 7, mast cell derived chemokines were shown to contribute 
to neutrophil recruitment to the atherosclerotic plaque and accumulation within 
the intima. In vitro and in vivo migration and influx studies confirmed a mast cell-
dependent role for the CXCL1-CXCR2 axis in neutrophils migration. The results of 
all the studies described in this thesis, as well as future prospects are discussed 
in Chapter 8. 
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Acute and chronic psychological stress as risk factors 
for cardiovascular disease: Insights gained from 
epidemiological, clinical and experimental studies
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Abstract 
 
Cardiovascular disease (CVD) remains a leading cause of death worldwide and 
identification and therapeutic modulation of all its risk factors is necessary to 
ensure a lower burden on the patient and on society. The physiological response to 
acute and chronic stress exposure has long been recognized as a potent modulator 
of immune, endocrine and metabolic pathways, however its direct implications for 
cardiovascular disease development, progression and as a therapeutic target are 
not completely understood. More and more attention is given to the bidirectional 
interaction between psychological and physical health in relation to cardiovascular 
disease. With atherosclerosis being a chronic disease starting already at an early 
age the contribution of adverse early life events in affecting adult health risk 
behavior, health status and disease development is receiving increased attention. 
In addition, experimental research into the biological pathways involved in stress-
induced cardiovascular complications show important roles for metabolic and 
immunologic maladaptation, resulting in increased disease development and 
progression. Here we provide a concise overview of human and experimental 
animal data linking chronic and acute stress to CVD risk and increased progression 
of the underlying disease atherosclerosis.
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Introduction
Cardiovascular diseases (CVD) remain one of the leading causes of death and 
disability worldwide1 and their high prevalence in Western society has been 
attributed to major changes in work and eating habits as well as income, 
educational and physical activity levels.2 The primary underlying pathology of CVD 
is atherosclerosis, a chronic inflammatory disease of the vessel wall of large- 
to medium-sized arteries. Atherosclerosis is characterized by the retention of 
cholesterol, packaged into low-density lipoproteins (LDL), in the artery wall. The 
subsequent modification, primarily oxidation, of these LDL particles is considered 
the key process driving the inflammatory response. Recruited macrophages take 
up modified LDL via scavenger receptors and become lipid-laden foam cells and 
further fuel local inflammation. With disease progression, cross-talk between innate 
and adaptive immune cells as well as the resident cells of the vessel wall eventually 
leads to the formation of a plaque consisting of an a-cellular debris-rich necrotic 
core covered by a fibrous cap. Degradation or erosion of the cap as a consequence 
of hemodynamic forces and inflammatory processes can cause exposure of the 
thrombogenic content to the blood, triggering a thrombotic response which may 
subsequently lead to occlusion of the vessel and acute cardiovascular syndromes 
(ACS) associated with CVD, such as myocardial infarction and stroke.3
Traditional risk factors for atherosclerosis are dyslipidemia, inflammation, 
obesity, hypertension, diabetes, genetic predisposition and several behavioral 
parameters, including smoking, alcohol intake and physical inactivity. Often 
disregarded are psychosocial factors such as job-strain, anxiety, depression and 
personality characteristics. Early work by Rosenman et al. provided solid evidence 
for a correlation between type A behavior, illustrated by time urgency, hostility, 
and achievement striving and the risk of developing coronary heart disease, 
demonstrating higher serum cholesterol, increased blood coagulation and an 
increased incidence of clinical heart disease in these subjects compared to subjects 
with the converse behavior type B.4,5 More recently, results from the INTERHEART 
study, a large case-control study evaluating over 11,000 patients with a first 
myocardial infarction (MI) and over 13,000 age- and sex-matched controls from 
52 countries world-wide, presented convincing associations between psychosocial 
factors and risk of MI.6,7 For example, in participants who had suffered from a 
MI, more than twice as many reported permanent stress at the workplace (odds 
ratio 2.12 [99%CI, 1.68-2.93]) compared with controls. Also, significantly more 
patients in the cohort reported to be exposed to two or more acute stressful life 
events (e.g. loss of a loved one, divorce, loss of job or business failure) in the 
previous year (odds ratio 1.48 [99%CI, 1.33-1.64]).7 However, inherent difficulties 
of delineating the pathological effects of different stressors as well as individual 
variations in the perception of stress make it difficult to implement psychosocial 
factors as a causal risk factor and therapeutic target.
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Despite these difficulties, much progress has been made over the last decades 
by means of epidemiological, clinical and experimental studies evaluating various 
psychosocial stressors (e.g. work stress, job insecurity, anxiety, social isolation) 
and their respective effect on CVD risk.8–11 Furthermore, the relative new field 
of psychoneuroimmunology, which addresses the multi-directional interactions 
between the central nervous system, the endocrine system and the immune 
system, is now providing mechanistic insight into ways by which (perceived) 
stressors can be translated into physiological changes.12
In this review we aim provide an overview of the contribution of acute and chronic 
stress to clinical and experimental atherosclerosis development and discuss the 
contribution of the stress response in triggering ACS, such as myocardial infarction 
and stroke. 
Stress and cardiovascular disease: the major systems involved 
The original concept of stress, first described in medical literature by Selye, was 
the non-specific (neuroendocrine) response of the body to any noxious stimulus.13 
Later this concept was refined by distinguishing between stressor and stress 
response and evaluating stress as the body’s response to environmental demands 
that exceed its natural regulatory capacity. The main systems activated by 
psychological stressors and mediating the stress response are the hypothalamus-
pituitary-adrenal (HPA) axis, the sympathetic adrenomedullary (SAM) system, the 
renin-angiotensin-aldosterone system (RAAS) and the cholinergic system, which 
are aimed at accessing and mobilizing the body’s energy stores and modulating 
the immune system in anticipation and response to a threat. A perceived threat is 
relayed through the limbic system (amygdala, hippocampus and prefrontal cortex) 
to the hypothalamus, resulting in corticotrophin releasing hormone (CRH) and 
arginine vasopressin (AVP) release from the paraventricular nucleus. CRH and AVP 
in turn trigger the synthesis of pro-opiomelanocortin (POMC) and the release of its 
cleavage product adrenocorticotropic hormone (ACTH) by the anterior pituitary. 
ACTH then acts on the adrenal cortex to synthesize and secrete the glucocorticoid 
(GC) hormone cortisol (in humans) or corticosterone (in rodents).14 In addition, 
the hypothalamus also activates the adrenal medulla via the sympathetic nervous 
system (SNS), resulting in the release of the catecholamines adrenalin and 
noradrenalin. ACTH, CRH and glucocorticoids (GCs) in turn provide negative 
feedback to dampen and cease the signaling cascade and return to homeostasis.15,16 
In addition, activation of the autonomic nervous system, both centrally and via 
afferent pathways, activates efferent neuronal circuits, including the cholinergic 
anti-inflammatory reflex.17 Although this systems has potent immune-modulatory 
properties, its direct implication in atherosclerosis development and progression 
remains unresolved.18-21 Nevertheless, the immune reflex and neuroendocrine 
control of metabolic pathways are clearly contributing factors in stress-mediated 
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pathologies, as for example reviewed by Kibler et al.22
Stress research can be roughly subdivided in the effects and mechanisms of 
chronic and acute stress. Chronic psychological stress in early life and adulthood 
has been demonstrated to result in maladaptive changes in both the HPA-axis 
and the sympathetic nervous system, causing elevated local and circulating levels 
of GCs, cathecholamines and several (growth) hormones and neuropeptides. 
As mentioned above, modulation of immune responses by stress is mediated 
via complex multi-directional interactions between the central nervous system, 
the endocrine system and the immune system. Although these interactions are 
designed to adapt the body to deal with threats, chronic exposure to stress-
induced factors have been shown to either enhance or even wear down the 
immune system, thus enhancing the risk of developing infectious diseases and 
prolong illness episodes. While acute and time-limited stressors seem to result 
in adaptive redistribution of all major leukocyte subpopulations to for example 
a site of inflammation23,24, more persisting stressors cause suppression of the 
(Th1-mediated) cellular immune response and a shift towards a (Th2-mediated) 
humoral response.25,26 As a consequence, chronic stress renders the individual 
susceptible to infection and cancer27,28 and increases a person’s vulnerability to 
autoimmune and allergic diseases.29
In the context of cardiovascular diseases, psychological stress exposure is known 
to activate specific brain regions leading to the activation of the HPA axis and 
the sympathetic system, which can directly affect the vessel wall (for review see 
Pereira et al., Golbidi et al.)30,31, by increasing heart rate and blood pressure, 
but also by causing endothelial dysfunction, which is actually one of the primary 
triggers for the development of atherosclerosis. Stress-mediated induction of the 
sympathetic nervous system and the HPA-axis results in an enhanced activation 
or the RAAS system, which directly results in endothelial activation and damage 
as indicated by increased adhesion molecule expression. This in turn mediates 
the recruitment, adhesion and transmigration of inflammatory cells across the 
endothelial layer, thus initiating atherosclerotic plaque formation. Furthermore, 
stress may accelerate atherosclerosis progression by facilitating a chronic low-
grade inflammatory response, characterized by increased levels of for example 
plasma C reactive protein (CRP), Interleukin (IL)-6 and tumor necrosis factor-α 
(TNFα). This low grade inflammatory response can further enhance heart rate and 
blood pressure via regulation through the central autonomic network32, potentially 
leading to a vicious circle that will culminate in disease progression. Along that 
line, the increased inflammatory response, which may be mediated by stress-
induced NFκB33, can reduce endothelial nitric oxide synthase (eNOS) expression 
by the already damaged endothelium, and induce the release of reactive oxygen 
species (ROS), resulting in a pro-oxidative milieu that can cause lipid oxidation. 
Finally, chronic stress can via the induction of the endocannabinoid system result 
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in insulin resistance and metabolic syndrome, which is yet another risk factor for 
the development of CVD (Figure 1).
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Figure 1: Schematic overview of the most prominent effects of the stress response on atherosclerosis 
development and progression. Stress perception culminates via activation of the hypothalamic-pituitary-
adrenal axis in the production and release of glucocorticoid hormones and via the sympathetic-adrenal-
medullary in synthesis of the catecholamines adrenalin and noradrenalin. Furthermore, it leads to 
activation of the renin-angiotensin-aldosterone system (RAAS), while neuropeptides are released from 
peripheral nerve endings. Together, these factors can affect e.g. the inflammatory response, induce 
endothelial dysfunction, increase heart rate and blood pressure, and increase the levels of oxidative 
stress. These processes in turn can impact atherosclerosis development and progression at each stage 
of the disease, eventually resulting in acute cardiovascular events due to plaque rupture or erosion. CRH 
= corticotrophin releasing hormone, AVP = arginine vasopressin, ACTH = adrenocorticotropic hormone.
The actual clinical outcomes such as MI or stroke, however, are most likely to be 
triggered by an acute event in people with high plaque burden in combination with 
an inflammatory and pro-coagulant status. The body’s response after exposure 
to a sudden and severe stressor such as bereavement34, an earthquake35,36 or a 
terrorist attack37,38 has been demonstrated to fulfill these criteria and associates 
with increased incidence of ACS. 
Chronic stress and cardiovascular disease
The onset of atherosclerosis starts already early in life, with the development of 
foam cell-rich fatty streaks in the vessel wall detectable in childhood.39 However, 
the disease progresses relatively slow and clinical symptoms, primarily caused 
by flow limiting stenosis, often do not manifest itself until middle or older age. 
Many risk factors for atherosclerosis act at multiple time points on the pathogenic 
process40 and stress may influence disease progression and other risk factors across 
the life course. Chronic stress, both in early life (sexual abuse, parental disease, 
poor socioeconomic status)41 and adulthood (job-strain, social isolation, caregiver 
syndrome) have been linked to increased coronary heart disease (CHD) risk42. The 
largest body of epidemiological evidence comes from work-related stressors such 
as job-strain – high job demands combined with low control - and effort-reward 
imbalance. For instance, the Whitehall II prospective cohort study demonstrated 
job insecurity in a population of British civil servants to be associated with a 1.38-
fold (95% CI, 1.01-1.88) risk of CHD even after adjustment for physiological and 
behavioral cardiovascular risk factors9 and similar results were obtained in the 
Copenhagen City Heart Study43 and the Primary Prevention Study.44 Although two 
recent meta-analysis indicated smaller risk-ratios of 1.2-1.3 due to publication 
and reverse causation bias8,45, work-related stress seems a robust risk factor and 
to be accountable for a significant proportion of CHD in the working population. 
Other chronic psychological conditions investigated in relation to cardiovascular 
morbidity are depression, anxiety, post-traumatic stress disorder (PTSD) and 
the before mentioned personality types. The prevalence of a major depression 
has been demonstrated to be high in patients with cardiovascular disease and 
consistent associations with cardiovascular morbidity and mortality rates have 
been established.46 The first reports of a higher incidence of CHD-related 
deaths in patients suffering from major depression originate from 1930.47 More 
recent epidemiological evidence from the Baltimore cohort of the Epidemiologic 
Catchment Area Study48 and the Nord-Trondelag Health Study49 reported an odds 
ratio of 4.45 (95% CI, 1.65-12.44) and a multi-adjusted hazard ratio of 1.41 
(95% CI, 1.07-1.87) for major depression associated heart failure, respectively. 
In the Nurses’ Health Study II, trauma exposure and high PTSD symptoms were 
shown to associate with an increased risk of CVD in women.50 Furthermore, 
progression of sub-clinical atherosclerosis as well as elevated blood pressure and 
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systemic increases in inflammatory markers have been studied in this context. 
Depressive symptoms have been associated with greater carotid intima-media 
thickness51,52 and aortic and coronary calcifications, although some contradicting 
reports also exist.53,54 This discrepancy could possibly be explained by differences 
in the assessment of atherosclerosis and failure to assess the persistence of the 
depressive symptoms.55
As mentioned, atherosclerotic plaque development begins already at a very 
young age and increasing recognition is given to the adverse effects of early 
life experiences on cardiovascular health later in life. These early life challenges 
include exposure to toxins and diet but also situations which induce behavioral 
and emotional stress, anxiety, fear and discomfort. While children can be exposed 
to a wide variety of chronic psychological stressors, most research in this area 
has focused on socioeconomic disadvantage and parental maltreatment.41 The 
Adverse Childhood Experiences (ACE) Study was one of the first studies describing 
the long-term relationship between childhood experiences and medical and public 
health problems.56 This large-scale project assessed childhood maltreatment 
(abuse, neglect and household dysfunction) retrospectively in over 17,000 adults. 
Clear dose-dependent correlations (by exposure to 0 up to 4 of the investigated 
types of ACE) were demonstrated for multiple leading causes of death in adults, 
including liver disease57, skeletal fractures, but also ischemic heart disease58 and 
stroke. Furthermore, the ACE Study provided strong evidence that the different 
adverse childhood events often co-occur and that these events are interrelated, 
which thus may have implications for other studies performed in this research 
area, evaluating a specific category of ACE.59 In line with these results, a recent 
meta-analysis examining the health consequences of childhood maltreatment 
in a combined cohort of 48,000 individuals showed similar correlations with 
neurological (migraines), musculoskeletal (arthritis, broken bones) as well as 
cardiovascular complications, such as myocardial infarction and stroke60, indicating 
the important role of early adverse events in life in affecting adult health risk 
behavior, health status and diseases, including cardiovascular disease. Another 
factor associated with cardiovascular health is socioeconomic status (SES). Low 
SES during adulthood is associated with a wide range of health issues including 
cardiovascular disease. Low SES is characterized by low environmental quality 
such as poor housing, air and water quality and limited food options, which can 
lead to adverse psychological effects like hyperactivity and aggression, but also to 
a sedentary life style, a poor diet and an increased susceptibility to infection, thus 
increasing the risk of CVD. Interestingly, recent data indicate that low childhood 
SES also seems to be a good predictor of adult cardiovascular morbidity and 
mortality independent of adult SES status, further stressing the importance of 
early life conditions on adult health.61 Family status, neighborhood crime, violence, 
deprivation of healthcare and substance use can have negative effects during 
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childhood, leading to psychological dysregulation early in life, which can affect 
cardiovascular health as an adult.
As mentioned above, chronic stress may contribute to atherosclerosis progression 
by inducing a chronic low-grade inflammatory response. CRP is an acute-phase 
reactant that is commonly used as a marker for systemic inflammation, and is 
also used as a determinant for the risk of cardiovascular disease. Interestingly, 
plasma CRP levels were generally found to be enhanced upon chronic psychosocial 
stress, as determined in a literature survey.62 For example, caregivers of a family 
member with dementia, who experienced daily stressors, were seen to have 
enhanced levels of systemic inflammation compared to noncaregiving controls, 
as plasma CRP as well as IL-6 levels were elevated.63 Similarly, CRP levels were 
higher in patients with PTSD compared to controls without PTSD.64 In fact, a 
positive association between PTSD and elevated inflammatory markers has been 
observed in a number of studies.65-67 Work-related stressors such as a burnout 
have also been demonstrated to correlate with inflammatory markers.68-70 Higher 
levels of total burnout symptoms in schoolteachers associated with increased 
TNFα levels68, while in another study females with a burnout showed elevated 
levels of CRP compared to healthy controls.69 In that study, males suffering from 
a depression were seen to display elevated levels of CRP, and a relation between 
depression and inflammation has been observed in other studies as well.71-72 
A literature study established that low SES associated with higher plasma CRP 
levels.73 Evidence illustrating stress-induced inflammation and its specific markers 
are summarized in Table 165-83, together clearly establishing that a variety of 
psychosocial disorders, such as burnout, depression, loneliness or PTSD, affect 
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the inflammatory status of the patient, mostly demonstrated by increased levels 
of plasma CRP and IL-6. Both plasma CRP and IL-6 have been associated with 
an increased risk of unstable cardiovascular diseases, and as such chronic stress 
may contribute to the cardiovascular disease burden. Indeed, e.g. depression 
was proven to be predictive for cardiovascular mortality, which was at least partly 
explained by the contribution of inflammation (i.e. CRP and IL-6 levels).84,85 
Effects of chronic stress on experimental atherosclerosis 
Human studies have clearly identified chronic stress as a risk factor for ACS, 
however these studies are in principle correlative in nature and do not prove 
causality or insight in the underlying mechanism of disease. This mechanistic 
insight into the multifaceted neurohormonal response induced by chronic 
stress is necessary to better understand its impact on the cardiovascular 
system and to identify new therapeutic targets. Over the years many small 
and larger animal models have been developed to investigate the processes 
involved in atherogenesis, which also involved effects of chronic stress 
on lesion development. Landmark studies on the effects of psychological 
stress were performed by Ratcliffe et al. and Kaplan et al. who demonstrated 
accelerated coronary atherosclerosis development in separated swines86 or in 
cynomolgus monkeys living in unstable hierarchies, independently of plasma 
lipid levels.87 Currently, hyperlipidemic mouse strains, such  as  the LDL receptor 
(LDLr-/-) or apolipoprotein E (apoE-/-) knockout mice which develop human-like 
atherosclerotic lesions when fed a high fat (Western-type) diet, are the mainstay 
for atherosclerosis studies.88 Furthermore, experimental protocols to mimic 
(aspects of) the human stress response and related diseases such as depression 
have been developed. Again a clear distinction between models aimed at eliciting 
an acute or chronic stress response can be made. While an acute trigger rapidly 
increases circulating GC and cathecholamine concentrations, which return to 
baseline quickly after cessation of the stressor, chronic exposure may result in 
lasting and variable neuroendocrine responses depending on the type of stressor 
and habituation to the stress protocol (Table 2a;b).
A number of studies have been performed to establish the effects of a single 
chronic stressor on the development and progression of atherosclerosis. For 
example, social isolation by means of individual housing of male apoE-/- mice 
significantly elevated plasma cholesterol and triglyceride levels and resulted 
in an increase in atherosclerotic plaque development in the innominate artery, 
suggesting dyslipidemia induced by the stressor as a driving force.89 However, 
another form of chronic stress, induced by introduction of an intruder mouse, also 
resulted in accelerated atherosclerosis in the aorta but without effects on lipid 
homeostasis. 
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In this study a significant increase in the pro-inflammatory cytokine IL-6 and the 
chemokine CXCL1 was observed directly after stress induction, which can lead 
to faster disease development.90 A recent study applying a chronic intermittent 
cold stress paradigm demonstrated increased lesion formation in the aortic root 
with features of increased plaque vulnerability, indicated by decreased vascular 
smooth muscle cell (VSMC) and collagen levels and an increased macrophage 
and lymphocyte content. Furthermore, the expression ratio of matrix degrading 
enzymes and their inhibitors was less favorable in the chronically stressed mice.91 
Interestingly, emotional stress alone or combined with a physical stressor, but 
not the physical stressor by itself seemed to contribute to lesion progression and 
destabilization in apoE-/- mice.92 Here, social defeat stress induced by exposing 
mice to a rat was sufficient to increase atherosclerotic lesion development and 
this effect was even potentiated when combined with the physical stress of 
water withdrawal. Lesions in the mice exposed to emotional stress or combined 
emotional and physical stress combined exhibited a significant increase in CD68+ 
macrophages and CD3+ T cells and a decrease in α-SMA+ VSMCs, suggesting a less 
stable phenotype. Najafi et al. recently combined a chronic stress regimen with 
the stress susceptible mixed background (C57BL/Sv129) apoE-/- mice on a lard 
diet, which resulted in a highly advanced plaque phenotype with large necrotic 
cores, thin fibrous caps, intraplaque hemorrhages and inflammatory infiltrates, 
which may be a useful model to evaluate therapeutic interventions aimed at 
plaque stabilization.93
2
Acute and chronic psychological stress as risk factors for cardiovascular disease  |  45
As repeated exposure to a single type of stressor has been shown to cause 
habitualization, and thus a different (pathological) phenotype94, various protocols 
inducing chronic unpredictable and variable stress have been developed. These 
protocols usually consist of exposure of animals to multiple randomly assigned 
stressors including restraint, forced swim, food or water deprivation, exposure 
to rat odor, housing in damp bedding, cage tilt, dark-light cycle changes and 
social isolation for several weeks. These models have been shown to cause robust 
increases in GC secretion, sensitization of the HPA-axis to new stressors, reduced 
body weight and behavioral changes in immobilization and anxiety tests, indicating 
the many central systems affected.95 Kumari et al. demonstrated a dose-dependent 
atherogenic effect of such a chronic stress protocol in apoE-/- mice.96 Bodyweight 
was significantly reduced in the chronically stressed mice, while displaying a 10-
fold increase in plasma corticosterone levels and three times more atheroma in 
the aorta compared to their unstressed littermates, however no direct mechanistic 
insights were provided. In line with these results, another chronic unpredictable 
stress regimen with ten different stressors induced heightened plasma lipid and 
inflammatory cytokines levels (CRP and IL-6) and accelerated atherosclerotic 
plaque formation.97,98 Lesions in the brachiocephalic artery of the stressed mice 
exhibited a less stable phenotype, with high numbers of infiltrated macrophages 
and T cells and a decrease in VSMCs. Experiments performed by Bernberg et al. 
however contradict a general pro-atherogenic response upon stress exposure. 
Although chronic exposure of apoE-/- mice to five different physical stressors 
induced a clear stress response, evidenced by acute increases in heart rate, 
46  |  Chapter 2
blood pressure and plasma corticosterone levels, neither significant differences in 
cholesterol levels nor disease progression in the thoracic aorta or aortic root were 
observed.99 It must be mentioned however, that differences in stress protocol and 
site of atherosclerosis measured may affect the outcome of the studies. 
Rodent models that approximate human early life stress involve maternal separation 
or decreased maternal care protocols during early postnatal life. During this stress 
hypo-responsive period, when neural development is still ongoing, repeated 
episodes of maternal separation have been demonstrated to induce long-lasting 
effects on cognitive functions and to change the responsiveness of the HPA axis and 
sympathetic nervous system under basal and stressed conditions. Although the 
described effects are quite diverse and sometimes species-specific, generally an 
increase in basal corticosterone levels and exaggerated ACTH and corticosterone 
responses upon exposure to novel stressors are observed.100 While such early 
life stress models have been used extensively to study its neuroendocrine and 
behavioral implications in the context of depression and cognitive function, no 
direct experimental results on atherosclerosis susceptibility and progression are 
available. 
Activation of the HPA-axis upon stress exposure culminates in the central and 
peripheral release of mineralocorticoids (MCs) and GCs. These steroid hormones 
have been utilized for their anti-inflammatory actions for decades. However, chronic 
exposure to elevated levels of GCs introduces a state of GC resistance, reducing 
the anti-inflammatory actions and actually increasing local concentrations of pro-
inflammatory cytokines.101 Furthermore, a prolonged or enhanced exposure to 
pro-inflammatory mediators, such as to IL-1 or IL-6, can induce a reduction in 
GC receptor function and even impairment, as illustrated by a reduced sensitivity 
for GCs102,103, which further enhances the pro-inflammatory response that can 
contribute to the progression of cardiovascular disease. In fact, patients with CVD 
were recently seen to exhibit a reduction in GC receptor expression and sensitivity, 
while showing increased inflammation.104 In addition, prolonged GC excess, as seen 
in patients with Cushing’s syndrome, correlates with cardiovascular complications. 
In animal studies however, GCs primarily demonstrate an athero-protective 
effect. For example administration of physiological levels of corticosterone in 
APOE*3-Leiden-CETP mice, which are atherosclerosis-prone and have human-
like lipoprotein metabolism, resulted in significantly less atherosclerotic lesion 
development.105 Furthermore, removal of endogenous GCs by adrenalectomy in 
LDLr-/- mice resulted in increased atherosclerotic plaque formation and this effects 
was reversed by adrenal transplantation.106 However, when combined with high 
fat diet, GC excess promoted fat accumulation in the APOE*3-Leiden-CETP106, 
while enhancing plasma lipid and insulin levels in C57BL/6 mice107, which all have 
potential negative cardiovascular implications. A similar experiment in apoE-/- mice 
treated with low dose corticosterone combined with a Western-type diet resulted 
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in 77% larger aortic root lesions compared to control mice. Furthermore, this 
increase was accompanied by a significant reduction in white blood cell count 
and serum IL-1β concentration, but elevated levels of LDL and very low-density 
lipoprotein (VLDL), suggesting clear strain-specific differences.108 Taken these 
animal studies together, exposure to chronic stress, either via a single stressor 
or by a combination of different stressors, results in enhanced development of 
atherosclerosis and in plaque destabilization as indicated by increased intraplaque 
inflammation and necrosis. These effects are generally caused by modulation of 
lipid homeostasis and an increased immune responses (Table 2c). 
Acute stress and acute cardiovascular syndromes
Chronic stress exposure increases cardiovascular disease susceptibility and 
progression through maladaptation of the neuroendocrine pathways involved. 
In contrast, acute stress-induced disorders are generally caused by the sudden 
increase of the major stress mediators in the context of a vulnerable background. 
Well known are stress-induced exacerbations of dermatologic and respiratory 
diseases, in which stressors can be directly linked to changes in skin barrier 
function and exaggerated immune responses in the lung.16,109 Following this line of 
thought, stress may contribute to cardiovascular morbidity and mortality through 
induction of acute cardiovascular events such as unstable angina, myocardial 
infarction, or sudden cardiac death. The key pathological events that causes most 
ACS are rupture of the thin fibrous cap or erosion of the intima of an advanced 
and vulnerable plaque, which then no longer shield the thrombogenic content of 
the plaque. Exposure to the blood’s coagulation system can subsequently lead 
to the formation of an occlusive thrombus resulting in a myocardial infarction or 
stroke. The risk of an ACS thus depends on the combination of the vulnerability 
of existing atherosclerotic plaques, the coagulant status of the blood and plaque 
erosion or rupture.110
Both acute physical (surgery, trauma and extreme physical exertion) and 
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psychological (anger, fear, depression) stressors may be implicated in the 
incidence of acute cardiovascular events. Furthermore, a distinction can be made 
between population-based studies evaluating the effects of an acute stressor 
such as a terrorist attack or natural disaster on cardiovascular risk and studies 
evaluating individual stressors in patients who have had an ACS. By comparing 
the incidence of ACS after a disaster with a similar event free time-period, for 
example the week or year before, associations have been established between 
the risk of ACS and the stressed caused by earthquakes, war, terrorist attacks as 
well as sporting events.111 For example, the threat of annihilation in the Israeli 
civilian population during the initial phase of the Gulf war seems to be responsible 
for the observed sharp rise in acute myocardial infarction and sudden cardiac 
death cases112 and hospital records from New Jersey and Brooklyn demonstrated 
a significant increase in the proportion of various cardiac diagnosis directly after 
the 9/11 terrorist attacks.37,38 Another population-based trigger which has been 
used to evaluate the correlation between acute stress and ACS are earthquakes. 
Analysis of all deaths after the 1994 earthquake in the Los Angeles area showed 
a significant increase in sudden deaths from cardiac causes of 24 on the day of 
the earthquake compared with an average of 4.6 per day in the week before. 
Similar results were obtained after the 1995 earthquake in the Kobe region of 
Japan113 and more recently after the two earthquakes that struck Christchurch, 
New Zealand.114  Acute psychological stressors at the individual level such as anger, 
fear and acute work-related stressors and their association with the incidence of 
ACS are best evaluated by case-crossover studies comparing the trigger period 
just before the onset of MI with the similar period the day before in the same 
individual. This method eliminates differences in the cardiovascular risk profiles 
between patients and controls and interpretation biases.115 Using such as study 
design, Mittleman et al. interviewed over 1600 patients within 4 days after acute 
MI and evaluated the occurrence of anger within the 2 hour period before the 
onset of symptoms with the same period 24 hours before and with the frequency 
in which such episodes occurred within the previous year. The relative risk of 
acute MI in the 2 hours after an episode of anger was 2.3 (95% CI, 3.2-1.7).116 A 
recent review and meta-analysis including additional cardiovascular events, such 
as ischemic stroke, ventricular arrhythmia, and ruptured intercranial aneurysm, 
demonstrated an increased risk for all those events in the hours after an anger 
outburst.117 In addition to the previously discussed chronic stress experienced 
by patients with depression, acute negative emotions can also act as a sudden 
trigger of ACS. Both acute work-related stressors and acute depressed mood were 
shown to increase the relative risk of ACS onset.118,119  Similar to the response to 
chronic stress, acute stress exposure has been demonstrated to result in a quick 
rise in plasma interleukins and inflammatory markers (Table 1120-126), such as IL-6, 
IL-1β and sICAM127,128, which have all been demonstrated to be pro-atherogenic. 
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Furthermore, the rise in plasma IL-6 was seen to associate with fibrin formation 
and pro-coagulant markers129, which may lead to an enhanced risk of thrombosis 
upon plaque rupture. Similarly, plasma CRP levels increase upon an acute 
mental stressor, and this response is even enlarged in patients with coronary 
artery disease.130 Combined, the current data clearly indicate an important role 
for emotional triggering of cardiac events and warrants further research to gain 
mechanistic insight and into preventative measures. 
Effect of acute stress on experimental cardiovascular diseases 
Atherosclerotic lesions in LDLr-/- or apoE-/- mice have many of the characteristics 
of human advanced and rupture-prone plaques, however, they hardly ever result 
in an acute MI or stroke. To model acute MI in mice one has to revert to surgical 
models, such as (transient) ligation of the left anterior descending coronary artery 
(LAD) or the ex vivo Langerdorf perfusion model.131 Mouse models of acute stress 
include single sessions of restraint, forced swim, shaking, electric foot shock 
or exposure to an (aggressive) intruder.132 Up to date, animal studies on the 
effects of acute stress on the cardiovascular system have primarily focused on 
cardiac function and injury (Table 3). Acute stress-induced release of adrenalin 
and noradrenalin almost instantaneously affects heart rate and blood pressure 
resulting in changes in cardiac output and regional blood flow.133 Furthermore, 
stress-induced cardiomyocyte cell death, resulting in reduced cardiac function, 
was shown in multiple animal models and elevated levels of cardiac enzymes (e.g. 
creatine kinase, aspartate aminotransferase and lactate dehydrogenase) can be 
readily detected in plasma after stress. Interestingly, administration of β-blockers 
completely protected against the leakage of these enzymes in a water-immersion 
stress model, strongly suggesting adrenergic pathways to be involved in cardiac 
cell death induced by stress.134
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Atherosclerotic plaque disruption is thought be the key event precipitating acute 
MI and stroke. However, experimental data on the effects of acute stress on 
atherosclerotic lesion progression and destabilization is scarce and concentrates 
on immune modulation by the stress hormones and neuropeptides. A single bout 
of acute restraint stress in apoE-/- mice was demonstrated to increase cardiac 
histamine and IL-6 levels in a mast cell-dependent manner, which was suggested 
to be mediated by the stress hormones CRH and urocortin, as the peptide CRH 
receptor antagonist Astressin was shown to significantly inhibit the stress-induced 
IL-6 release.135,136 Unfortunately, no additional analysis of atherosclerotic lesion 
composition after acute stress exposure was reported. Interestingly, Dutta et 
al. recently demonstrated the contribution of acute MI on atherosclerotic lesion 
progression and risk of re-infarction. They showed in mice that the anxiety and 
pain as a result of an acute MI activates the SNS, which subsequently triggers an 
innate immune response aimed at repairing the injury. However, the increase in 
production and release of hematopoietic stem and progenitor cells (HSPC) from the 
bone marrow and increased myelopoiesis in the spleen did not only aid in restoring 
the heart, but also fueled the inflammatory process in the atherosclerotic plaque, 
as demonstrated for example by increased inflammatory monocyte accumulation 
in the aorta.137 Pretreatment with a β3-adrenoreceptor blocker significantly 
reduced the progenitor release and lesional immune cell influx after MI, possibly 
by affecting the expression of retention factors such as CXCL12, angiopoietin and 
stem cell factor. These results further stress the important role the brain-immune 
connection can play in atherosclerosis. In line with an increase in HSPC release 
after acute MI, exposure of apoE-/- mice to a chronic stress paradigm resulted in 
similarly elevated levels of circulating progenitor cells and increased inflammatory 
status of the atherosclerotic plaque.138
While distribution of immune cells over the different hematopoietic compartments 
is known to be crucial for effective immune surveillance and function, the 
redistributing effect stress can have on the immune system has been relatively 
underappreciated. Time-course studies in rats recently demonstrated the individual 
contribution of the principal stress hormones (corticosterone, epinephrine 
and norepinephrine) on acute redistribution of leukocytes. Early during stress 
mobilization of monocytes, neutrophils and lymphocytes from the spleen, bone 
marrow, lung and marginated leukocyte pool was observed resulting in a quick 
rise in numbers of these cells in the blood. During the second phase (>30 minutes) 
a drop in blood leukocyte numbers suggest trafficking of those cells to sites of 
inflammation, for instance the atherosclerotic plaque, or recirculation to spleen, 
bone marrow, lung or lymph nodes.139 Interestingly, while all the major hormones 
act in concert to achieve efficient redistribution, epinephrine and norepinephrine 
were primarily responsible for the initial mobilization, while epinephrine and 
corticosterone mediated trafficking towards the target tissues, thus implying 
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different types of responses to different types of stressors. Taken together, the 
animal studies described here demonstrate that acute stress effectively activates 
the immune system, resulting in an enhanced inflammatory response, which 
can be directed towards the area of disease, such as an ischemic heart or the 
atherosclerotic plaque.
Therapeutic modulation of psychosocial risk factors in patients with CVD
Despite increased public awareness of its risk factors and improvements 
in healthcare and treatment options, cardiovascular disease and its clinical 
complications remain a leading cause of death worldwide. In addition to traditional 
risk factors, such as dyslipidemia, inflammation, smoking, diabetes and high 
blood pressure, psychological stress is receiving increased recognition as both a 
clinically important contributor to cardiovascular morbidity and mortality and as a 
therapeutic target. 
A large body of clinical and experimental research demonstrates correlations 
between chronic stress exposure during early life as well as adulthood and 
cardiovascular disease risk. Together, a number of human association studies 
have firmly established that patients with psychological disorders or people 
subjected to chronic stress are at risk for the development of CVD. Experimental 
studies have contributed to the elucidation of the underlying mechanisms. The 
experimental studies generally have established that chronic stress enhances 
progression of atherosclerosis predominantly by negatively affecting lipid and 
immune homeostasis, and by increasing inflammatory mediators, such as CRP and 
IL-6, phenomena that are also seen in patients with psychosocial disorders and are 
associated with the development of atherosclerosis (Table 1). Maladaptation, due to 
the chronic activation of the immune system, results in a low-grade inflammatory 
response which fuels the development and progression of the atherosclerotic 
plaque, and thus increases the risk of acute cardiovascular syndromes. Also acute 
stress may contributes to the incidence of acute cardiovascular disorders, as 
experimental studies have established that acute stress results in direct effects 
on heart rate and blood pressure, as well as on circulating inflammatory markers 
and cardiac cell death. These effects can act in concert to induce adverse cardiac 
events in patients with established atherosclerosis. Together, data from these 
clinical and experimental studies have established a clear connection between 
stress exposure and CVD, but also provide potential therapeutic options to prevent 
acute cardiovascular events. The emerging field of behavioral cardiology tries to 
address the expanding number of psychosocial risk factors in clinical practice. 
Clinical management of negative emotions, chronic stress and social dysfunction 
by psychotherapy and psychological interventions all aim to promote healthy 
behavior and improve psychosocial functioning.140 Accumulating evidence shows 
that the positive counterparts (e.g. optimism and strong social integration) of 
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risk factors such as pessimism, depression and social isolation correlate with an 
array of cardiovascular benefits, including reduced heart failure.141,142 Changing 
behavior or emotional status of patients suffering from psychological disorders 
often requires pharmacologic treatment options. As such, treatment of depression 
during cardiac rehabilitation has been assessed in multiple trials, including the 
SADHART (Sertraline AntiDepressant Heart Attack Trial), ENRICHD (Enhancing 
Recovery in Coronary Heart Disease) and MIND-IT (Myocardial Infarction and 
Depression Intervention Trial) trials. In these randomized trials, although the 
depression was adequately treated, limited to no beneficial effect on cardiovascular 
disease morbidity or mortality was observed.143 This apparent discrepancy might 
be caused by the often large standard deviation in psychological parameters, 
necessitating huge samples sizes to show correlations with “hard” cardiovascular 
end points (e.g. MI or stroke). Also, such trials are generally set up to determine 
the safety of the use of specific drugs in patients with cardiovascular disorders, 
who are at risk of depression, and in that sense the number of patients included 
is too limited to be able to draw any conclusions regarding their increased risk of 
having an acute cardiovascular event. Furthermore, dose response relationships 
in behavioral research are difficult to determine as therapy frequency and duration 
to achieve a certain psychological improved vary much between patients.143 More 
information on cardiovascular risk after treatment with e.g. antidepressants 
may be gathered from larger clinical trials including patients suffering from 
psychological disorders, but without prior cardiovascular issues. Future research 
should also be aimed at early diagnosis of both cardiovascular disease and chronic 
psychological conditions in individual patients. In light of the reciprocal interactions 
between brain-initiated and peripheral mechanism, interventions in psychological 
or cardiovascular disease, or especially both combined, could thus have a major 
impact on cardiovascular health.
Conclusions 
In conclusion, acute cardiovascular syndromes and its underlying disease 
atherosclerosis remain a leading cause of death and identification and 
understanding of all its risk factors is key in combating this disease. Psychological 
stress is receiving increased attention as a substantial but also modifiable risk 
factor for various diseases, including cardiovascular disease, however the exact 
mechanism underlying these effects have not been completely elucidated yet. 
Here, we reviewed current literature on both clinical and experimental data on the 
association between acute and chronic stress exposure and the incidence of CHD 
and myocardial infarction as well as biological pathways affecting stress-induced 
atherosclerosis development and progression. Increased insight in the causal 
processes will improve patient care and have implications beyond cardiovascular 
disease.
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Abstract 
 
Objective: Mast cells accumulate in the perivascular tissue during atherosclerotic 
plaque progression and contribute to plaque development and destabilization. 
However, the specific triggers for mast cell activation in atherosclerosis remain 
unresolved. We hypothesized that psychological stress-induced activation of mast 
cells may contribute to plaque destabilization.
Methods and Results: To investigate this, apoE-/- mice on Western-type diet 
were exposed to 120’ restraint stress with or without treatment with the mast cell 
stabilizer cromolyn. A single episode of restraint caused a significant increase in 
mast cell activation in the heart. In addition to a rise in serum corticosterone and 
changes in circulating leukocyte populations, we observed a transient increase 
in the circulating pro-inflammatory cytokine interleukin-6 in the stressed mice. 
Subsequent characterization of the atherosclerotic plaques revealed a significant 
reduction in lesion collagen content and a higher incidence and larger size of 
intraplaque hemorrhages in stressed versus non-stressed mice. These effects 
were partially inhibited by cromolyn treatment and completely absent in mast 
cell-deficient mice, strongly indicating the involvement of a mast cell-dependent 
response to stress in atherosclerotic plaque destabilization.
Conclusions: We demonstrate that acute stress activates mast cells, which 
contributes to plaque destabilization in vivo, identifying acute stress as a risk 
factor for atherosclerotic plaque destabilization.
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Introduction
Acute coronary syndromes (ACS), such as acute myocardial infarction, stroke and 
sudden cardiac death remain principle causes of death worldwide.1,2 These events 
often occur in patients with severe (coronary) atherosclerosis and the underlying 
pathology is generally rupture or erosion of such advanced atherosclerotic lesions 
accompanied with thrombosis.3 Besides dyslipidemia, vascular inflammation is a 
driving force behind atherosclerosis development and progression4 and modulation 
of the immune system has been shown to contribute to the course of the disease. 
In addition to traditional risk factors for atherosclerosis such as dyslipidemia, 
hypertension, diabetes, obesity and genetic predisposition, (psychological) stress 
is receiving increased attention as both a contributing factor to and consequence 
of various diseases, including cardiovascular disease.5 Physical and psychological 
stress, acting via activation of the hypothalamic-pituitary-adrenal axis and the 
sympathetic nervous system, results in the systemic and local release of multiple 
hormones and neuropeptides and has been demonstrated to exhibit potent 
immunomodulatory effects. Although more established for its role in exacerbating 
allergic responses, there is accumulating evidence for a pathological role of stress 
in cardiovascular disease. For instance, results of the INTERHEART study (a case-
control study with >24000 participants) indicate that the presence of psychosocial 
stressors greatly increase the risk of acute myocardial infarction in men6 and 
a recent meta-analysis of prospective cohort studies evaluating job-strain and 
cardiovascular disease showed an increased hazard ratio for coronary heart disease 
of 1.2-1.3 in participants reporting job strain.7 However, to study the cardiovascular 
implications of stress exposure in humans is complex due to strong differences in 
individual perception of stress. Furthermore, the direct effects of acute stress as a 
precipitating factor for ACS are difficult to establish, due to reverse causation bias. 
Thus, to gain mechanistic insight into the molecular pathways involved in stress-
induced cardiovascular complications remains challenging.  
Extensive research into the characteristics and morphology of the vulnerable 
plaque, which is prone to disruption and give rise to clinical complications, has 
demonstrated that especially the highly inflamed shoulder regions are common 
sites of rupture.8 Previously, we and others have established a key role for an 
innate immune cell type, the mast cell, in atherosclerotic disease progression and 
especially in the subsequent destabilization of advanced atherosclerotic plaques.8,9,10 
In animal models of atherosclerosis, both systemic and local activation of (peri)
vascular mast cells resulted in increased lesion progression, and importantly also 
decreased lesion stability. Mast cells mediate these effect via the release of pro-
inflammatory cytokines, extracellular matrix degrading proteases and microvessel 
inducing growth factors.9,10 Furthermore, these experimental animal data are in 
line with recent human immunohistochemical data, correlating perivascular mast 
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cell numbers and activation status with disease progression and acute coronary 
events.11 
As mast cells are tissue-resident immune cells and shown to accumulate near 
atherosclerotic lesions, these cells are uniquely located to respond to acute 
(perivascular) triggers and subsequently release their pro-atherogenic content. 
Despite extensive knowledge on mast cell biology and activation routes, the 
specific mast cell triggers in relation to ACS remain unresolved. Being in close 
proximity to perivascular neurons12 and expressing different types of neuropeptide 
and hormone receptors, this neuron-mast cell connection is likely to play an 
exacerbating role in cardiovascular diseases. Previously, plasma histamine and 
IL-6 levels were seen to be increased in a mouse model of acute physical and 
psychological stress13, suggesting that mast cells are indeed activated after the 
induction of acute stress. 
Combined, the epidemiological and experimental data strongly indicate a pro-
atherogenic role for stress-induced mast cell activation. However, the direct 
implications for atherosclerotic lesion progression and composition have not been 
established. In this study we evaluated mast cell-dependent effects of acute stress 
on atherosclerotic lesion stability by applying a restraint stress model in apoE-/- 
and mast cell deficient RMB-apoE-/- mice.14 
Material and Methods
Animals
All animal work was approved by the Leiden University Animal Ethics committee 
and performed in compliance with the Dutch government guidelines and the 
Directive 2010/63/EU of the European Parliament. 10-12 weeks old male 
apoE-/- mice were obtained from the local animal breeding facility. The inducible 
mast cell deficient red mast cell and basophil (RMB) mice were obtained from the 
lab of Prof. Pierre Launay14 and were backcrossed with apoE-/- mice to obtain RMB-
apoE-/- mice. 
Restraint-stress model
All stress experiments were performed between 9am and noon, a period in which 
individual differences in corticosterone levels in mice are relatively small.31 24 
male apoE-/- mice were subjected to restrained stress by immobilization in a well-
ventilated 50 mL Corning tube for 30’, 60’, 90’ or 120’ (n=6) while control mice 
were left undisturbed in their home cage. Directly after the indicated stress-time 
the mice were terminally anaesthetized and sacrificed. Total cell count, neutrophils, 
monocyte, lymphocyte, and eosinophil counts in blood were analyzed using an 
automated XT-2000iV veterinary hematology analyzer (Sysmex Europe GMBH, 
Norderstedt, Germany). Serum IL-6, (BD Biosciences) levels were determined by 
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ELISA according to the manufacturer’s protocol. Heartswere excised and briefly 
fixated in 3.7% neutral-buffered formalin (Formal-Fixx; Shandon Scientific Ltd, 
UK) before further processing. 
Corticosterone analysis
Blood samples for basal corticosterone analysis were drawn by tailcut between 
9:00 and 12:00 AM. Levels of corticosterone were determined using a 125-I 
radioimmuno assay (RIA) with a lower detection limit of 5 ng/ml, according to the 
manufacturer’s specifications (MP Biomedicals, Illkirch-Graffenstaden, France).
Β-hexosaminidase assay
To measure β-hexosaminidase levels 50 μL of serum was added to 50 μL 2 mM 
4-nitrophenyl N-acetyl-b-D-glucosaminide (Sigma, Germany) in 0.2 M citrate (pH 
4.5) in a 96-well plate (Greiner Bio-One, The Netherlands) and incubated at 37 °C 
for 2 hours. After addition of 150 μL 1 M Tris (pH 9.0), absorbance was measured 
at 405 nm. 
Atherosclerosis
Atherosclerotic lesion formation was induced by feeding male apoE  mice (n=39) 
a Western-type diet (0.25% cholesterol and 15% cocoa butter; Special Diet 
Services, Witham, Essex, UK) for 6 weeks. A schematic representation of the 
experimental setup is depicted in Supplemental figure 1A. Blood samples were 
taken at the start of the experiment, at 2 and 5 weeks of WTD feeding by tail-cut 
and plasma was obtained by centrifugation at 8,000 rpm for 10 min. Levels of 
total plasma cholesterol were measured spectrophotometrically using enzymatic 
procedures (Roche Diagnostics, Almere, the Netherlands). At 6 weeks mice were 
randomly assigned to either the undisturbed control, 120’ restraint stress or 120’ 
restraint stress + cromolyn group (n=13 per group) and subjected to the stress 
protocol. Cromolyn-treated mice were injected 30’ prior to the stressor and once 
daily over the next three days with the mast cell stabilizer cromolyn (50 mg/kg, 
i.p). Three days after stress all mice were terminally anaesthetized and sacrificed. 
Blood was processed for fluorescence flow cytometry (Sysmex) or ELISA/RIA as 
described above. Heart, skin and lung tissue were fixated in 3.7% neutral-buffered 
formalin (Formal-fixx; Shandon Scientific Ltd, UK) before further processing. A 
similar experimental setting was used to evaluate the pro-atherogenic effects 
of stress in mast cell deficient RMB-apoE-/-mice (supplemental figure 2A). Three 
intraperitoneal injections of 1 µg of diphtheria toxin (#322-326, Calbiochem, CA, 
USA) in these mice resulted in complete eradication of all mast cells, including in 
the aortic root (supplemental figure 2B). 
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Plaque morphometry and immunohistochemistry
Harvested hearts were fixated in 3.7% neutral-buffered formalin solution (Formal-
fixx; Shandon Scientific Ltd, UK) and embedded in O.C.T compound (Tissue-Tek, 
Sakura Finetek, CA, USA). Once the aortic root was identified by the appearance 
of aortic valve leaflets, transverse 10-µm sections were prepared on a Leica CM 
3050S Cryostat (Leica Instruments, Nassloch, Germany) and mounted on gelatin-
coated slides. Mean lesion area (in µm2) was calculated from six Oil-Red-O stained 
sections in distal direction starting at the point where all three aortic valve leaflets 
first appeared. Leica Qwin image analysis software was used for morphometric 
analysis of the atherosclerotic burden. 
Mast cells were visualized by chloroacetate esterase staining according to 
manufacturer’s protocol (CAE, Sigma, Germany) and degranulation status was 
assessed manually by bright-field microscopy as described previously10. A mast 
cell was considered resting when all granulae were maintained inside the cell, 
while mast cells were assessed as activated when granulae were deposited in the 
tissue surrounding the mast cell.
In addition, immunohistochemical stainings were performed to assess plaque 
composition and stability. Sections were stained for collagen (picrosirius red) and 
macrophages (MOMA-2) as described previously32. Necrotic core area was defined 
as the a-cellular, debris-rich plaque area and represented as percentage of total 
plaque area. Apoptosis was visualized using a terminal dUTP nick-end labelling 
(TUNEL) kit (Roche Diagnostics). As another measure of lesions destabilization the 
amount and surface area of intraplaque hemorrhages (IPH) were determined as 
described before.15 Presence of masses of intimal erythrocytes, free in the plaque 
matrix or filling the necrotic core, was classified as intraplaque hemorrhage.18 
For detection of intraplaque hemorrhage, we analyzed all hematoxylin & eosin-
stained sections (at 50 µM intervals) for each mouse having atherosclerotic 
plaques. Furthermore, erythrocytes were visualized by fluorescence microscopy 
(erythrocyte autofluorescence at 560 nm emission wavelength). All morphometric 
analyses were performed by blinded independent operators (IB and HML).
Statistical analysis
Data are expressed as mean ±  SEM. A two-tailed student T-test was used to 
compare normally distributed data between individual groups. For comparison 
of three or more different groups, data were analyzed with a one-way ANOVA 
followed by Tukey’s multiple comparisons test. Frequency data analysis was 
performed by means of the Fisher’s exact test. Probability values of P<0.05 were 
considered significant.
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Results
Restraint stress dose-dependently activates cardiac mast cells in male apoE-/- mice
To evaluate the effect of acute physical and psychological stress on cardiac 
and vascular mast cell activation we subjected male apoE-/- mice to a restraint 
stress protocol. A time course experiment (n=6 per timepoint) was performed to 
determine the optimal stress time resulting in mast cell activation. As depicted 
in figure 1A, restraint stress induced a quick and strong increase in circulation 
glucocorticoid levels (169.4 ± 50.9 ng/ml in unstressed vs 332.3 ± 35.7 ng/ml 
in 60’ stressed mice, P<0.05), indicating HPA-axis activation. Next, we assessed 
cardiac mast cell numbers and activation status by immunohistochemical staining 
of heart cross-sections at the level of the aortic root. While absolute numbers of 
cardiac mast cells were similar in all groups, the percentage of activated mast 
cells, scored by the presence of granules deposited outside the mast cell (figure 
1B), was significantly increased upon stress exposure (37.3 ± 1.8 % unstressed 
vs 50.7 ± 5.0% in 120’ stressed mice, figure 1C, P<0.05). Furthermore, the 
length of stress exposure (and thus severity) seemed to correlate with the degree 
of mast cell activation. Serum levels of the mast cell-granule derived mediator 
β-hexosaminidase significantly correlated with the percentage of activated cardiac 
mast cells (figure 1D). As apoE-/- mice subjected to 2 hours of restraint stress 
showed the most prominent increase in cardiac mast cell activation we used this 
experimental setup for subsequent experiments. 
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Figure 1. Restraint stress time course in apoE-/- mice. A) Restraint stress rapidly and significantly 
increased plasma corticosterone levels. B) Representative pictures of resting (non-activated) and 
degranulating (activated) cardiac mast cells. C) Restraint stress severity-dependently increased cardiac 
mast cell activation status. D) Percentage of activated cardiac mast cells significantly correlated with 
serum β-hexosaminidase level. E) 120’ restraint stress significantly increased serum IL-6 levels. *P<0.05, 
**P<0.01, ***P<0.001
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To further investigate the effect of mast cell-specific responses to acute stress 
exposure on circulating cells and blood cytokine levels an additional pilot 
experiment was performed. Again the control mice were left undisturbed, while 
treated mice were subjected to 120’ restraint stress. A subset of the stressed 
mice was pre-treated with the mast cell stabilizer cromolyn. As before, acute 
stress resulted in a strong increase in serum corticosterone levels, indicating 
stress responsiveness. Furthermore, we observed a significant decrease in blood 
monocyte and lymphocyte numbers, while the amount of circulating neutrophils 
was not affected by stress. Therefore the relative leukocyte composition in blood 
shifted to an increased percentage of neutrophils and a reduction in lymphocytes 
and monocytes. Pre-treatment with cromolyn did not significantly affect the blood 
leukocyte distribution after stress. (supplemental figure 3). Also, the overall 
inflammatory status of the mice tended to be increased by acute stress exposure, 
as significantly higher serum IL-6 levels were observed in the stressed mice. (21.9 
± 8.0 pg/mL in unstressed versus 94.1 ± 26.9 pg/mL in 120’ stressed mice, 
P=0.015) (figure 1E). 
Acute stress activates cardiac mast cells in close proximity to atherosclerotic 
plaques
Having established that mast cells are indeed activated after a single exposure 
to an acute stressor, we next investigated the effects of acute stress-induced 
mast cell activation in an atherosclerotic setting. Mice were sacrificed three days 
after exposure to the stressor, a time point after which mast cell activation has 
previously been shown to have the most prominent effects on the composition of 
the atherosclerotic lesion15 (supplemental figure 1A). 
In line with our pilot experiment results, 120’ restraint produced a strong stress 
response, indicated by a transient rise in glucocorticoid levels (supplemental 
figure 1B). As expected  three days after a single restraint stress episode, lesion 
size in the aortic root was similar between all three treatment groups (figure 2A). 
At this time-point, we did not observe a significant increase in the percentage of 
activated cardiac mast cells in the stressed mice (figure 2B). 
Decreased lesional collagen content and increased incidence of intraplaque 
hemorrhages. 
As increasing evidence associates both stress and mast cell activation with 
cardiovascular complications such as cardiac ischemia and MI16, we analyzed the 
degree of lesion stability in our animal model. Important features of the vulnerable 
and rupture prone lesion are a decrease in relative collagen content and the 
presence of large necrotic cores.3,17,18 We did not observe significant differences 
in apoptotic cell numbers or relative necrotic core area between stressed and 
unstressed mice. However, collagen content, expressed as percentage of total 
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plaque area, was significantly reduced in aortic root lesions of the stressed mice 
(figure 3A; B). Furthermore, this decrease was not observed in the cromolyn 
treated mice, supporting an, at least partial, mast cell-dependent effect on 
lesion stability. Another hallmark of rupture-prone lesions is the presence of 
intraplaque hemorrhages (IPH).19 In 5 out of 13 mice in the stress group these 
IPH, characterized by the presence of intimal erythrocytes, were observed (figure 
3D). In contrast, only one IPH was detected in the unstressed mice versus two in 
the stressed cromolyn-treated mice. In addition, when we quantified the relative 
area of the intimal erythrocytes, the IPH in the stressed mice were significant 
larger compared to control mice. These results further strengthen the previous 
observations that exposure to acute stress leads to a more vulnerable plaque 
phenotype.
Lack of intraplaque hemorrhages in stressed mast cell deficient mice.
To firmly establish the contribution of mast cells to the stress-dependent effects on 
plaque stability, we next evaluated the effects of acute stress on plaque stability 
in a mast cell deficient mouse model. As we depleted mast cells only just prior to 
the induction of acute stress, the number of mast cells and thus its contribution 
to atherosclerotic lesion development was completely comparable between the 
apoE-/- mice and the RMB mice up to the moment of mast cell depletion at 5 weeks 
of lesion development. This is an advantage compared to often used constitutive 
mast cell-deficient mice models (e.g. Kit(W-sh/W-sh) mice), in which mast cells are 
absent during lesion development and thus affect plaque stability already prior 
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Figure 2. A) Atherosclerotic plaque size in the aortic root of apoE-/- mice was not significantly different 
between the treatment groups. B) Cardiac mast cell number and activation status three days after stress 
exposure.
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to the moment of stress. Interestingly, plasma IL-6 was not detectable in non-
stressed RMB-apoE-/- mice, and only in low amounts upon stress induction (figure 
4A), suggesting that the rise in plasma IL-6 upon acute stress is largely mast cell 
derived. The stress-response itself, based on its effects on blood composition of 
the different leukocyte subpopulations, was similar as compared to the apoE-/- 
mice (supplemental figure 4).
Figure 3. A) Representative pictures of picrosirius red stained aortic root sections. Less dense (collagen) 
staining was observed in the stressed hearts compared to control. The 20x magnification insert 
demonstrates limited collagen and a thin fibrous cap in a plaque of a stressed mouse. B) Quantification 
of the lesional collagen content showed a significant reduction in the stressed mice compared to non-
stressed controls. This effect was not observed in cromolyn treated stressed mice. C) Representative 
pictures of an intraplaque hemorrhage (IPH), displaying erythrocytes inside the atherosclerotic lesion. D) 
Amount and relative percentage of intraplaque hemorrhages in each treatment group. E) Quantification 
of the IPH area demonstrated significantly larger bleedings in the stressed mice compared to the non-
stressed controls. 
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No significant differences in plaque size were observed between the stressed 
and non-stressed RMB-apoE-/-mice, while we also did not observe a significant 
difference in collagen content of the plaques (figure 4B). Strikingly, no intraplaque 
hemorrhages could be detected in any of the aortic root plaques of either the non-
stressed or stressed mice, suggesting that stress-induced plaque destabilization 
is, at least partly, mediated by a mast cell-dependent response (figure 4C).
3
Figure 4. A) Circulating IL-6 in non-stressed and stressed mast cell deficient RMB-apoE-/- mice. B) 
Representative pictures and quantification of the lesional collagen content demonstrating no significant 
difference between the stressed and non-stressed mast cell deficient RMB-apoE-/- mice. C) Amount and 
relative percentage of intraplaque hemorrhages in both treatment groups.
Discussion
In the current study we show that restraint stress, a mouse model for acute physical 
and psychological stress, activates cardiac mast cells which resulted in a more 
unstable atherosclerotic plaque phenotype. Acute cardiovascular syndromes (ACS) 
such as myocardial infarction and stroke remain leading causes of death and warrant 
further research into the physiological and molecular mechanisms contributing to 
these complications of the underlying vascular disease, atherosclerosis. Despite 
much effort and increased insight into the development and morphology of the 
rupture prone atherosclerotic plaque, the triggers of acute cardiovascular events 
remain incompletely understood. Plaque inflammation and degradation of the 
plaque’s fibrous cap are clear prerequisites for plaque rupture and identifying 
risk factors fueling the inflammatory response is key in preventing ACS.20 
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The stress response and its main mediators (glucocorticoids, adrenalin and 
noradrenalin) are among the most potent immune modulatory agents known 
to men. Considerable evidence exist for a detrimental and bi-directional role for 
psychological stress in allergies, asthma and skin diseases.21,22 However, such 
implications for atherosclerosis development and ACS are less well understood. 
In line with previous results showing cardiac mast cell degranulation and histamine 
secretion upon acute stress exposure23, we demonstrate that exposure of 
apoE-/- mice to a single episode of restraint stress (up to 120 minutes in duration) 
significantly increased cardiac mast cell activation in a stress-severity dependent 
manner. Furthermore, acute stress induced a significant increase in serum IL-6 
levels, which was dampened in mast cell deficient mice. While such a mast 
cell dependent pro-inflammatory response has been described previously13, 
it’s implication for atherosclerotic lesion progression was not addressed. In 
the current study, we applied this restraint stress protocol to 6-week WTD-fed 
male apoE-/- mice, which have already established atherosclerotic lesions in the 
aortic root. Analysis of the plaques three days after stress exposure revealed a 
significant reduction in lesional collagen content and an increase in the amount 
of intraplaque hermorrhages in the stressed animals compared to non-stressed 
controls, indicative of an unstable plaque phenotype. Importantly, these stress-
induced effects were reduced in cromolyn-treated mice and abolished in the mast 
cell deficient RMB-apoE-/- mice. 
The immunomodulatory effects of acute and chronic stress are often considered 
contradictory with the acute stress response resulting in immunoprotection (e,g, 
increased bacterial and parasitic resistance, efficient wound healing and vaccine-
induced memory) and chronic stress resulting in immunopathology (e.g. general 
immunosupression followed by a maladaptive stress and inflammatory state).24 As 
such, stress research in relation to cardiovascular disease has focused primarily 
on the detrimental effects of chronic stress. In humans, significant correlations 
have been found between chronic stress induced by job strain or effort-reward 
imbalance and the incidence of coronary heart disease.7 A number of chronic 
stress models in mice have shown the proatherogenic effects of chronic stress to 
be mediated via both the induction of chronic inflammation (IL-6 and CXCL1)25 
and by effecting lipid homeostasis.26 Here, exposure to acute stress induced a, 
possibly mast cell dependent, inflammatory IL-6 response, while not affecting 
plasma lipid levels.
Interestingly, the potential benefit or harm of acute stress-induced enhanced 
immune function also seems to depend largely on the effects on leukocyte 
distribution and the timing between stress exposure and immune activation.27 The 
atherosclerotic plaque represents a continuous site of inflammation in the vessel 
wall and stress-induced local immune cell activation is thus likely to aggravate the 
disease. Mast cells are uniquely located in the perivascular tissue and shoulder 
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regions of the atherosclerotic plaque and are, in concert with other (recruited) 
inflammatory cells capable of inducing lesion progression and destabilization28. 
Previous work from our group and others has demonstrated that mast cell-derived 
mediators such as chemokines, specific proteases (chymase and tryptase) and 
cytokines (IL-6, TNFα) enhance macrophage infiltration, vascular smooth muscle 
cell apoptosis29, collagen degradation30 and overall inflammatory status of the 
plaque9, thereby contributing to a more rupture-prone phenotype. Interestingly, 
the presence and activation status of mast cells in carotid endarterectomy 
specimens was recently shown to associate with the incidence of future adverse 
cardiovascular events.11 Furthermore, a recent literature review indeed showed 
that stress can precipitate acute coronary syndromes and demonstrated an 
important role for coronary mast cell activation through the stress hormone 
corticotropin-releasing hormone as well as other neuropeptides.16 
In conclusion, we here demonstrate that a single episode of restraint stress, is 
sufficient to significantly activate cardiac mast cells, resulting in an increase in 
serum IL-6 and β-hexosaminidase levels. Such acute stress-induced mast cell 
activation in mice with established atherosclerotic lesions significantly affected 
plaque stability by reducing plaque collagen content and by inducing intraplaque 
hemorrhages. Combined these results provide further evidence for the important 
role of mast cells in modulating atherosclerotic plaque vulnerability and highlight 
the acute stress response as a risk factor and therapeutic target.
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Supplemental figure 1. A) Schematic overview of the experimental setup to evaluate the mast cell 
contribution to acute stress-induced cardiovascular complications. B) Stress-induced increase in 
circulating corticosterone level was not affected by cromolyn pre-treatment.
Supplemental figure 2. A) Schematic overview of the experimental setup to evaluate the pro-atherogenic 
stress response in mast cell deficient RMB-apoE-/- mice. B) Cardiac mast cell staining of apoE-/- and DT-
treated RMB-apoE-/- mice, confirming the absence of cardiac mast cells in the inducible knockout model.
Supplemental figure 3. Automated differential cell count analysis of blood from non-stressed, 120’ 
stressed or 120’ stressed mice pretreated with cromolyn apoE-/- mice, showed a significant decrease in 
circulating lymphocytes and monocytes directly after stress exposure suggesting glucocorticoid induced 
cell death and/or recruitment to sites of inflammation. Circulating neutrophil numbers were slightly 
increased in a mast cell dependent manner. *P<0.05, **P<0.01, ***P<0.001
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Supplemental data
3
Supplemental figure 4. Differential cell count analysis of blood from non-stressed and 120’ stressed 
mice mast cell deficient RMB-apoE-/- mice, demonstrated a similar stress-response compared to the 
response observed in apoE-/- mice. Significant decreases in circulating lymphocytes and monocytes 
directly after stress exposure and non-affected neutrophil numbers were observed. *P<0.05, **P<0.01, 
***P<0.001
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Abstract 
Objective: Atherothrombosis is the major cause of myocardial infarction and 
stroke. Rupture or erosion of an advanced atherosclerotic lesion exposes the 
thrombogenic content of the plaque and initiates platelet activation and blood 
coagulation, which can result in a vessel occluding thrombus. Psychological 
stress has been increasingly implicated as a risk factor for atherosclerosis and 
atherothrombotic complications. Here we assessed the effects of acute stress 
exposure on blood composition, coagulation and thrombus formation. 
Methods and Results; 120’ restraint stress in apoE-/- mice resulted in a transient 
but significant reduction in circulating leukocytes and a shift in the relative amount 
of the different leukocyte subpopulations, without affecting platelet and red blood 
cell counts or haematocrit values. Tail bleeding time was significantly increased 
directly after stress and clot retraction was impaired for up to 24 hours after a 
single acute stressor. Acute stress did however not result in platelet activation 
or have a significant effect on FeCl3-induced thrombus formation. In addition, 
we analysed the contribution of mast cell-derived pro-inflammatory and pro-
thrombotic mediators herein by means of mast cell deficient (RMB-apoE-/-) mice. 
A significant proportion of the observed stress-induced increase in circulating 
IL-6 could be attributed to mast cell dependent responses and the stress-induced 
increase in tail bleeding time was not observed in the mast cell deficient mice. 
However clot retraction was similarly affected by stress exposure in the mast 
cell deficient mice compared to controls. Interestingly, while acute stress did not 
contribute to thrombus formation in a FeCl3-induced thrombosis model, mast cell 
deficiency by itself prolonged the time to occlusion.
Conclusion: Combined, our results demonstrate that acute stress exposure causes 
a transient increase in circulating inflammatory markers and a redistribution of 
blood leukocyte subpopulations, in part via the activation of mast cells. However, 
no direct contributing role for the acute stress response to thrombus formation 
could be observed in the current experimental setup, indicating additional factors 
to be involved in stress induced atherothrombic complications.
80  |  Chapter 4
Introduction
Atherothrombosis is defined as the process in which an advanced and unstable 
atherosclerotic lesion ruptures and gives rise to a vessel-occluding thrombus. 
Such atherothrombotic complications, resulting in a myocardial infarction or 
a stroke, are a leading cause of death worldwide. Like atherosclerotic lesion 
development itself, the pathophysiological pathways and mechanisms involved in 
atherothrombosis are complex and multifactorial. In addition to procoagulant and 
thrombogenic factors such as fibrinogen and tissue factor (TF) released from the 
ruptured atherosclerotic plaque, blood composition and blood-borne mediators 
play a pivotal role in this disease process and influence the magnitude and stability 
of the resulting thrombus.1  
Atherosclerosis is a lipid-driven chronic inflammatory disease and vascular 
inflammation is intimately linked to the risk of arterial thrombosis.2 As elegantly 
reviewed by Engelmann and Massberg, thrombosis may be considered the 
pathological deviation of hemostasis and involves two main components, platelets 
and the coagulation system.3 In addition, there is a significant bi-directional 
interaction with cells of the innate immune system, including neutrophils, 
monocytes and mast cells which promote coagulation and the formation of a stable 
clot or thrombus. Previously we and others have demonstrated the importance of 
arterial mast cells in atherosclerotic lesion formation and plaque destabilization.4,5 
Pro-inflammatory and matrix modifying cytokines and proteases released from 
activated (peri)vascular mast cells contribute to the ongoing inflammatory 
response and compromise plaque integrity.6 Furthermore, mast cell also contain 
various vasoactive mediators such as histamine and heparin which affect platelet-
collagen interactions and growth of the thrombus.7 Within the vessel wall, mast 
cell express numerous surface receptors and may be activated by various stimuli 
such as IgE molecules via crosslinking of the FcεR, inflammatory mediators and 
complement factors, lipid mediators as well as neurogenic stimuli.8 
With respect to acute triggers of acute cardiovascular syndromes, the psychological 
stress response is among the most potent endogenous immunomodulatory 
pathways known to men. Acute mental stress, for example outbursts of 
anger9 or exposure to traumatic events10, has been demonstrated to strongly 
associate with the incidence of acute coronary syndromes. Especially, stress-
induced changes in hemostatic factors and inflammatory mediators have been 
suggested to play an important role herein.11 Enhanced platelet activation and 
coagulation may be considered part of the fight-or-flight response aimed at 
preparing the organism for possible injury. However, chronic stress exposure or 
acute stress exposure in a vulnerable individual with advanced atherosclerosis, 
the stress-induced inflammatory response and hypercoagulabililty of the blood 
can result in atherothrombotic complications. The direct impact of acute stress 
4
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on platelet aggregation has been evaluated in humans and multiple animal 
models demonstrating diverse effects on aggregation depending on the stress 
conditions. Especially the duration of stress exposure may be important as a 
recent study demonstrated only chronic, but not acute stress exposure to result 
in enhanced agonist-induced aggregation of mouse platelets.12 As vascular 
inflammation is intimately linked to atherosclerosis progression and the incidence 
of atherothrombotic complications, we focused in this study on stress-induced 
changes in immune cell composition of the blood and circulating pro-inflammatory 
cytokines levels as well as subsequent effects on coagulation and fibrinolysis. With 
the mast cell uniquely located in the vessel wall, packed with pro-inflammatory 
and thrombogenic mediators and previously shown to be activated upon acute 
stress exposure (Lagraauw et al, manuscript in preparation ), we also aimed to 
dissect out mast cell-specific effects to acute stress-induced changes in platelet 
activation, coagulation and thrombosis.
To this end, acute stress was induced in apoE-/- mice and mast cell deficient red 
mast cell and basophil (RMB) apoE-/- mice by means of 2 hour restraint, followed by 
subsequent analysis of blood composition, bleeding time, clot retraction capacity 
and thrombus formation.
Materials and Methods
Animals and acute restraint stress model
All animal work was approved by the Leiden University Animal Ethics committee 
and performed in compliance with the Dutch government guidelines and the 
Directive 2010/63/EU of the European Parliament. 10-12 weeks old male 
apoE-/- mice were obtained from the local animal breeding facility. The inducible 
mast cell deficient red mast cell and basophil (RMB) mice were obtained from 
the lab of Prof. Pierre Launay13 and were backcrossed with apoE-/- mice to obtain 
RMB-apoE-/- mice. In all experiments mice were kept under standard laboratory 
conditions, and administered a Western type diet, containing 0.25% cholesterol 
and 0.15% cocoabutter (SDS, Sussex, UK) 2 weeks prior to stress exposure and 
throughout the experiment. To induce acute stress, mice were subjected to 2 hours 
restraint stress by immobilization in a well-ventilated 50 mL conical centrifuge 
tube. This setup was previously shown to result in a robust stress response as 
indicated by a 10-fold increase in plasma corticosterone levels (Lagraauw et al., 
manuscript in preparation). Directly or 24 hours after the acute stress protocol the 
mice were terminally anaesthetized and sacrificed. Blood was collected from the 
eye, anti-coagulated with 3.8% sodium citrate in a ratio of 1:10 and subsequently 
processed for fluorescence flow cytometry (Sysmex and FACS analysis), clot 
retraction measurement and ELISA. 
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Blood composition
Total white blood cell count, red blood cell count, platelet count, mean platelet 
volume and neutrophil, lymphocyte, monocyte and eosinophil counts in blood 
were analyzed using an automated XT-2000iV veterinary hematology analyzer 
(Sysmex Europe GMBH, Norderstedt, Germany). 
 
Tail bleeding time
Tail bleeding time after acute stress exposure was assessed in anesthetized mice 
by surgical removal of the distal 3-mm segment of the tail. Bleeding time was 
subsequently monitored by absorbing the blood droplets with filter paper at 
15-second intervals, without touching the wound, as described previously.14
Clot retraction
Clot retraction was assessed in anti-coagulated blood diluted 1:20 in HBS (10 
mM HEPES; 150 mM NaCl; 1 mM MgSO4; 5 mM KCl; pH 7.4). After addition of 1 
mM CaCl2 clot retraction was monitored by taking photographic images every 15 
minutes. Clot area was subsequently quantified with ImageJ software (National 
Institute of Health, Washington, DC).
Cytokine analysis
Serum interleukin-6 (IL-6) and macrophage inhibitory factor (MIF) levels were 
determined by ELISA according to manufacturer’s protocol (IL-6 ELISA from BD 
Biosciences, MIF ELISA from R&D Systems).
FeCl3-induced arterial thrombosis model
Western-type diet fed male apoE-/- or RMB-apoE-/-, which were exposed to 120’ 
restraint stress 24 hours or just before FeCl3-induced thrombosis measurement 
and their respective non-stressed controls, were anaesthetized by subcutaneous 
injection of ketamine (60 mg/kg; Eurovet Animal Health, The Netherlands) and 
hypnorm (5%; VetaPharma, UK). Subsequently, the right carotid artery was 
dissected free and equipped with an ultrasonic 0.5 PSB Doppler flow nanoprobe 
and T420-PB-flowmeter (Transonic Systems Europe B.V., Maastricht, The 
Netherlands) and subsequently assessed for stable blood flow. After topical 
application of a 1x2mm filter paper saturated with 20% FeCl3 for 3 minutes, flow 
was monitored until complete occlusion of the vessel was observed. Mice were 
subsequently sacrificed by exsanguination and blood was collected for serum 
cytokine analysis. The occluded carotid artery was harvested for morphometric 
and immunohistochemical analysis.
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Thrombus morphometry and immunohistochemistry
The harvested thrombi were fixed in 4% formaldehyde solution (FormalFix) 
and embedded in O.C.T compound. 10 μm thick transverse cryosections were 
prepared on a Leica CM 3050S cryostat (Leica Instruments, Nassloch, Germany). 
Morphological analysis of the thrombi was performed on hematoxylin-eosin stained 
section. Thrombus collagen content was assessed by picrosirius red (SR; Direct 
Red 80, Sigma-Aldrich) staining and polarized light (PL) microscopy (Leica DM-RE 
microscope and LeicaQwin software, Leica Imaging Systems, Cambridge, UK). 
Statistical analysis
Data are expressed as mean  ± SEM. An unpaired two-tailed Student’s t-test was 
used to compare normally distributed data between two groups of animals. Data 
of three groups were analyzed with one-way ANOVA and data of two groups with 
more than one variable were analyzed by two-way ANOVA, both followed by 
Tukey’s multiple comparison test. A level of P<0.05 was considered significant.
Results
Acute stress-induced changes in blood composition
Exposure to acute stress has been demonstrated to strongly affect blood leukocyte 
distribution and to differentially affect the different leukocyte subpopulations.15,16 
In this study, 120’ restraint stress induced a strong but transient decrease in white 
blood cell count, which was primarily due to significant reductions in the amounts 
of circulating lymphocytes and monocytes (figure 1A). As depicted in figure 1B, 
also the relative blood leukocyte content is drastically changed upon acute stress 
exposure. As described in literature, neutrophils are actually mobilized and indeed 
demonstrate an increase in relative amounts in the circulation. Recent data 
indicate contributing roles for neutrophils17,18 in the induction of arterial and deep 
venous thrombosis, and the relative increase in circulating neutrophil numbers 
seen after acute stress exposure may impact thrombus formation and the stability 
of the developing thrombus.  
Platelet count as well as mean platelet volume, red blood cell count and hematocrit 
levels were not significantly affected by the stress protocol. Interestingly, all stress-
induced changes were completely reversed to baseline (non-stressed control) 
level 24 hours after acute stress exposure. Stress responsiveness, assessed by 
the effects on blood leukocyte distribution, was similar between apoE-/- and the 
mast cell deficient RMB-apoE-/- mice (supplemental figure 1A and B).
Acute stress-induced increase in circulating IL-6 and MIF partly mast cell derived
In addition to a quick rise in circulating levels of the principal stress hormones 
(corticosterone, adrenalin, noradrenalin) primarily released from the adrenal 
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glands, acute stress exposure causes immune cell activation and pro-inflammatory 
cytokine to be released in the circulation. In the context of mast cell-derived 
pro-inflammatory and atherothrombotic mediators we focused on IL-6 and MIF. 
IL-6 has been demonstrate to promote coagulation without affecting fibrinolysis19 
and although many immune cells produce and secrete IL-6, mast cells contribute 
significantly to the amount of circulating IL-6 after acute stress exposure.20 MIF is 
another potent cytokine with a well-established contributing role in atherosclerosis 
progression.21 Furthermore, MIF seems to serve as the endogenous counterpart 
of glucocorticoids to dampen and regulate their potent anti-inflammatory effects 
and thus its circulating levels are strongly affected by the acute stress response.22 
Similar to previous results, 120’ restraint stress resulted in a significant increase 
in serum IL-6 levels, an effect that was dampened in the RMB-apoE-/- mice, 
suggesting that part of the circulating IL-6 to be mast cell derived (figure 2). MIF 
demonstrated a similar secretion pattern after stress in apoE-/- mice. In mast cell-
deficient mice however, acute stress did not significantly increase the circulating 
amount of this cytokine (figure 2). 
4
Figure 1. A) Blood platelet count, red blood cell count (RBC), hematocrit and leukocyte distribution 
directly and 24 hours after acute restraint stress exposure in apoE-/- mice. B) Relative blood leukocyte 
composition after acute stress, demonstrating a significant increase in the percentage of circulating 
neutrophils and decreases in lymphocytes and monocytes.     
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Acute stress exposure increases in tail bleeding time in a mast cell-independent 
manner
To assess the effect of acute stress exposure on hemostasis, a tail bleeding assay 
was performed in 120’ stressed apoE-/- mice and their non-stressed controls. 
Interestingly, bleeding time was significantly increased in stressed mice compared 
to non-stressed controls (376 ± 131 seconds in control mice compared to 718 ± 
306 seconds after acute stress exposure (figure 3)). Previous results from our lab 
indicate the acute stress response as a potent activator of (cardiac) mast cells 
(Lagraauw et al. manuscript in preparation) and the mast cell-derived vasoactive 
mediators, histamine and heparin have been implicated in bleeding abnormalities. 
Therefore, a similar experiment was performed in the mast cell depleted RMB-
apoE-/- mice. In contrast to the results obtained in apoE-/- mice, no acute stress-
induced increase in tail bleeding time was observed in the mast cell deficient mice, 
suggesting an important role for mast cell-derived mediators (e.g. heparin) in 
stress-induced impaired hemostasis.
Figure 2. Serum IL-6 and MIF levels are significantly increased directly after acute stress exposure in 
apoE-/- mice. Basal circulating IL-6 and the stress-induced increase in IL-6 is less prominent in mast cell 
deficient mice. MIF levels were generally higher in the mast cell deficient mice and no apparent stress-
induced increase in circulating MIF could be observed in those mice. *, p<0.05 vs no stress (apoE-/-). 
$$ p<0.01 vs no stress (RMB-apoE-/-).
Figure 3. Acute restraint stress resulted in increased tail bleeding times in apoE-/- mice, but not in mast 
cell deficient apoE-/- mice. *, p<0.05 vs no stress. 
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Acute stress induces a lasting decrease in clot retraction without affecting platelet 
count or activation induced αIIbβ3 expression
Another measure of platelet function and blood coagulation is the clot retraction 
capacity, which is mediated by the interaction of fibrin with platelet integrin αIIbβ3 
resulting in actin and myosin cytoskeleton rearrangements and contraction of 
the platelet-rich fibrin clot. Although platelet number and activation capacity, 
determined by basal αIIbβ3 expression level, did not differ between non-stressed 
control mice and mice, clot retraction upon recalcification was at least partly 
impaired in the stressed mice (figure 4). Interestingly, these effects disappeared 
in time, as clot retraction was normal 4 days after inducing acute stress (data not 
shown). In contrast to the effect on tail bleeding time, no clear mast cell-dependent 
contribution could be observed and clot retraction was similarly impaired in the 
stressed RMB-apoE-/- mice.
4
Figure 4. Acute restraint stress exposure in both apoE-/- and RMB-apoE-/- mice caused a direct and at least 
24h lasting decrease in clot retraction capacity  as indicated by an increased clot area. Clot retraction 
upon recalcification was assessed under non-stresses conditions (-) and directly or 24 hours after 120’ 
stress exposure (+). 
FeCl3-induced arterial thrombosis
To determine acute stress-mediated effects on arterial thrombosis, we applied 
an arterial thrombosis model upon stress induction. Arterial thrombosis primarily 
results from rupture of a destabilized atherosclerotic plaque and exposure of the 
subendothelial matrix which, induces platelet adhesion to the exposed matrix, 
platelet activation, aggregation and blood coagulation. Animal models of arterial 
thrombosis mainly consist of methods to induce vascular damage, either by 
photochemical injury, laser injury or ferric chloride application. Topically applied 
ferric chloride diffuses through the vascular smooth muscle cell layer and results in 
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rapid removal of the endothelial layer without affecting the internal elastic lamina23 
and the resulting thrombi share a strong morphological similarity with the human 
situation. 120’ restraint stressed mice were subjected directly or 24 hours later to 
this FeCl3-induced thrombosis model and compared to non-stressed control mice. 
No significant difference in time to occlusion of the treated right carotid artery nor 
the time between initial drop in blood flow and complete occlusion, the ‘thrombus 
formation time’, could be observed between stressed and non-stressed mice 
(figure 5). As mast cell-derived mediators, including heparin, histamine, chymase, 
typtase and proinflammatory cytokines (e.g. IL-6) could affect the formation of 
a stable clot, we assayed thrombus formation in the mast cell deficient mice. 
Interestingly, mast cell deficiency by itself significantly prolonged the initiation 
of thrombus formation. However, once initiated the thrombus formed similarly 
in the RMB mice. Polarized light microscopy can be used to analyze the fibrin 
architecture and structural integrity of thrombi.24 However, morphological analysis 
of the isolated thrombi did not reveal any striking differences between the groups 
and mouse strains (supplemental figure 2). 
Figure 5. FeCl3-induced thrombus formation in apoE-/- and RMB-apoE-/- mice. A) Representative blood 
flow curve trough the right carotid artery upon FeCl3 application for 3 minutes. Time to initial thrombus 
formation represents the time at which initiation of an eventually occlusive thrombus could be observed, 
while time to occlusion represents total time until vessel occlusion. Thrombus formation time is calcu-
lated from initiation till complete occlusion of the vessel. B-D) While no significant effect of acute stress 
exposure on thrombus formation could be observed, mast cell deficiency did prolong the initiation and 
eventual time till occlusion.
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Discussion
Arterial thrombosis, which primarily occurs upon rupture of destabilized 
atherosclerotic lesions, results in exposure of plaque derived pro-thrombotic 
factors and vessel wall components, which subsequently initiates platelet activation 
and triggers blood coagulation. In line with recently increased appreciation for 
the contribution of psychological risk factors, including stress, to cardiovascular 
disease, we here aimed to demonstrate acute stress-induced changes in blood 
composition and coagulation. 
Exposure of acute stress, by means of 120’ restraint, resulted in significant 
redistribution of blood leukocyte subpopulations in both apoE-/- and mast cell-
deficient RMB-apoE-/- mice. As previously intensively investigated by Dhabhar et 
al15, monocyte and lymphocyte counts were strongly reduced after acute stress 
exposure, while circulating neutrophils amounts were increased. Recent data 
indicate the importance of platelets, monocytes and neutrophils in both arterial and 
deep venous thrombosis17,18, suggesting the possibility of a direct contributing role 
for stress-induced immunomodulation in the development of atherothrombosis. 
In the current study, acute stress was shown to induce a significant increase 
in circulating IL-6 and MIF. IL-6 has demonstrated pro-coagulant effects via 
upregulation of various members of the coagulation cascade (e.g. fibrinogen, 
tissue factor, factor VIII) and to enhance platelet production.19 In contrast, the 
pleiotropic inflammatory cytokine MIF, has recently been reported to delay clot 
retraction.25 
A recent study, evaluating the effects of both chronic and acute stress on platelet 
aggregation demonstrated limited differences in platelet responsiveness after a 
2 hour restraint stress protocol, while chronic stress (2h/day for 3 weeks) did 
significantly enhance agonist-stimulated platelet aggregation. These chronic 
stress-induced changes were blocked in adrenalectomized mice, suggesting 
the contribution of the main stress hormones, corticosterone, adrenalin and 
noradrenaline.12 In our study, exposure to an acute episode of restraint stress 
did not alter platelet counts, mean platelet volume, or agonist-induced platelet 
αIIbβ3 expression. However, tail bleeding time was significantly increased and 
clot retraction was reduced in the stressed mice, suggestive of impaired platelet 
function and/or coagulation. Despite these changes, acute stress in the current 
experimental setting did not result in an increased prothrombotic potential in a 
ferric chloride-induced arterial thrombosis model. Detailed analysis of the thrombi 
may however provide more evidence on the composition and stability of the 
thrombi after acute stress.
Interestingly, severe restraint stress (20 hours) was previously shown to increase 
circulating levels of tissue factor (TF), the main initiator of coagulation, possibly 
accounting for enhanced thrombus formation in that model. This stress-induced 
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effect on thrombus formation could be prevented by chemical sympathectomy, 
suggesting the involvement of the sympathetic nervous system. In contrast to 
our results after 2 hours restraint stress, tail bleeding time was not affected in 
this study. Sympathetic innervation of the vessel wall regulates vasoconstriction 
and dilatation, but also modulates (resident) immune cell responses via the local 
release of various neuropeptides and hormones. Previous results from our lab 
indicate the acute stress response as a trigger of perivascular mast cell activation, 
resulting in increased inflammation and intraplaque hemorrhages (Lagraauw et 
al., manuscript in preparation). Furthermore, mast cell activation has been shown 
to take part in mediating leukocyte recruitment to sites of inflammation and 
vascular damage.26 To dissect out the contribution of mast cells in the observed 
stress-induced increase in tail bleeding time and impaired clot retraction, we 
performed similar experiments in mast cell deficient RMB-apoE-/- mice. While 
blood composition was similar, mast cell deficiency limited the stress-induced 
increase in bleeding times, which is possibly due to a lack in mast cell derived 
heparin, but prolonged thrombus formation. Stress-induced IL-6 levels were 
diminished, identifying a significant proportion of the IL-6 to be mast cell-derived. 
Clot retraction capacity however, was similarly impaired up to 24 hours after acute 
stress exposure, while also thrombus formation time was similar in these mice.
Combined, our results indicate that acute stress significantly affects multiple 
components of the immune and coagulation system, which however did not result 
in an enhanced thrombus formation. Further research may identify more specific 
effects of acute stress on platelet function and aggregation, and may provide 
more evidence of mast cell mediated effects on the coagulation system.
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Supplemental data
Supplemental figure 1. A) Blood platelet count, red blood cell count (RBC), hematocrit and leukocyte 
distribution directly after acute (120’) restraint stress exposure in RMB-apoE-/- mice. B) Relative blood 
leukocyte composition after acute stress, demonstrating a significant increase in the percentage of circu-
lating neutrophils and decreases in lymphocytes and monocytes.
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Supplemental figure 2. FeCl3-induced thrombus morphology and collagen content was assessed in both 
apoE-/- and RMB-apoE-/- mice. No clear morphological differences could be observed between the groups 
and mouse strains. 
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Abstract 
Objective:  Neuropeptide  Y  is  an  abundantly  expressed  neurotransmitter 
capable  of modulating  both  immune  and  metabolic  responses  related  to 
the  development  of atherosclerosis. NPY receptors are expressed by a number 
of vascular wall cell types, among which mast cells. However, the direct effects 
of NPY on atherosclerotic plaque development and progression remain to be 
investigated. In this study we thus aimed to determine whether NPY is expressed 
in atherosclerotic plaques and to establish its role in atherosclerotic plaque 
development. 
Methods and Results: NPY expression was seen to be increased up to 2-fold 
in unstable human endarterectomy plaques, as compared to stable plaques, 
and to be significantly upregulated during lesion progression in apoE-/- mice. In 
apoE-/- mice focal overexpression of NPY in the carotid artery significantly increased 
atherosclerotic plaque size compared to controls, while plaque composition was 
unaffected. Interestingly, perivascular mast cell activation was significantly 
higher in the NPY-overexpressing mice, suggesting that NPY may impact plaque 
progression in part via mast cell activation. Furthermore, in vitro NPY-induced 
murine mast cell activation resulted in the release of pro-atherogenic mediators 
including IL-6 and tryptase.
Conclusion: Our data show that NPY expression is increased during atherogenesis 
and in particular in unstable plaques. Furthermore, perivascular overexpression 
of NPY promoted plaque development and perivascular mast cell activation, 
suggestive of a role for NPY-induced mast cell activation in lesion progression.
96  |  Chapter 5
Introduction
Atherosclerosis is a lipid-driven inflammatory disease characterized by endothelial 
dysfunction, vascular inflammation and deposition of lipids, cholesterol and cellular 
debris within the vessel wall.1 Being the principle cause of myocardial infarction 
and stroke it remains a leading cause of death in westernized society.2 These 
clinical outcomes are generally caused by rupture of an advanced and unstable 
atherosclerotic plaque, leading to a subsequent thrombotic response and luminal 
obstruction. Despite the identification and management of multiple risk factors 
for atherosclerosis, including hyperlipidemia, genetic background, hypertension, 
obesity and smoking, the precise triggers that cause a plaque to rupture remain 
unclear. 
Vessels that are affected by atherosclerotic lesion formation, such as the coronary 
arteries, generally are richly innervated, suggesting a role for the nervous system 
in disease progression and plaque stability.3,4 The idea of neurotransmitters 
influencing vascular tone and remodeling as well as immune functions is generally 
accepted, however the precise implications for atherosclerosis progression are still 
unclear. Sympathetic activity, e.g. due to exposure to a stressor, mediated by its 
transmitters noradrenalin, ATP and neuropeptide Y (NPY) is believed to promote 
atherosclerosis primarily indirectly via vasoconstrictive actions.5 However, more 
recent studies have demonstrated additional actions of NPY in vascular and 
metabolic disease models6 in which NPY acts as a trophic factor on vascular smooth 
muscle cells (VSMC) and endothelial cells7,8 and induces metabolic alterations and 
growth of adipose tissue.9  
Neuropeptide Y is a 36-amino acid long peptide abundantly present in both the 
central and peripheral nervous system, primarily exerting its actions trough 
G-protein coupled Y receptors and is modified by endogenous peptidases such 
as dipeptidyl peptidase IV (DPPIV) into Y2 receptor-specific NPY(3-36).10 NPY has 
also been implicated in modulating innate and adaptive immune responses and 
expression of NPY and its receptors were shown to increase following activation 
of macrophages, granulocytes, T- and B-cells.11,12 The link between NPY signaling 
and cardiovascular complications is further strengthened by the identification 
of several SNPs associated with increased risk of early-onset atherosclerosis13 
and a gain-of-function polymorphism, Leu7Pro7, commonly found in Northern 
European populations which is now associated with hyperlipidemia, accelerated 
atherosclerosis and diabetic retinopathy.14,15 The present insight into the immune 
modulatory actions of NPY during atherosclerotic lesion progression is currently 
mostly limited to descriptive studies evaluating NPY, its receptor system (Y1-Y6) 
and plaque characteristics.16 While providing valuable indications for a pathogenic 
role of NPY in atherosclerosis the direct effects of increased perivascular NPY on 
atherosclerotic plaque progression remain ill-defined.
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In this study we thus aimed to determine the expression levels of NPY during the 
progression of atherosclerosis and establish the effects of increased perivascular 
NPY levels on atherosclerotic plaque development and vascular inflammation.
Materials & Methods
NPY (receptor) gene expression during lesion development in apoE-/- mice
This study was performed in compliance with Dutch government guidelines and the 
Directive 2010/63/EU of the European Parliament. All animal experiments were 
approved by the animal welfare committee of the Leiden University Medical Center 
(approval reference numbers 11106 and 12102). Male apoE-/- mice obtained from 
the local animal breeding facility were fed a Western type diet, containing 0.25% 
cholesterol and 0.15% cacaobutter (SDS, Sussex, UK) two weeks prior to surgery 
and throughout the experiment. Mice were anaesthetized by subcutaneous 
injection of ketamine (60 mg/kg, Eurovet Animal Health, Bladel, The Netherlands), 
fentanyl citrate and fluanisone (1.26 mg/kg and 2 mg/kg respectively, Janssen 
Animal Health, Sauderton, UK). The adequacy of the anaesthesia was monitored 
by keeping track of the breathing frequency and the response to toe pinching of 
the mice. Atherosclerotic carotid artery plaque formation was induced by bilateral 
collar placement as described previously.17 From week 0 to week 8 after collar 
placement every 2 weeks a subset of mice (n=6) was anesthetized and perfused 
with PBS after which both carotid arteries were harvested, snap-frozen in liquid 
nitrogen and stored at -80°C until RNA isolation.18 
RNA isolation and gene expression analysis
Three arteries were pooled per sample (n=3-4), homogenized and total RNA was 
isolated using Trizol reagent according to manufacturer’s instructions (Invitrogen, 
Breda, The Netherlands). RNA was reverse transcribed using M-MuLV reverse 
transcriptase (RevertAid, MBI Fermentas, Leon-Roth) and used for quantitative 
analysis of gene expression with an ABI PRISM 7700 Taqman apparatus (Applied 
Biosystems, Foster City, CA) as described previously19, using the PCR primers 
listed in  supplementary table 1.  
NPY expression profiling in human stable and unstable carotid artery plaques
For NPY expression analysis in human stable (n=9) and unstable (n=12) plaques, 
RNA as well as corresponding paraffin embedded sections were obtained from the 
AtheroExpress Biobank.20 Plaques from all patients in this study were previously 
phenotyped by two independent observers using the following criteria. Fibrous 
plaques low in inflammatory cell and fat content with strong staining for collagen 
and smooth muscle cells were considered stable, while lesions were categorized 
unstable atheromathous plaques if they had strong staining for macrophages and 
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no or minor staining for collagen and smooth muscle cells.21,22,23 Gene expression 
was analyzed as described for mouse gene expression during plaque progression 
using PCR primers listed in supplementary table 1. 
Immunohistochemical analysis of NPY expression in both stable and unstable 
carotid endarterectomy specimens was performed with a rabbit anti-NPY antibody 
(1:1500, Ab30914, Abcam, Cambridge, UK), a goat anti-rabbit IgG poly-HRP 
conjugated secondary antibody (Powervision, Leica, Rijswijk, the Netherlands) 
and Nova-Red (Vector labs, Peterborough, United Kingdom) as enzyme substrate 
resulting in a red-brown color. The negative control to determine the specificity of 
the NPY staining in human endarterectomy specimens was obtained by omitting 
the primary antibody in the staining protocol (supplemental figure 1C).
Lentivirus vector construction and production
To obtain full length cDNA for murine NPY total RNA was extracted from 
mouse brain tissue, obtained from male apoE-/- mice sacrificed by cervical 
dislocation. The cDNAs were amplified using the following primers: forward: 
5’-CCGCCGCTCAGCGACGACTG-3’ and reverse: 5’-GTTTCATTTCCCATCACCA 
CATGGAAGGGT-3’. Primers contained extra Xhol and HindIII restriction sites to 
facilitate cloning into the pRRI-cPPt-CMV-PreSIN vector. Sequencing by means 
of vector specific primers confirmed 100% identity of the inserted NPY gene. 
Virus was produced as described previously24 using transient calcium phosphate 
cotransfection of 293T cells with the LV.Empty or LV.NPY vector together with 
pMDL/RRE, pRSV-REV and pVSV-G. Viral titers were determined as essentially 
described by Sastry et al.25 and modified by Bot et al.26 
In vitro lentiviral NPY overexpression
The overexpression capacity of the lentiviral NPY construct was determined in 
293T HEK cells, the endothelial cell-line H5V and a murine vascular smooth muscle 
cell (VSMC) cell-line. 293T, H5V, VSMC were cultured in a humidified atmosphere 
(5% CO2) at 37°C in Dulbecco’s Modified Eagle Medium (DMEM) containing 10% 
Fetal Bovine Serum (FBS), 2mmol/L L-glutamine, 100U/mL penicillin and 100U/
mL streptomycin (all from PAA, Colbe, Germany). Cells were transduced with 
concentrated LV.NPY for 24h, after which the medium was refreshed and the cells 
incubated for another 36-48 hours. Total RNA was extracted from these cells with 
GTC, reverse transcribed using M-MuLV reverse transcriptase (RevertAid, MBI 
Fermentas, Leon-Roth, Germany) and expression of NPY was measured by qPCR 
on an ABI PRISM 7500 Taqman apparatus (Applied Biosystems, Foster City, CA).
Lentiviral perivascular overexpression of NPY in apoE-/- mice
Local perivascular overexpression of NPY was assessed in the previously described 
carotid artery collar model for accelerated atherosclerosis. 24 male apoE-/- mice, 
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fed a Western type diet throughout the experiment, were equipped with bilateral 
carotid artery collars and treated perivascularly with either an empty (pRRI-cPPt-
CMV-PreSIN)27, designated LV.Empty, n=12) or NPY expression vector (pRRI-
cPPt-CMV.NPY-PreSIN, designated LV.NPY, n=12; 4*108 TU/mouse) in a pluronic 
F-127 gel (25% w/v, 20 µl/mouse, Sigma, Zwijndrecht, The Netherlands). Blood 
samples were taken biweekly from the mice by tail-cut and plasma was obtained 
by centrifugation at 8,000 rpm for 10 min. Levels of total plasma cholesterol 
were measured spectrophotometrically using enzymatic procedures (Roche 
Diagnostics, Almere, the Netherlands). Four weeks after collar placement the 
animals were anesthetized, perfused with PBS and the carotid arteries harvested 
for morphometric and immunohistochemical analysis. 
Plaque morphometry and immunohistochemistry
Harvested carotid arteries were fixed in 4% formaldehyde solution (FormalFix) 
and embedded in O.C.T compound (Tissue-Tek, Sakura Finetek, CA, USA). 
Transverse 5µm cryosections were prepared on a Leica CM 3050S Cryostat (Leica 
Instruments, Nassloch, Germany). Hematoxylin-eosin stained sections of the 
common carotid arteries were used for morphometric analysis. Each vessel was 
assessed approximately 0.5 mm proximal to the collar and the site of maximal 
stenosis was used for morphometric assessment of lesion size and necrotic core 
area (defined as the a-cellular, debris-rich plaque area as percentage of total 
plaque area) using Leica Qwin image analysis software. Immunohistochemical 
analysis of NPY expression was performed with a rabbit anti-NPY (1:1500, #Abcam, 
Cambridge, UK) and goat anti-rabbit poly-HRP conjugated secondary antibody 
(Immunologic, Duiven, The Netherlands). Both positive and negative controls 
were used to determine the specificity of the NPY staining. Mouse brain tissue 
showed clear NPY positivity in the cerebral cortex and cerebellum (supplemental 
figure 1G;H), while no staining was observed in negative control samples of 
collar-induced murine lesions (supplemental figure 1E;F) or mouse brain tissue 
(supplemental figure 1I) in which the primary antibody was omitted. In addition, 
immunohistochemical stainings were performed to assess plaque composition and 
stability. Sections were stained for collagen (picosirius red), macrophages (MOMA-
2) and vascular smooth muscle cells (α-SMA) as described previously.28 Mast cells 
were visualized by chloroacetate esterase staining according to manufacturer’s 
protocol (CAE, Sigma, Germany) and degranulation status was assessed manually 
by bright-field microscopy as described previously.29 A mast cell was considered 
resting when all granulae were maintained inside the cell, while mast cells were 
assessed as activated when granulae were deposited in the tissue surrounding 
the mast cell. All morphometric analyses were performed by blinded independent 
operators (HML and IB).
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NPY-induced mast cell activation
The capacity of NPY to activate murine mast cells was further studied on bone 
marrow derived mast cells (BMMCs) skewed towards either a mucosal-like 
(MMC) or connective tissue-like (CTMC) phenotype. BMMCs were cultured by 
culturing bone marrow cells, obtained from male apoE-/- mice sacrificed by cervical 
dislocation, at a density of 0.25*106 cells in T175 culture flasks (Greiner Bio-One, 
The Netherlands) in RPMI containing 10% fetal bovine serum (FBS), 2 mmol/L 
l-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin and mIL3 for 3 weeks. 
Cells were then stimulated towards a MMC phenotype by continued culture in mIL-
3 containing medium or a CTMC phenotype in complete medium with 300 U/ml 
mIL-4 and 50 ng/ml SCF (PeproTech, Inc., Rocky Hill, NJ) for another week.30 In 
vitro mast cell activation was assessed by 4 hour incubation with NPY-conditioned 
medium obtained from LV.NPY-transduced VSMC or control VSMC conditioned 
medium. Stimulated BMMCs (1*106 cells; n=3 per condition) were centrifuged 
(1500 rpm, 5 minutes) and the releasate was used for further experiments. 
IL-6 and Monocyte Chemoattractant Protein (MCP)-1 levels in the mast cell 
releasate and conditioned medium itself were determined by ELISA according to 
manufacturer’s protocol (eBioscience). In a similar in vitro experimental setup, 
we evaluated skewing of bone marrow-derived macrophages (grown for 7 days 
in RPMI containing 20% fetal bovine serum (FBS), 2 mmol/L l-glutamine, 100 U/
mL penicillin, 100 μg/mL streptomycin and 10ng/ml M-CSF) towards either an M1 
or M2 phenotype by NPY. Four hours after incubation with either NPY or control 
medium (n=3 per condition) cells were harvested and total RNA extracted as 
described previously. M1 and M2 phenotype was assessed by qPCR analysis of 
M1 (ao. CCL2, iNos, TNFα, IL-6) or M2 (ao. IL-10, YM-1, CD206, Arg-1) marker 
gene expression. Primers are listed in supplemental table 1. To further determine 
the NPY concentrations capable of activating murine mast cells, BMMCs (0.5*106 
cells; n=3 per condition) were activated by incubation with compound 48/80 (0.5 
μg/mL, Sigma) or recombinant NPY (10-5M – 10-12M, Tocris Bioscience) for 30 
minutes at 37°C in HEPES-tyrode supplemented with 0.1% fatty acid free bovine 
serum albumin (BSA, Sigma). Stimulated BMMCs (0.5*106 cells) were centrifuged 
(1500 rpm, 5 minutes) and the releasate was used for further experiments. For 
total (100%) content measurements, mast cells were lysed with 10% Triton 
X-100 and untreated control cell supernatant served as 0% release controls. 
β-Hexosaminidase activity was determined by adding 50 μL of releasate to 50 
μL 2 mM 4-nitrophenyl N-acetyl-b-D-glucosaminide (Sigma) in 0.2 M citrate (pH 
4.5) and incubated at 37 °C for 2 hours. After addition of 150 μL 1 M Tris (pH 
9.0), absorbance (optical density, OD) was measured at 405 nm. To measure 
tryptase release after degranulation, 50 μL supernatant was added to 2 mM 
S-2288 (tryptase substrate, Chromogenix, Lexington, USA) in PBS supplemented 
with 100 U/mL heparin. After 2 hours (tryptase) at 37°C, OD405 was measured.
5
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Statistical analysis
Data are expressed as mean ± SEM. A 2-tailed Student’s t-test was used to 
compare individual groups. Non-Gaussian distributed data were analyzed using a 
Mann-Whitney U test. A level of P<0.05 was considered significant.
Results
NPY expression is increased in unstable versus stable human atherosclerotic 
plaques.
As NPY is an abundantly expressed neuropeptide and has well known growth 
promoting and immune modulatory actions on various cells implicated in 
atherogenesis we first assessed the abundance of vascular NPY expression. Plaques 
from all patients in this study were previously phenotyped, enabling the comparison 
between stable and unstable plaques.20 Fibrous plaques low in inflammatory 
cell and fat content with strong staining for collagen and smooth muscle cells 
were considered stable, while lesions were categorized unstable atheromathous 
plaques if they had strong staining for macrophages and no or minor staining for 
collagen and smooth muscle cells. NPY immunostaining in stable and unstable 
carotid endarterectomy specimens revealed NPY positive staining to be primarily 
localized to intimal vascular smooth muscle cell-rich regions in the stable lesions 
(brown staining in figure 1A; B and supplemental figure 1A) and both smooth 
muscle cell- and macrophage-rich areas in the unstable plaques (supplemental 
figure 1B). Interestingly, significantly higher lesional NPY expression could be 
detected in unstable compared to stable plaques (>2-fold, P=0.036, figure 1C), 
thus suggesting that NPY may actively participate in plaque progression.  
               
Vascular neuropeptide Y expression correlates with plaque progression in 
apoE-/- mice.
Next, we measured expression of NPY and its receptors during atherogenesis in 
hyperlipidemic apoE-/- mice. Gene expression analysis both by microarray and 
qPCR showed NPY to be increasingly expressed from week 0 (non-diseased artery) 
to week 8 and the expression maintained a high level till at least 8 weeks after 
initiation of plaque development (figure 1D). We further confirmed the presence of 
NPY by immunohistochemistry and show that similar to the human atherosclerotic 
plaques, lesional NPY (figure 1E and G) colocalized with vascular smooth muscle 
cells (figure 1H) and to some extent with infiltrated macrophages or foam cells 
(figure 1I) . Interestingly, strong NPY positive staining was also observed in neurons 
innervating the perivascular tissue (figure 1F). In vitro analysis of NPY expression 
in several cell types involved in atherosclerosis indeed showed high relative gene 
expression in VSMC and neuronal cell lines as well as in bone marrow-derived 
macrophages (supplemental figure 1D). 
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Perivascular overexpression of NPY during lesion development in apoE-/- mice.
To address the atherogenic potential of increased vascular NPY expression we 
constructed an NPY-expressing lentivirus for perivascular application at the site 
of atherosclerotic lesion formation. Initially, NPY gene transduction was assessed 
in vitro by transducing 293T, VSMC and endothelial (H5V) cell lines with LV.NPY 
followed by mRNA expression analysis, resulting in overexpression of NPY in all 
cell lines tested (supplemental figure 2A).
In vivo, overexpression was assessed by treating apoE-/- mice focally at the lesion 
site with LV.NPY or LV.Empty at the time of collar placement. NPY expression 
was determined two weeks after lentiviral application by qPCR analysis and 
demonstrated a 1.5-fold increase in NPY expression compared to LV.Empty 
treated vessels (supplemental figure 2B). No systemic effects on bodyweight 
5
Figure 1.  NPY gene expression (C) in stable (n=9) and unstable (n=12) human carotid endarterectomy 
specimens, demonstrating NPY expression in the plaque, especially in the medial vascular smooth muscle 
cells (A, B: 100x magnification; brown staining (arrows)). Murine carotid NPY expression was quantified 
during atherogenesis by (D) qPCR (n=3-4 per timepoint) or (E) visualized by immunohistochemical 
staining (arrows, 200x magnification). Perivascular NPY colocalized with neuronal structures 
(F, arrowheads). Higher magnification (1000x) inserts display NPY positive staining (G) to 
correlate with (H) vascular smooth muscle cells (α-SMA) and (I) macrophages (MOMA-2) *P<0.05, 
**P<0.01, ***P<0.001   
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gain, serum cholesterol level or white blood cell levels between the treatment 
groups was observed using this experimental setup (supplementary figure 2C; D). 
After 4 weeks the mice were sacrificed and the atherosclerotic plaques analyzed. 
Morphometric analysis of the carotid lesions revealed a significant increase in 
atherosclerotic area in the NPY-overexpressing mice compared to control (LV.NPY: 
54 ± 9*103 μm2 versus LV.Empty: 31 ± 6*103 μm2, P=0.047, figure 2A; E; F) and 
a concomitant decrease in lumen size (figure 2B). 
Furthermore, medial size was significantly increased in the NPY-overexpressing 
carotids (36 ± 2*103 μm2 versus 30 ± 2*103 μm2, P=0.041, figure 2C) without 
signs of outward remodeling (total vessel area: LV.NPY 142 ± 7*103 μm2 versus 
LV.Empty: 129 ± 4*103 μm2, P=0.370, figure 2D). 
Next, we assessed the composition of the plaques. While the absolute necrotic core 
area showed a trend towards an increase in the NPY group (LV.NPY: 25 ± 6*103 
μm2 versus LV.Empty: 14 ± 4*103 μm2, P=0.097, Figure 3A), the relative necrotic 
area to intima area was similar (LV.NPY: 44.0 ± 4.4 % versus LV.Empty: 37.9 ± 5.1 
%, P=0.365, figure 3A). Furthermore, picrosirius red staining of the carotid artery 
sections revealed no differences in collagen content (LV.NPY: 14.5 ± 2.1 % versus 
LV.Empty: 12.6 ± 1.3 %, P=0.460, figure 3B). As NPY was previously shown to 
have a chemotactic effect on monocytes31, a MOMA-2 staining was performed to 
quantify the amount of infiltrated macrophages. As depicted, the foam cell rich 
areas stained strongly positive without clear differences between both groups 
(16.1 ± 2.9 % versus 17.2 ± 2.8 %, P=0.792) (supplemental figure 3A). 
Figure 2. Advanced plaque formation was induced by semi-constrictive collar placement with addition of 
local perivascular NPY or empty lentivirus treatment in male apoE-/- mice (n=12 per group) fed a Western-
type diet for 4 weeks. (A) LV.NPY treatment significantly increased lesion size and a (B) concomitant 
decrease in lumen area. (C) A small but significant increase in medial area was observed, while (D) the 
total vessel area was similar in both treatment groups. Representative cross-sections of  LV.empty (E) or 
LV.NPY (F) carotid artery lesions stained with hematoxylin & eosin. 100x magnification, *P<0.05
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Another immune cell, which warrants attention when investigating atherosclerotic 
lesion progression and stability, is the mast cell. Previously, we and others have 
shown perivascular mast cell accumulation during atherogenesis and a destabilizing 
role for the mast cell protease chymase.18,29,32 As mast cells contain receptors for 
NPY, the abundant vascular NPY expression and neuronal release of NPY near 
blood vessels may be an important endogenous trigger of mast cell activation 
in the context of atherosclerosis development. Interestingly, while the absolute 
number of perivascular mast cells did not differ between the groups (LV.NPY: 9.5 
± 1.2 MC/mm2 versus LV.Empty: 7.3 ± 1.5 MC/mm2, P=0.29), the amount of 
activated mast cell in the NPY-overexpressing mice, was significantly increased as 
compared to the controls (48.1 ± 4.0 % versus 30.2 ± 6.0 %, P=0.018, figure 4). 
These data thus suggest that NPY may contribute to lesion progression, in part, 
by its capacity to activate perivascular mast cells.
Increased vascular smooth muscle cell NPY expression promotes a proinflammatory 
and proatherogenic environment
We further established the effects of NPY on mast cell function and activation in 
vitro. PCR analysis of MC/9 and connective tissue-like bone marrow-derived mast 
cells (CTMC), the predominant mast cell type in the vessel wall, revealed expression 
of NPY and Y1, Y2 and Y5 receptors on murine mast cells as well (figure 5A). 
Furthermore, in vitro incubation of CTMC with LV.NPY-conditioned VSMC medium 
5
Figure 3. No difference in necrotic core area and relative collagen content of the lesions between LV.NPY 
or LV.Empty treated mice (n=12 per group). (A) Necrotic core area was defined as the a-cellular, debris-
rich plaque area as percentage of total plaque area. (B) Collagen content of the plaque was determined 
by picosirius red staining and polarized light microscopy. 100x magnification
Despite an increase in the medial layer upon NPY-overexpression, the relative 
area of α-actin positive VSMCs in both treatment groups was comparable 
(supplementary figure 3B).    
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induced IL-6, but not MCP-1 release into the medium (figure 5B; C). In addition, 
acute activation (30’) with recombinant NPY caused release of β-hexosaminidase 
and tryptase already at picomolar concentrations with effectiveness compared to 
the positive control compound 48/80. Taken together, these data demonstrate 
that NPY can activate murine mast cells resulting in the release of pro-atherogenic 
mediators. 
Figure 4. (A) Representative sections of perivascular tissue stained with Naphthol AS-D Chloroacetate 
to visualize activated and non-activated mast cells in close proximity to the atherosclerotic vessel. (B) 
Perivascular mast cell activation, but not mast cell number, is significantly increased in LV.NPY treated 
mice compared to controls (n=12 per group). 100x magnification, inserts 400x magnification. *P<0.05
Figure 5. (A) Murine bone marrow-derived mast cells express neuropeptide Y receptors, with Y1R as the 
main receptor expressed in our cultures. Incubation of BMMCs with LV.NPY-conditioned VSMC medium 
resulted in significant IL-6 (B), but not MCP-1 release into the medium (C). Recombinant NPY activates 
BMMCs both at micromolar and picomolar concentrations. D) β-hexosaminidase activity and tryptase re-
lease in the releasate after 30’ activation with NPY. (n=3 per condition) *P<0.05, **P<0.01, ***P<0.001
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Discussion
Neuropeptide Y (NPY) is an abundant neurotransmitter peripherally co-released 
with noradrenaline upon stress and could therefore well be implicated in 
atherosclerotic plaque destabilization. Previously, several SNPs in the NPY gene and 
a gain-of-function polymorphism was associated with increased atherosclerosis in 
human.13,14,15 Furthermore, lesional expression of NPY and its receptors (Y1-6) 
was assed immunohistochemically in patients with peripheral artery disease (PAD) 
and healthy volunteers, demonstrating a 3-fold increase in NPY-positive area in 
PAD.33 
Here, we demonstrate a similar increase in NPY expression in the vessel wall 
during atherogenesis and importantly, that its expression is additionally higher in 
unstable compared to stable lesions and may thus have a contributing effect to 
both lesion progression and destabilization. We now confirm a pathogenic role for 
perivascular NPY by using a lentivirus to overexpress NPY near advanced murine 
carotid artery plaques, which resulted in increased plaque progression. Previously, 
it was established in rats that angioplasty in combination with NPY pellets near the 
injured vessel caused rapid occlusive restenosis, with macrophage rich lesions and 
thrombus formation.6 Similar results were obtained in carotid or femoral artery 
endothelial denudation models in mice, demonstrating decreased restenosis 
upon NPY Y1R antagonism or increased restenosis upon NPY overexpression, 
respectively.13,34 Although valuable, the models used in these studies are 
predominantly injury based and exert their effects via smooth muscle cell 
proliferation resulting in intimal hyperplasia and as such are less representative for 
the complex lesion composition observed in atherosclerotic vessels. In contrast, 
we are the first to show a direct pro-atherogenic effect of NPY in a mouse model of 
shear and flow dependent atherosclerosis, which results in heterogeneous lesions 
more closely resembling human atherosclerotic plaques.17,35 As described before, 
the collar-induced plaques contain lipid and extracellular matrix deposits and 
consist of an acellular necrotic core with well-defined fibrous cap.17 
Interestingly, local NPY overexpression in our model resulted in increased 
perivascular mast cell degranulation, suggesting that NPY-mediated mast cell 
activation may be an underappreciated mechanism by which NPY contributes 
to atherosclerotic plaque progression. In line with these results we and others 
have previously demonstrated that systemic mast cell activation contributes to 
atherosclerotic lesion development.29,32  Mast cell activation was shown to affect 
lesion progression and destabilization in a mast cell-dependent manner at multiple 
locations including the aorta, aortic root32, brachiocephalic artery29, but also collar-
induced carotid artery plaques.36,37 The results obtained in this study indicate that 
NPY may be an effective endogenous mast cell activator, particularly as NPY is 
highly expressed in advanced stages of atherosclerosis, when also the number 
5
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of mast cells that have accumulated within the lesion and perivascular tissue is 
high.4 Furthermore, immunohistochemical and gene expression analysis of NPY 
localization in and near the atherosclerotic lesion suggest  NPY to be primarily 
derived from perivascular neurons and medial vascular smooth muscle cells. 
These results provide further evidence for a role of NPY in triggering mast cells, as 
they also accumulate near the intima-media interface.38
Current literature on NPY-mediated mast cell activation is limited. While earlier 
studies have demonstrated that high (μM) concentrations of NPY potently 
trigger histamine release from isolated human skin mast cells or rat peritoneal 
and dural mast cells, no further characterization of the mast cell releasate was 
described.39,40,41,42 Although specific NPY receptor antagonists were not widely 
available at that time, the use of receptor-specific truncated forms of NPY did not 
conclusively point towards a specific receptor pathway and at high concentrations 
even suggested receptor-independent G-protein activation.39 Various other 
neuropeptides are known to activate mast cells both in a receptor-independent 
and receptor-dependent manner, at high (μM) and low (pM - nM) neuropeptide 
concentrations, respectively.42 Here we show that mouse BMMCs express the NPY 
receptor Y1, and to a lesser extent Y2 and Y5 and release several pro-atherogenic 
mediators including IL-6, tryptase and β-hexosaminidase in response to NPY. 
Whether activation of BMMCs at the different concentrations depends on one or a 
combination of specific NPY receptor types remains to be elucidated. The potent 
release of IL-6 from NPY-stimulated BMMCs is especially interesting, as mast cell 
derived IL-6 and IFN-γ, but not TNFα, were previously shown to be the prime 
factors necessary to restore atherogenesis in mast cell reconstitution experiments 
in mast cell-deficient mice.32 As physiological levels of NPY, both in human43 and 
mice44 seem to be in the high picomolar range to low nanomolar range, activation 
and release of pro-inflammatory mediators at these concentrations is relevant for 
disease progression. Several studies have shown destabilization of atherosclerotic 
lesions by acute mast cell activation, illustrated by increased incidence of 
intraplaque hemorrhaging and vascular smooth muscle cell apoptosis.4,45,36 Here 
we demonstrate that despite an increase in perivascular mast cell activation, no 
apparent differences in collagen content and overall stability of the plaques. This 
may suggest a difference in the pathological effects of acute mast cell activation 
compared to the prolonged presence of mast cell triggers. Furthermore, these data 
are in line with our previous studies, in which systemic mast cell activation also 
resulted in increased plaque progression, while not affecting lesion composition.29 
In contrast to sustained high or accumulating NPY concentrations, acute NPY 
release from sympathetic nerve terminals, for example after exposure to certain 
types of stressors, may induce acute mast cell activation in the vessel wall and 
have an additional impact on plaque stability.  
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Although the proinflammatory mast cell mediator release upon NPY treatment 
seems an attractive mechanisms by which perivascular NPY overexpression 
contributes to atherosclerosis development in our model, we cannot exclude 
additional mast cell-independent effects. In addition to well-described vasopressor 
effects, NPY has been shown to affect monocyte and macrophage function.11,31 
While we did not observe significant differences in relative macrophage content 
of the lesions, functional differences may have been underappreciated.  However, 
in vitro incubation of bone marrow-derived macrophages with NPY, a condition 
which resulted in pro-inflammatory mediator release from mast cells, did not 
skew the expression of several macrophage phenotype markers towards a more 
pro-inflammatory M1 state. The current experimental setup primarily focused the 
effects of NPY to the adventitial side of the carotid artery, thus without systemic 
effects on vascular tone. Therefore, we argue that, if any, possible effects on 
vascular tone and endothelial cells are probably indirectly mediated. 
In conclusion, we here demonstrate that NPY is increasingly expressed during 
human and murine atherosclerosis development with a 2-fold increase in unstable 
compared to stable lesions. Local overexpression of NPY at the site of plaque 
formation resulted in a 70% increase in neointima area, while relative composition 
of the plaques was similar. Importantly NPY overexpression caused a significant 
increase in perivascular mast cell activation, which may be, at least partly, 
responsible for the increased progression of atherosclerosis. In favor of this, we 
demonstrate that NPY induces proinflammatory mediator release from isolated 
mast cells. The above results highlight NPY as an important factor in plaque 
progression and an endogenous trigger of perivascular mast cell activation.  
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Supplemental figure 1.  Representative micrographs of NPY immunohistochemical staining (brown 
color, arrows) in stable (A) and unstable (B) human carotid endarterectomy specimens, demonstrating 
NPY expression in medial vascular smooth muscle cells and lesional macrophages. 200x magnification. (C) 
Human endarterectomy specimen negative control staining without primary antibody. 100x magnification. 
(D) RT-PCR analysis of in vitro NPY expression (n=3 per condition) in vascular smooth muscle cells 
(VSMC), endothelial cells (H5V), neuronal cells (PC12), bone marrow-derived macrophages (BMDM) and 
bone marrow-derived mast cells (BMMC). (E, F) Murine carotid artery plaque negative control staining 
without primary antibody. 200x and 1000x magnification. (G-H) NPY positive control staining of mouse 
brain tissue, demonstrating clear NPY-positive soma and processes. 200x magnification. (I) Negative 
control. nd, not detectable.
Supplemental data
112  |  Chapter 5
Supplemental figure 3. No difference in relative macrophage content and α-smooth muscle cell positive 
area between LV.NPY and LV.Empty treated mice (n=12 per group). (A) Macrophage content of the lesions 
was determined by MOMA-2 staining. 100x magnification. (B) Contractile smooth muscle cell content of 
the medial and intimal layer was determined by α-SMA staining. 200x magnification. 
5
Supplemental figure 2. (A) Lentiviral NPY overexpression (n=3 per condition) was determined in vitro 
in three cell lines, 293T cells, VSMC and the endothelial cell line H5V. (B) In vivo NPY expression in the 
carotid artery was determined 2 weeks after collar placement and lentivirus application, demonstrating a 
45% increase in NPY expression (n=4 per group). (C) No systemic effects on bodyweight, total cholesterol 
or circulating white blood cell levels upon LV. NPY treatment (n=12 per group).
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Supplemental figure 4.  RT-PCR analysis of macrophage M1 (A) and M2 (B) phenotype marker gene 
expression in bone marrow-derived macrophages incubated with control or NPY conditioned medium. No 
significant differences were observed between the two treatments (n=3 per condition).
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Abstract 
Objective: Neuropeptide Y is an abundantly expressed stress–related hormone 
capable of modulating metabolic and immune responses involved in the 
development and progression of atherosclerosis. NPY mediates its effects via 
multiple G-protein coupled receptors (Y1-Y6), which are differentially expressed 
throughout the central nervous system and the periphery. Here we investigated 
the therapeutic potential of systemic NPY Y1, Y2 or Y5 receptor antagonism on 
atherosclerosis development in LDLr-/- mice.
Methods and Results: Gene expression profiles of NPY and its receptors were 
obtained by qPCR analysis of collar-induced atherosclerosis specimens and guide 
wire-induced restenotic carotid arteries. NPY was significantly increased during 
disease progression in both models, while Y1 receptor expression was almost 
completely abolished. Expression of Y2 and Y5 as well as DPPIV was generally 
increased, rendering intervention in Y2 and Y5 signalling of therapeutic interest. 
Systemic treatment of high fat diet-fed LDLr-/- mice with the Y1 (BIBO-3304), Y2 
(BIIE-0246) or the Y5 (CGP-71683) antagonists for 6 weeks resulted in increased 
lesion development, especially in the Y2 receptor antagonist treated mice. 
Changes in triglyceride metabolism in white adipose tissue and a general increase 
in systemic inflammation, e.g. the pro-inflammatory and proatherogenic IL-12 
family cytokines, seem to contribute to the observed increase in atherosclerosis.
Conclusions: NPY and its receptor system is highly involved in a wide array 
of physiological and pathological processes including atherosclerosis. Here we 
provide evidence for a pro-atherogenic effect of chronic systemic NPY receptor 
antagonism acting through both metabolic changes and inflammatory cytokine 
production.
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Introduction
Neuropeptide Y (NPY), a 36-amino acid peptide, is a ubiquitous hormone with well-
established central and peripheral functions, ranging from regulation of energy 
balance to modulation of immune responses. NPY is expressed in the brain and 
peripheral nervous system and acts through multiple G-protein coupled receptors 
(Y1-Y6), which are differentially expressed throughout the body.1 
After its discovery by Tatemoto et al. in 19822, NPY-like immunoreactivity was 
demonstrated in specific areas of the brain, especially the hypothalamic brain 
structures, and peripherally throughout the sympathetic nervous system. Peripheral 
NPY distribution parallels that of tyrosine hydroxylase (TH) and dopamine-beta-
hydroxylase, both rate limiting enzymes in the catecholamine synthesis. NPY 
is often co-stored and co-released with norepinephrine and dopamine. High 
concentrations of NPY were demonstrated in highly innervated tissues, such as the 
heart, spleen, kidney and around blood vessels. The connection with the stress 
response is further strengthened by bidirectional modulation of the expression of 
NPY by glucocorticoids and vice versa.3
The first identified biological function of NPY was its potent vasoconstrictive effect 
on multiple vascular beds, including the cerebral and renal arteries4,5,6 and points 
towards involvement of NPY signalling in vascular homeostasis and disease. 
Extensive work by Zukowska et al. elucidated potent growth promoting properties 
of NPY on vascular smooth muscle cells, endothelial cells and adipocytes. Signalling 
through its Y1 or Y2 receptor was demonstrated to induce vascular smooth muscle 
cell and endothelial cell proliferation contributing to angiogenesis.7,8 Furthermore, 
the NPY-NPY2R system was shown to be involved in stress-induced augmentation 
of obesity and metabolic syndrome by stimulation adipogenesis, as well as white 
adipose tissue inflammation and angiogenesis.9
While all animals express NPY and its receptors, clear species differences exist. 
For example, the Y4 receptor is found in rodents and has high affinity for the 
NPY-related peptide PP but is not found in humans. The Y6 receptor is expressed 
in many species except the rat and only in a truncated form in various primates, 
including humans.10 In addition, the different receptors have different binding 
preferences for NPY-family members and truncated forms of the NPY protein. A key 
enzyme involved in the proteolysis of NPY is the abundantly expressed dipeptidyl 
peptidase IV (DPPIV) cleaving NPY into NPY3-36, which lacks Y1 receptor affinity 
and thus shifts the responses towards Y2- and Y5 receptor mediated effects. High 
vascular expression of NPY is considered to be pro-atherogenic. A gain-of-function 
mutation in the preproNPY gene strongly correlates with increase intima media 
thickness11 and increased expression of NPY and the Y1, Y2 and Y5 receptors was 
demonstrated in patients with peripheral artery disease in the carotid or femoral 
arteries by means of immunohistochemical stainings.12 In addition, NPY signalling 
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was shown to be intimately linked to stress induced accelerated atherosclerosis 
in various animal models.12,13,14 Furthermore, we recently indicated plaque NPY 
to be associated with plaque vulnerability and NPY-induced mast cell activation 
as a contributing mechanism to atherosclerosis development.15 Like mast cells, 
many, if not all, cells of the immune system express functional NPY receptors. 
For example, NPY induced polarization of T cell responses16 and pro-inflammatory 
cytokine production by macrophages17 are likely mechanisms involved in NPY-
mediated accelerated atherosclerosis.
With respect to NPY receptor antagonism in atherosclerosis, the main focus 
has been on the Y1 receptor-mediated vasoconstrictive and growth promoting 
properties, mostly in concert with Y5. Accelerated angioplasty-induced restenosis 
by local NPY treatment was shown to be completely blocked continuous infusion 
with H409/22 or CGP71683, which are Y1 or Y5 receptor antagonists, respectively.13 
Similar beneficial results were obtained in a restenosis model in apoE-/- mice by 
BIBP-3226 treatment, another Y1 receptor specific antagonist.18 In contrast, a 
recent study evaluating systemic Y1 receptor antagonism in apoE-/- mice fed 
a high fat diet, a model of atherosclerosis rather than restenosis, surprisingly 
demonstrated accelerated atherosclerosis in NPY and Y1 receptor antagonist 
treated mice.19 Mainly pro-atherogenic inflammatory IL-12 production and possibly 
increased leptin secretion was thought to result in increased atherosclerosis under 
hyperlipidemic conditions.
Considering the proatherogenic effects of NPY, and the vascular expression of the 
different NPY receptors and differential expression at specific stages of human 
disease progression20, we aimed to determine NPY receptor expression during 
the development and progression of atherosclerosis and subsequently evaluate 
the therapeutic potential of systemic Y1, Y2 or Y5 receptor antagonism in the 
prevention of atherosclerosis.
Materials and Methods
Neuropeptide Y and receptor expression during atherosclerosis development and 
restenosis
All animal studies were performed in compliance with Dutch government guidelines, 
the Directive 2010/63/EU of the European Parliament and were approved by 
the animal welfare committee of the Leiden University Medical Center (approval 
reference number 12102). Diet and water were provided ad libitum.
To determine the gene expression profiles of NPY, Y1R, Y1R, Y1R and DPPIV 
during atherosclerotic lesion progression apoE-/- mice were put on Western type 
diet containing 0.25% cholesterol and 15% cacao butter (SDS, Sussex, UK) and 
equipped with bilateral semi-constrictive collars (2mm long, 0,3mm in diameter) 
around the left and right common carotid artery as described by von der Thusen et 
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al.21  Before and at 2 week intervals after collar placement, 6 mice were sacrificed 
and the carotids isolated for gene expression analysis. Total RNA was extracted 
from 3 pooled carotids (n=4 per timepoint) with the guanidium thiocyanate-
phenol-bromochloropropane extraction method22 and RNA concentration, purity 
and integrity were examined by nanodrop (Nanodrop® Technologies). RNA was 
reverse transcribed by M-MuLV reverse transcriptase (RevertAid, MBI Fermentas, 
Landsmeer, The Netherlands) and used for quantitative PCR analysis with an 
ABI PRISM 7700 Taqman apparatus (Applied Biosystems). Murine HPRT, RPL27, 
Gusb and 36B4 were used as standard housekeeping genes. qPCR primer pairs 
are given in supplemental table 1. A similar setup was used to determine the 
gene expression of NPY and its receptors during progression of restenosis using 
a wire-induced denudation model as described previously.23,24 In short, the right 
carotid artery was dissected free and denudated using a 0.36-mm guide wire, 
which results in a proliferative VSMC-rich lesions within 4 weeks. Before and every 
week after denudation 6 mice were sacrificed and the carotids isolated for gene 
expression analysis.
Systemic NPY receptor (Y1, Y2 or Y5) antagonism during atherosclerosis 
development
To study the effect of NPY receptor antagonism on atherosclerosis development 
we fed low-density lipoprotein receptor deficient (LDLr-/-) mice a Western-type 
diet (WTD) for eight weeks. Mice were obtained from the local animal breeding 
facility (Gorlaeus Laboratories, Leiden, The Netherlands) and treatment groups 
were randomized based on age and weight at the start of the experiment. After 2 
weeks on WTD and onwards mice were injected i.p. three times a week with 100ul 
PBS (1% DMSO), Y1 receptor antagonist BIBO-3304 trifluoroacetate (400μM; 
#2412; Tocris Bioscience, Ellisville, MO, USA), Y2 receptor antagonist BIIE-
0246 (350μM; #1700; Tocris Bioscience) or Y5 receptor antagonist CGP 71683 
hydrochloride (750μM; #2199; Tocris Bioscience). Bodyweight, serum cholesterol 
and triglyceride levels were checked regularly throughout the study. Hematological 
parameters (including white blood cell count and leukocyte subpopulations) 
were analyzed using an automated XT-2000iV veterinary hematology analyzer 
(Sysmex Europe GMBH, Norderstedt, Germany). After 6 weeks of treatment, mice 
were anaesthetized by subcutaneous injection of ketamine (60 mg/kg, Eurovet 
Animal Health, Bladel, The Netherlands), fentanyl citrate and fluanisone (1.26 
and 2 mg/kg, respectively, Janssen Animal Health, Sauderton, UK). Adequacy of 
anaesthesia was monitored by regular visual inspection and toe pinch reflex. Mice 
were exsanguinated via orbital bleeding and in situ perfused with PBS after which 
the hearts were excised and stored in 3.7% neutral-buffered formalin (Formal-
Fixx, Shandon Scientific Ltd., Runcorn, UK) for further analysis. 
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Histological analysis and morphometry
To determine plaque size, serial 10 µm cryosections of the aortic root were cut using 
a Leica CM3050S cryostat and stained with Oil-Red-O and hematoxylin (Sigma-
Aldrich, Zwijndrecht, The Netherlands). Plaque size was analyzed in 5 consecutive 
sections, starting at the point where all three aortic valve leaflets first appeared, 
with a Leica DM-RE microscope and LeicaQwin software and represented as mean 
plaque area and total plaque volume (AUC). Corresponding sections on separate 
slides were stained with a macrophage specific antigen (MOMA-2, monoclonal rat 
IgG2b, Serotec, Raleigh, NC, US) and alkaline phosphatase conjugated secondary 
antibody (Sigma-Aldrich). A Masson’s trichrome (Sigma-Aldrich) staining was 
performed to analyze plaque collagen content and necrotic core area, which 
was defined as the a-cellular, debris-rich plaque area. Macrophage, collagen and 
necrotic core area were measured as percentage of total plaque area. Medial and 
intimal vascular smooth muscle cell content was determined by α-smooth muscle 
cell actin staining (Sigma-Aldrich). Mast cells were visualized with a naphthol 
AS-D chloroacetate esterase staining kit (Sigma-Aldrich) and counted manually. A 
mast cell was considered resting when all granula were maintained inside the cell, 
while mast cells were assessed as activated when granula were deposited in the 
tissue surrounding the mast cell. All morphometric analyses were performed by 
blinded independent operators.
Spleen and liver RNA isolation and gene expression
At sacrifice spleen and liver tissue were isolated, immediately snap frozen in liquid 
nitrogen and stored at -80°C until RNA isolation. After tissue homogenization with 
a Potter tissue homogenizer Total RNA was extracted, reverse transcribed and 
used for gene expression analysis as described above. 
Serum cholesterol and triglyceride levels
Serum concentrations of total cholesterol and triglyceride were determined by 
enzymatic colorimetric assays (Roche Diagnostics, Mannheim, Germany) in 96- 
well plates (Greiner Bio-One, Alphen aan den Rijn, The Netherlands). Precipath 
(standardized serum, Roche Diagnostics) was used as internal standard in the 
cholesterol and triglyceride assay.
Statistical analysis
Data are expressed as mean ± SEM. An unpaired two-tailed Student’s t-test was 
used to compare normally distributed data between two groups of animals. Data 
of three groups were analyzed with one-way ANOVA and data of two groups with 
more than one variable were analyzed by two-way ANOVA, both followed by 
Tukey’s multiple comparison test. A level of P<0.05 was considered significant.
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Results
Differential expression of NPY and its receptors during atherosclerosis and 
restenosis
To investigate the involvement of NPY signaling through its G-protein coupled 
receptors Y1, Y2 or Y5, in atherosclerotic lesion development we first determined 
gene expression levels in two different vascular disease models (i.e. a collar-
induced atherosclerosis model and a wire-induced denudation model of 
restenosis). Atherosclerotic lesions were induced in apoE-/- mice fed a Western-
type diet by means of bilateral collar placement. Similar to previously published 
microarray results15, expression of NPY was significantly increased during 
atherosclerotic lesion development (figure 1A). Interestingly, while Npy1r was 
highly expressed in healthy carotid arteries, its expression was almost completely 
abolished upon disease initiation and remained low during the whole experiment. 
Expression of Npy2r and Npy5r fluctuated but was generally higher in advanced 
atherosclerosis. Interestingly, DPPIV expression was highly induced and mirrored 
the effect on expression of the Y1 receptor, possibly further inducing NPY signaling 
via the Y2 and Y5 receptors. As NPY is known to have potent vasoconstrictive 
and angiogenic properties, we analyzed the expression NPY and its receptors 
in restenotic vessels, which is a primarily VSMC proliferation-driven process, in 
contrast to atherosclerosis, which is known to mainly be macrophage- and lipid-
driven. Strikingly, the expression profiles were very similar to the atherosclerotic 
lesions, with increased NPY expression especially at later stages of the disease 
and a severe reduction in Npy1r expression (figure 1B). In contrast to the 
atherosclerotic lesions, Npy2r and Npy5r expression was initially reduced after 
endothelial denudation, but recovered gradually to baseline expression levels at 
4 weeks. 
Effects of systemic NPY receptor antagonism on bodyweight, cholesterol and 
triglyceride homeostasis and glucocorticoid levels.
The differential expression of the NPY receptors on various tissues and cell 
types involved in atherosclerosis combined with the expression profiles during 
atherosclerosis development prompted us to investigate the effects of Y1, 
Y2 and Y5 receptor antagonists in an atherosclerotic mouse model. To induce 
atherosclerosis we fed male LDLr-/- mice a high cholesterol diet for 8 weeks combined 
with systemic antagonist treatment for the Y1, Y2 or Y5 receptor. As  central 
NPY is a potent orexigenic hormone, mediating appetite, hepatic triglyceride (TG) 
secretion and TG storage in white adipose tissue25,26, we determined bodyweight, 
total cholesterol and triglyceride levels throughout the study. No apparent effect 
of the antagonist on bodyweight or serum cholesterol could be observed (figure 
2A; B), however plasma triglyceride levels were significantly elevated at 4 weeks 
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of Y1 treatment (figure 2C). As previous research indicated the effect of central 
NPY infusion on TG levels to act within 2 hours, we determined plasma TG levels 
1,5 hour after injection with the antagonists. A significant increase in plasma TG 
levels upon Y1 and Y5, but not Y2 receptor antagonism could be observed (figure 
2D). NPY is co-released with catecholamine and glucocorticoids during stress 
and NPY receptor expression is abundant on the adrenal glands.27 To account 
for the possible contribution of changes in circadian levels of glucocorticoids, 
we measured morning and late afternoon plasma corticosterone levels after 5 
weeks of receptor antagonist treatment. As depicted in figure 2E, no significant 
differences in circulating hormone levels could be observed.
Figure 1. Gene expression levels of NPY, its receptors Y1, Y2, Y5 and peptidase DPPIV the during (A) 
carotid artery atherosclerosis progression induced by semi-constrictive collar placement and (B) carotid 
guide wire-induced restenosis.
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Chronic NPY receptor antagonism during atherosclerotic lesion progression.
In our study we monitored circulation levels of the main leukocyte subpopulations 
(i.e. neutrophils, lymphocytes, monocytes and basophils) during systemic 
antagonist treatment. We observed limited effects on these cell populations 
(supplemental figure 1), only Y5 antagonism reduced neutrophil monocyte 
numbers at two weeks of treatment and  Y2 antagonism significantly increase the 
neutrophil count at sacrifice, after 6 weeks of treatment. 
Next we analyzed the atherosclerotic plaque burden in the aortic root by means 
6
Figure 2. A) Bodyweight throughout the experiment. Mice were put on Western type diet t = -2 weeks 
before the start of NPYr antagonist treatment at t = 0. B) Total serum cholesterol levels at 2 week 
intervals during the treatment period. C) Plasma triglyceride levels at two week intervals during the 
antagonist treatment period. Significant increase in TG levels at 4 weeks of Y1 receptor antagonist 
treatment compared to control. D) Plasma triglyceride levels 1,5 hour after antagonist injection at 5 
weeks of treatment. E) Plasma corticosterone levels in the resting (early morning) and active phase (late 
afternoon). P <0.05 vs control treatment is considered significant.
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of Oil-red-O staining of histological sections. While all antagonist-treated mice 
appeared to have a higher plaque burden compared to control (1% DMSO) mice, 
only the Y2 treated mice had statistically significant larger plaques (figure 3A; 
1.4-fold increase). In addition to plaque burden, lesion stability or vulnerability to 
erosion or rupture is an important measure of disease progression and strongly 
correlates with clinical outcome. We determined lesion stability by quantifying the 
macrophage and collagen content of the plaque, as well as and the necrotic core 
area. The amount of intimal macrophages (as percentage of total plaque area) 
was significantly reduced in Y1 and Y2 antagonist treated mice (Figure 3B). 
As most lesions were early lesions, intimal collagen deposition was limited and 
not significantly different between treatment groups (figure 4A). Also the amount 
of necrosis was not significantly different, although appeared somewhat more 
Figure 3. A) Atherosclerotic lesion formation in the three valve area of the aortic root was assessed by 
Oil-red-O staining. B) Macrophage content of the lesions as determined by MOMA-2 staining and depicted 
as percentage of lesion area. 
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prominent in the larger lesions of Y2 antagonist treated mice. Intimal smooth 
muscle cells, measured by α-smooth muscle staining, were decreased by Y2 
antagonist treatment (2.41 ± 0.006% vs 4.43 ± 0.007% in control mice) and 
demonstrated a trend towards a decrease in the media of Y2 and Y5 antagonist 
treated mice (figure 4B). Combined, the morphological analysis at least partly 
confirm the pro-atherogenic effect of systemic Y1 receptor antagonism, but 
provides additional evidence for an even more pronounced pro-atherogenic role 
for Y2 receptor antagonist treatment. 
6
Figure 4. A) Collagen content of the atherosclerotic lesions in the three valve area of the aortic root was 
assessed by Masson’s trichrome staining as percentage of total lesion area. B) Intima and media vascular 
smooth muscle was determined by alpha smooth muscle actin staining and represented as percentage of 
the intima or media area.
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Mast cell accumulation upon systemic Y2 receptor antagonist treatment.
Previous results from our lab have implicated NPY-induced perivascular mast cell 
activation as a potential contributing factor to atherosclerotic lesion development.10 
To evaluate the effect of systemic NPY receptor antagonist treatment on perivascular 
mast cell responses we quantified the amount of cardiac mast cells in the aortic 
root sections and determined their activation status. A trend towards more mast 
cells in the Y2 antagonist treated mice (p=0.055) could be observed (figure 5A). 
However, the percentage of activated mast cells was similar between treatment 
groups (figure 5B), suggesting the increased number to primarily reflect the more 
advanced and inflamed plaque in the Y2 antagonist mice. 
Figure 5. A) Mast cells were visualized and scored by naphtol AS-chloroacetate staining. B) Activation 
status is illustrated by the presence of granules in the surrounding tissue.
NPY receptor antagonist induced changes in the pro-atherogenic IL-12 cytokine 
family.
Earlier data on systemic Y1 receptor treatment indicated an important role for the 
pro-inflammatory cytokine IL-12 in mediating the increase in atherosclerosis.19 
To evaluate the contribution of the IL-12 cytokine family, we determined the 
expression levels of p40, p35, p19, p28 and Ebi3 in the liver and spleen. The IL-
12 subunits p40 and p35 were not significantly altered by antagonist treatment, 
however we did observe a significant reduction in p35 expression in the liver after 
Y5 antagonist treatment. The observed changes in gene expression in correlated 
to some extent with the circulating levels of IL-12 at sacrifice, demonstrating 
higher levels in the Y1 and Y2 treated mice and a reduction upon Y5 antagonist 
treatment (Suppl fig. 2A; top left panel). Interestingly, expression of Ebi3, which 
in complex with p28 forms the proatherogenic cytokine IL-2729, was significantly 
higher in the Y1 treated mice and trended towards higher expression in the Y5 
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mice. Liver expression levels of Ebi3 were similarly increased in Y1 antagonist 
treated mice, but reduced in Y5 treated mice. (supplemental figure. 2B)
Discussion
Atherosclerosis and its clinical manifestations remain a leading cause of death 
and an enormous burden on society. Both metabolic- and immune-dysregulation 
are key pathological processes involved in atherosclerotic lesion development 
and progression. In addition, increased recognition is given to the brain-immune 
and brain-gut axis in contributing to various diseases, including cardiovascular 
disease. Neuropeptide Y is an abundant (stress-related) hormone with variety 
of known functions both in health and disease. Being co-released with and 
potentiating the effects of norepinephrine and ATP released from sympathetic 
neurons innervating for instance the vasculature, NPY has been shown to be pro-
atherogenic and responsible for mediating stress-induced accelerated restenosis 
and atherosclerosis.30
In the current study we investigated the therapeutic potential of systemic 
NPY receptor antagonism of each of its three main receptors, Y1, Y2 and Y5 
in atherosclerosis. First, expression of NPY and its receptors was assessed in 
atherosclerotic and restenotic carotid artery specimens. As previously reported 
by us and others, NPY expression was significantly increased in atherosclerotic 
arteries. Similar to expression levels observed in human carotid endarterectomy 
specimens20, Npy1r receptor expression was significantly reduced upon disease 
initiation, which possibly questions the usefulness of Y1 receptor antagonism. 
However, contrasting data demonstrating increased expression of all three NPY 
receptors in the carotids and femoral arteries of patients with peripheral artery 
disease compared to healthy iliac arteries also exist.12 In our study, Npy2r and 
Npy5r expression was generally increased and combined with the strong induction 
of DPPIV may suggest a shift towards Y2 and Y5-mediated effects.
Morphological analysis of the plaque burden in the aortic root after 6 weeks of NPY 
receptor antagonist treatment revealed a significant increase in plaque size in the 
Y2 receptor antagonist treated mice. In fact, also Y1 and Y5 receptor antagonism 
showed a trend towards more advanced lesions. Although the amount of circulating 
monocytes, or any of the other main white blood cell subpopulations, was not 
significantly altered during the treatment period, plaque macrophage content was 
significantly decreased by Y1 and Y2 antagonist treatment. Whether this is a 
direct effect on macrophage function or on monocyte recruitment via changes 
in endothelial adhesion molecule expression requires addition research. In vitro 
neutrophil and monocyte adhesion to human umbilical vein endothelial cells was 
previously shown to be significantly increased upon incubation with NPY31 and 
NPY has been shown to have a variety of stimulatory and inhibitory functions on 
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macrophages and T cells via its different receptors.16, 17
We and others previously observed increased NPY expression in vulnerable 
atherosclerotic lesions compared with stable lesions, suggesting the involvement 
of NPY in lesion destabilization.15,20 In line with previous results obtained with 
local Y1 receptor antagonism in an endothelial denudation model18, systemic 
administration of NPY receptor antagonists did not result in a significant 
difference in collagen content nor a difference in necrotic core area of the 
plaques between the treatment groups. However, lesions were relatively small 
and primarily foam cell-rich lesions, which generally lack a clear collagen rich 
cap or intimal necrosis. Furthermore, no extensive differences in VSMC content 
of the lesions was observed except for a significant decrease in intimal α-SMA 
staining in the Y2 antagonist treated mice and a trend towards a decrease in 
the Y5 receptor antagonist treated mice. Previous results from restenosis models 
actually observed reduced intimal hyperplasia upon antagonism of the Y1 or Y5 
receptor or both receptors combined13,18, resulting of reduced smooth muscle cell 
proliferation. Lack of such effects in our atherosclerosis model may be reflect the 
strongly reduced Y1 receptor expression and relative initial, and thus smooth 
muscle cell poor, lesions. Perivascular mast cell activation and IL-6 secretion was 
previously shown to contribute to NPY-induced accelerated lesion development 
in apoE-/- mice15, suggesting the potential anti-inflammatory benefit of NPY 
receptor antagonism. However, in line with an overall increase in atherosclerosis 
progression and inflammation in the Y2 receptor antagonist treated mice, mast 
cell numbers were actually increased in the cardiac tissue surrounding the aortic 
root without significant differences in activation status. Interestingly, plasma 
triglyceride levels were transiently increased at 4 weeks of Y1 receptor antagonist 
treatment and especially elevated shortly (1,5h) after both Y1 and Y5 antagonist 
injection. Previous results on acute central NPY infusion demonstrated increased 
food intake and triglyceride secretion in rats mediated via the Y1 receptor.32 In 
mice however, NPY administration increased food intake without affecting hepatic 
VLDL-TG production. Whether the observed increase in TG secretion in our model 
reflects central modifications or peripheral effects deserves further investigation.
In agreement with previous results demonstrating an increased systemic 
inflammatory response upon Y1 receptor antagonism, splenic and liver expression 
of subunits of the pro-inflammatory cytokine IL-12 family were increased in the 
Y1 and Y5 treated mice and somewhat reflected in increased circulating level of 
IL-12 p70. Interestingly, especially Ebi3, which in complex with p28 form the 
atherogenic cytokine IL-27, was significantly increased by systemic Y1 receptor 
antagonism, suggesting the potential proatherogenic effect of Y1 antagonism to 
be mediated by multiple IL-12 family members. Of note, Y2 receptor antagonism 
did not affect the IL-12 cytokine family similarly, suggesting other mechanisms 
to account for accelerated atherosclerosis in those mice. The limited data on the 
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effects of Y2 signaling points toward its involvement in monocyte migration33 and 
angiogenesis34, which do not necessarily explain the increase in atherosclerosis 
observed here. Interestingly, recent clinical trial data of DPPIV antagonist use for 
glycemic control in T2DM patients indicated increased heart failure upon long-
term use.35  While NPY signaling was not evaluated, reduced signaling via the Y2 
receptor may be a contributing factor.
In conclusion, our data provides further insight in the intricate role of NPY and its 
widely expressed receptor system in atherosclerosis development and progression. 
In contrast to the beneficial effects local application of Y1 receptor antagonists at 
sites or restenosis, systemic Y1, Y2 and Y5 receptor antagonism in a hyperlipidemic 
atherosclerosis model resulted in increased lesion development. Here, especially 
Y2 receptor antagonism increased lesion progression resulting in a more advanced 
state of the lesions in those mice. In light of recent detrimental cardiovascular 
side effects of long term DPPIV inhibitor treatment in T2DM patients35,36, systemic 
modulation of the NPY-receptor system should be approached with caution and 
further research especially into pathological mechanisms of Y2 receptor signaling 
is warranted. 
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6
Supplemental data
Supplemental figure 1. Relative blood leukocyte composition at two week intervals after the start of 
antagonist treatment, demonstrating no clear systemic effects on leukocyte subpopulations in blood.
Supplemental table 1: qPCR primers
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Supplemental figure 2. Gene expression of IL-12 family subunits in A) spleen and B) liver after 6 weeks 
of systemic NPY receptor antagonist treatment.
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Abstract 
Objective: Activated mast cells have been identified in the intima and perivascular 
tissue of human atherosclerotic plaques. As mast cells have been described to 
release a number of chemokines that mediate leukocyte fluxes, we propose 
that activated mast cells may play a pivotal role in leukocyte recruitment during 
atherosclerotic plaque progression. 
Methods and Results: Systemic IgE-mediated mast cell activation in apoE-/-μMT 
mice resulted in an increase in atherosclerotic lesion size as compared to control 
mice, and interestingly, the number of neutrophils was highly increased in these 
lesions. In addition, peritoneal mast cell activation led to a massive neutrophil 
influx into the peritoneal cavity in C57Bl6 mice, whereas neutrophil numbers in 
mast cell deficient Kit(W-sh/W-sh) mice were not affected. Within the newly recruited 
neutrophil population, increased levels of CXCR2+ and CXCR4+ neutrophils were 
observed after mast cell activation. Indeed, mast cells were seen to contain and 
release CXCL1 and CXCL12, the ligands for CXCR2 and CXCR4. Intriguingly, 
peritoneal mast cell activation in combination with anti-CXCR2 receptor antagonist 
resulted in decreased neutrophil recruitment, thus establishing a prominent role 
for the CXCL1/CXCR2 axis in mast cell-mediated neutrophil recruitment. 
Conclusions: Our data suggest that chemokines, and in particular CXCL1, 
released from activated mast cells induce neutrophil recruitment to the site of 
inflammation, thereby aggravating the ongoing inflammatory response and thus 
affecting plaque progression and destabilization. 
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Introduction
Acute cardiovascular syndromes such as myocardial infarction and stroke remain 
the principal cause of death in western society despite increasing insight in the 
mechanisms of atherosclerosis, which is the main underlying cause of disease.1 
Atherosclerosis has been identified as a lipid-driven inflammatory disorder, in 
which various immune cells such as monocytes, macrophages but also mast cells 
and neutrophils have been implicated.2,3 Although statin treatment has reduced 
the risk of acute cardiovascular events by its lipid-lowering and anti-inflammatory 
effects4, this treatment is still insufficient for 70% of the patients, thus establishing 
the need for further research to obtain new therapeutic leads.
The mast cell, a potent inflammatory innate immune cell, is mainly known for its 
role in allergy and asthma. Nowadays, the mast cell is regarded detrimental in 
the development of atherosclerosis and acute cardiovascular syndromes as well. 
For example, we and others have previously established that mast cells induce 
atherosclerotic plaque growth and destabilization in a number of different mouse 
models of atherosclerosis.5,6 In human atherosclerotic plaques, mast cell presence 
has been established7,8 and more importantly, mast cell numbers have recently 
been shown to correlate with plaque progression and to associate with future 
cardiovascular events9, thereby emphasizing the potential crucial contribution of 
mast cells to plaque destabilization. Currently, the identification of endogenous 
mast cell activators in atherosclerosis is of major interest. Immunoglobulin E (IgE) 
is commonly known for its acute effects on mast cell activation in allergy. In men 
with hyperlipidemia and in patients with acute cardiovascular disorders10, plasma 
IgE levels were shown to be increased as well. Additional in vitro and in vivo 
evidence has also established a role for complement factors11,12, neuropeptides13,14, 
immune complexes15 and lipid mediators16 in mast cell activation during the 
development and progression of atherosclerosis. 
Mast cells exert their detrimental effects on plaque stability by the release of 
a number of mediators, such as the mast cell specific proteases chymase and 
tryptase, histamine, and a number of cytokines, such as TNFα, IL-6, and IFNγ.6,17 
We have previously established that chymase released from mast cells can induce 
plaque progression.18 Additionally, it has been shown that mast cells can promote 
apoptosis of various cell types present in the plaque, such as vascular smooth 
muscle cells19, endothelial cells20 and macrophages5, thereby contributing to plaque 
necrosis and destabilization. However, as mast cells also secrete chemokines such 
as MCP-1 and IL-8, in this study we aimed to establish to which extent mast cells 
are involved in inducing leukocyte recruitment towards the plaque, thereby fuelling 
the ongoing inflammatory response and possibly aggravating plaque progression. 
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Materials and Methods
Systemic mast cell activation
This study was performed in compliance with Dutch government guidelines and 
the Directive 2010/63/EU of the European Parliament. All animal experiments 
were approved by the animal welfare committee of the Leiden University Medical 
Center (approval reference number 08014). Mice were obtained from the local 
animal breeding facility (Gorlaeus Laboratories, Leiden, The Netherlands). In all 
animal experiments, treatment groups were randomized based on age and weight. 
We used 10-12 weeks old male B-cell deficient apoE-/-μMT mice, kindly provided 
by Prof. BH Toh (Monash University, Melbourne, Australia) for our observational 
study. These mice lack endogenous IgE, due to a selective deficiency in B cells.21,22 
Previous observations in our lab indicated that Western-type diet feeding results in 
increased circulating levels of IgE, which in turn leads to a higher basal mast cell 
activation level in WTD-fed apoE-/- mice. To control for this effect, we performed 
the systemic IgE-mediated mast cell activation in apoE-/-μMT mice. All mice were 
fed a western-type diet containing 0.25% cholesterol and 15% cacao butter (SDS, 
Sussex, UK) for eight weeks. During these eight weeks, the mice were challenged 
with IgE (n=13) or PBS (n=10) control for 6 times (~every 1.5 weeks). In order 
to do so, mice were given 1 µg of anti-DNP-IgE (monoclonal mouse IgE anti-
dinitrophenyl antibody, clone SPE-7, #D8406, Sigma-Aldrich, Zwijndrecht, The 
Netherlands) by intraperitoneal injection, and 24 hours later the mice received 
an intravenous injection containing 0.5 mg DNP-HSA (#A6661, Sigma-Aldrich). 
This treatment regimen did not affect body weight or general health status of the 
mice. At sacrifice, mice were anaesthetized by subcutaneous injection of ketamine 
(60 mg/kg, Eurovet Animal Health, Bladel, The Netherlands), fentanyl citrate and 
fluanisone (1.26 and 2 mg/kg, respectively, Janssen Animal Health, Sauderton, 
UK). Adequacy of anaesthesia was monitored by regular visual inspection and 
toe pinch reflex. Mice were exsanguinated via orbital bleeding and in situ fixation 
through the left cardiac chamber was performed, after which the hearts were 
excised for further analysis. The hearts were dissected just below the atria and 
sectioned perpendicular to the axis of the aorta, starting within the heart and 
working in the direction of the aortic arch. Once the aortic root was identified by 
the appearance of aortic valve leaflets, 10 µm sections were taken and mounted 
on gelatin-coated slides. Mean lesion area (in µm2) was calculated from six Oil-
Red-O stained sections in distal direction starting at the point where all three 
aortic valve leaflets first appeared. Collagen content in the lesion was determined 
with a Sirius Red staining, while macrophages were visualized with a Moma-2 
antibody (1:1000, #MCA519G, Serotec, Puchheim, Germany). The necrotic core 
size was defined as the a-cellular, debris-rich plaque area as percentage of the 
total plaque area. The aortic roots were quantified by the Leica image analysis 
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system (Leica Ltd, Cambridge, UK). T cell numbers in the intima and adventitia 
were determined by staining for CD3 (1:50, Neomarkers, Fremont, CA, USA) and 
were counted manually. Mast cells and neutrophils were visualized by staining 
of 10 μm cryosections with a naphthol AS-D chloroacetate esterase staining kit 
(#91C, Sigma-Aldrich) and counted manually. A mast cell was considered resting 
when all granula were maintained inside the cell, while mast cells were assessed 
as activated when granula were deposited in the tissue surrounding the mast cell. 
Neutrophils were identified as round cells with a characteristic lobular nucleus and 
pink granular cytoplasm. All morphometric analyses were performed by blinded 
independent operators.
Leukocyte influx
Mice were obtained from the local animal breeding facility (Gorlaeus Laboratories, 
Leiden, The Netherlands). Peritoneal mast cells of either male C57BL/6 or mast 
cell deficient male Kit(W-sh/W-sh) mice were activated by intraperitoneal injection 
of compound 48/80 (1.2 mg/kg). After 30 minutes and 3 hours (n=4 per group), 
mice were anaesthetized as described above, after which peritoneal cells were 
collected by flushing the peritoneal cavity with 10 ml PBS. After collection of the 
peritoneal fluid, mice were sacrificed via cervical dislocation. Total cell count and 
neutrophil, lymphocyte, monocyte and eosinophil counts in blood were analyzed 
using an automated XT-2000iV veterinary hematology analyzer (Sysmex Europe 
GMBH, Norderstedt, Germany). After centrifugation of the cells (1500 rpm for 
5 minutes), supernatant was collected for protease activity as described below 
and for chemokine quantification by ELISA according to manufacturer’s protocol. 
Subsequently, leukocyte suspensions were incubated with 1% mouse serum in 
PBS and stained for surface markers (0.25 μg/0.2*106 cells, eBioscience, San 
Diego, CA, USA), after which surface marker expression was determined by FACS 
analysis (FACS Canto, BD Biosciences, Breda, The Netherlands).
An additional influx study was performed in order to investigate CXCR2 mediated 
neutrophil influx after mast cell activation. Male apoE-/- mice (n=8) were injected 
intraperitoneally with anti-CXCR2 (5 µg/mouse, #MAB2164, R&D systems, 
Minneapolis, MN, USA) or PBS. One day later the mice received a second 
injection with anti-CXCR2 an hour prior to intraperitoneal mast cell activation with 
compound 48/80 (1.2 mg/kg) or PBS. 3 Hours later mice were anaesthetized and 
peritoneal fluid was collected as described above, after which mice were sacrificed 
via cervical dislocation. Subsequently, cells were stained for CD11b, Ly6C, Ly6G 
,CXCR2 and CXCR4 after which they were analyzed by FACS. 
β-Hexosaminidase activity was determined by adding 50 μL of peritoneal fluid to 
50 μL 2 mM 4-nitrophenyl N-acetyl-b-D-glucosaminide (Sigma) in 0.2 M citrate (pH 
4.5) and incubated at 37 °C for 2 hours. After addition of 150 μL 1 M Tris (pH 9.0), 
absorbance (optical density, OD) was measured at 405 nm. To measure chymase 
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release after degranulation, 50 μL peritoneal fluid was added to 2 mM S-2586 
(chymase substrate, #820894, Chromogenix, Llanelli, UK) in PBS supplemented 
with 100 U/mL heparin. After 24 hours at 37 °C, OD405 was measured. Values 
are expressed as percentage of total content. The CXCL1 ELISA was performed 
according to manufacturer’s protocol (#DY453, R&D systems).
Neutrophil isolation 
Neutrophils were isolated by negative selection as described earlier.23 To obtain 
large quantities of functionally competent neutrophils for in vitro analysis of mast 
cell-mediated neutrophil migration, we isolated neutrophils from bone marrow. 
Previous results have indicated the bone marrow to be an excellent source of 
functional neutrophils with longer survival rates in culture compared to blood-
derived neutrophils.24 These functional bone marrow-derived neutrophils have 
been suggested replace peripheral neutrophils and to be recruited at times of 
increased demand during infection. In short, C57BL/6 mice were anaesthetized as 
described above and sacrificed via cervical dislocation after which bone marrow 
was isolated by flushing the femurs and tibias. Cell suspensions were incubated 
with an antibody cocktail containing α-CD5, α-CD45R, α-CD49b, α-CD117, α-F4/80 
and α-TER119 (eBioscience) (4°C, 10 minutes under constant shaking). After 
washing, cells were incubated with α-biotin microbeads (4°C, 10 minutes under 
constant shaking, Miltenyi, Leiden, the Netherlands). Subsequently neutrophils 
were isolated by magnetic bead isolation (magnetic-activated cell sorting LS 
column, Miltenyi). We obtained neutrophils at ~90% purity, as validated by flow 
cytometry and histology25, which were used for further experiments. 
Cell culture
C57BL/6 mice were anaesthetized as described above and sacrificed via cervical 
dislocation after which bone marrow was isolated by flushing the femurs and 
tibias. Bone marrow derived mast cells (BMMCs) were grown by culturing bone 
marrow cells at a density of 0.25*106 cells in RPMI containing 10% fetal bovine 
serum (FBS), 2 mmol/L l-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin 
(PAA, Cölbe, Germany) and 10% mIL3 supernatant (supernatant from WEHI cells 
overexpressing murine Interleukin (IL)-3) for 4 weeks in T175 tissue culture 
flasks (Greiner Bio-one, Alphen aan den Rijn, Netherlands). BMMCs (5*105) were 
activated by incubation with compound 48/80 (0.5 μg/mL, Sigma, Zwijndrecht, 
the Netherlands (n=4 per condition) for 15-30 minutes at 37°C in HEPES-tyrode 
supplemented with 0.1% fatty acid free bovine serum albumin (BSA, Sigma-
Aldrich). For total (100%) content measurements, mast cells were lysed with 
10% Triton X-100 and untreated control cell supernatant served as 0% release 
controls. CXCL1 and CXCL12 ELISAs were performed according to manufacturer’s 
protocol (#DY453, #DY350, R&D Systems)
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Migration assay
BMMCs were degranulated as described above and the supernatant was collected. 
Neutrophils (105 per well) were applied to the upper chamber of a transwell 
system (24 wells, 8 µm pore size, PAA) in RPMI containing 10% fetal bovine 
serum (FBS), 2 mmol/L l-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin. 
Mast cell releasate was added to the basolateral chamber. To establish the role 
of neutrophil derived CXCR2 and CXCR4, anti-CXCR2 or AMD3100 (500 ng/mL, 
#A5602, Sigma-Aldrich) were added to the system. After 4 hours incubation, the 
number of migrated neutrophils was counted manually.
RNA isolation, cDNA synthesis and qPCR
Total RNA was extracted from BMMCs with the guanidium thiocyanate-phenol-
bromochloropropane extraction method.26 RNA concentration, purity and 
integrity were examined by nanodrop (Nanodrop® Technologies). RNA was 
reverse transcribed by M-MuLV reverse transcriptase (RevertAid, MBI Fermentas, 
Landsmeer, The Netherlands) and used for quantitative analysis of the mouse 
genes CXCL1 and  CXCL12 with an ABI PRISM 7700 Taqman apparatus (Applied 
Biosystems). Murine HPRT and RPL27 were used as standard housekeeping genes. 
For qPCR primer pairs refer to supplemental table 1.
Statistical analysis
Data are expressed as mean ± SD. An unpaired two-tailed Student’s t-test was 
used to compare normally distributed data between two groups of animals. Data 
of three groups were analyzed with one-way ANOVA and data of two groups with 
more than one variable were analyzed by two-way ANOVA, both followed by 
Tukey’s multiple comparison test. A level of P<0.05 was considered significant.
Results
Mast cell activation correlates with increased neutrophil influx to the plaque 
In this study, we used apoE-/-μMT mice, which lack endogenous IgE due to its B 
cell deficiency, and in these mice, mast cells were systemically activated by IgE 
administration during the development of atherosclerosis. Repeated treatment of 
apoE-/-μMT mice with anti-DNP IgE and subsequent DNP-HSA challenge did not 
significantly affect total mast cell numbers in the aortic root (controls: 15.8 ± 2.2 
mast cells/section versus IgE: 20.5 ± 3.1 mast cells/section), but did result in 
a significant increase in mast cell activation (controls: 35.2 ± 3.9% versus IgE: 
48.2 ± 3.4%, P<0.05, Figure 1A). Concomitantly, plaque size in the aortic root 
increased with 40% from 2.0 ± 0.2*105 µm2 in control mice to 2.8 ± 0.3*105 µm2 
in IgE treated mice (P=0.05, Figure 1B). 
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Collagen content of the plaques tended to be decreased by systemic mast cell 
activation, although this did not reach statistical significance (controls: 12.0 ± 
1.7% versus IgE: 9.6 ± 1.0%, P=0.10, Figure 1C). 
Figure 1. IgE induced mast cell activation in apoE-/-μMT mice. During eight weeks, male apoE-/-μMT mice 
treated with anti-DNP IgE followed by DNP-HSA challenge (n=13) or PBS (n=10) control for 6 times (every 
10 days). IgE-DNP treatment resulted in enhanced mast cell activation within the aortic root (A) and 
concomitant lesion progression (B). (C) Collagen content tended to be reduced by the IgE induced mast 
cell activation (P=0.10), while macrophage content was significantly reduced (D). (E) Necrotic core area 
was somewhat, but not significantly increased in the IgE treated group. (F) T cell numbers in the intima 
or the perivascular tissue did not differ between the groups (G) Total neutrophil numbers were increased 
after IgE treatment, resulting from an increase in both intimal neutrophils, and even more pronounced, 
in neutrophil number in the perivascular tissue. (F) Representative images of aortic root sections stained 
with a naphtol chloroactetate esterase staining, illustrating large neutrophil accumulations within the 
lesion (middle panel) and the perivascular tissue (lower panel) after IgE treatment, but not in control 
mice (upper panel). Magnifications: left panels 100x, right panels 400x. *P<0.05, ***P<0.001.
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These data are in line with previous studies, establishing that mast cell activation 
can result in collagen degradation, primarily via chymase release.18,26 Macrophage 
staining revealed a significant decrease in relative MOMA-2+ area (controls: 27.4 
± 2.7% versus IgE: 9.9 ± 1.7%, P<0.001, Figure 1D). Necrotic core area was 
increased from 51.7 ± 14.2*103 µm2 in the control mice to 82.6 ± 18.6*103 µm2 in 
the IgE treated group (Figure 1E), which may be caused by increased macrophage 
apoptosis upon mast cell activation as established previously.5 Furthermore, 
intimal and adventitial T cell numbers did not differ between the groups (Figure 
1F). Interestingly, IgE mediated mast cell activation resulted in a 3.2-fold increase 
in the number of neutrophils in the intima (controls: 12 ± 3 versus IgE: 39 ± 
12 neutrophils/mm2 tissue, P=0.06). In the perivascular tissue, we observed a 
striking 3-fold increase in the number of neutrophils (controls: 58 ± 11 versus 
IgE: 183 ± 39 neutrophils/mm2 tissue, P<0.05, Figure 1G,H). Taken intima and 
perivascular tissue together, we observed 70 ± 12 neutrophils/mm2 in control 
mice, versus 222 ± 48 neutrophils/mm2 in mice treated with IgE (P<0.05, Figure 
1G,H). Furthermore, mast cell activation status was seen to positively correlate 
with the number of perivascular neutrophils (P<0.05, R2=0.261). Separate 
analysis of each treatment group revealed that the correlation is primarily caused 
by effect in the IgE-DNP treated mice, i.e. controls: P=0.891 (R2=0.003), IgE: 
P=0.064 (R2=0.278).
In vivo mast cell activation results in neutrophil recruitment 
To further investigate whether neutrophil recruitment is indeed mast cell mediated, 
we activated peritoneal mast cell in mast cell competent C57BL/6 mice and mast 
cell deficient Kit(W-sh/W-sh) mice, by intraperitoneal injection of the commonly used 
mast cell activator compound 48/80. This resulted in acute mast cell activation as 
indicated by β-hexosaminidase (Figure 2A) and chymase (Figure 2B) activity in 
the peritoneal cavity of C57BL/6 mice, but not in that of Kit(W-sh/W-sh) mice, at 30 
minutes and up to 3 hours after injection. Leukocyte differentiation analysis using 
Sysmex revealed a striking influx of predominantly neutrophils in response to 
mast cell activation. Mast cell activation did not lead to recruitment of monocytes 
and lymphocytes, and its numbers were even slightly decreased after mast cell 
activation with compound 48/80 and these numbers remained identical between 
C57BL/6 and Kit(W-sh/W-sh) mice (Figure 2C-E). By means of flow cytometry 
we confirmed the influx of CD11b+Ly6GhighCD71- neutrophils in C57BL/6 mice 
as displayed in Figure 3A. Interestingly, the recruited neutrophils were CXCR2 
and/or CXCR4 positive (Figure 3B,C), suggesting that the ligands of these specific 
receptors, i.e. CXCL1 (or KC, the murine analogue of IL-8) and CXCL12, are 
involved in mast cell mediated neutrophil recruitment.
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Figure 2. Mast cell induced neutrophil recruitment in vivo. C57BL/6 or mast cell deficient 
Kit(W-sh/W-sh) mice (n=4) were intraperitoneal injected with compound 48/80, which resulted in acute 
mast cell activation as indicated by increased β-hexosaminidase (A) and chymase (B) activity in the 
peritoneal cavity of C57BL/6 mice (black bars) at 30 minutes and still at 3 hours after injection, which did 
not occur in mast cell deficient Kit(W-sh/W-sh) mice (white bars). Acute peritoneal mast cell activation by 
compound 48/80 induced recruitment of neutrophils (C), but not of lymphocytes (D) or monocytes (E) 
in C57BL/6 mice as measured by Sysmex cell differentiation analysis. Injection of compound 48/80 did 
not significantly affect the composition of these peritoneal cell populations. *P<0.05 compared to T=0, 
**P<0.01 compared to T=0, ***P<0.001 compared to T=0, ##P<0.01 compared to C57BL/6.
Figure 3. Mast cells recruit CXCR2+ and CXCR4+ neutrophils. C57BL/6 or mast cell deficient Kit(W-
sh/W-sh) mice (n=4) were intraperitoneal injected with compound 48/80 (A). FACS analysis confirmed 
the recruitment of CD11b+Ly6GhighCD71- neutrophils in response to compound 48/80 induced mast cell 
activation in C57BL/6 mice but not in Kit(W-sh/W-sh) mice. The mast cell dependent neutrophil influx 
appeared to be CXCR2 (B) and CXCR4 (C) dependent. **P<0.01 compared to T=0, ***P<0.001 compared 
to T=0, ##P<0.01 compared to C57BL/6, ###P<0.001 compared to C57BL/6.
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Mast cells express and secrete CXCL1 and CXCL12 
Next, we aimed to establish whether mast cell induced neutrophil recruitment 
was mediated via CXCL1 or CXCL12, the ligands for CXCR2 and CXCR4. MRNA 
expression of these chemokines was measured in cultured bone marrow derived 
mast cells (BMMCs). Indeed, we observed that both CXCL1 (relative mRNA 
expression: 0.005 ± 0.004) and CXCL12 (0.002 ± 0.001) were expressed by 
BMMCs. In the lysate of 5*105 unstimulated BMMCs, we measured 1.5 ± 0.3 ng 
of CXCL1. After activation with compound 48/80, CXCL1 was released by BMMCs 
(102 ± 15 pg/mL compared to 6 ± 12 pg/mL in the releasate of unstimulated 
control cells, P<0.05). Similarly, we observed an increase in CXCL12 release after 
stimulation with compound 48/80 (0.82 ± 0.08 ng/mL versus 0.12 ± 0.04 ng/mL 
in the releasate of unstimulated control BMMCs, P<0.01). These data indicate that 
mast cells, in accordance with previous literature, express and secrete chemokines 
such as CXCL1 and CXCL12 that can recruit neutrophils to the site of mast cell 
activation. 
7
Figure 4. Mast cell induced neutrophil recruitment 
in vitro. Supernatant from IgE stimulated 
BMMCs resulted in enhanced migration of freshly 
isolated neutrophils, which could be inhibited by 
a CXCR2 blocking antibody. **P<0.01 compared 
to supernatant of unstimulated control BMMCs. 
#P<0.05 compared to IgE stimulated BMMCs.
Neutrophil recruitment in vitro
To substantiate our in vivo findings, we isolated neutrophils from bone marrow 
by negative selection as described previously23 and allowed these cells to migrate 
towards supernatant of BMMCs stimulated with IgE. As expected, neutrophil 
migration towards the basolateral side of the migration chamber was significantly 
increased upon mast cell stimulation as compared to supernatant of unstimulated 
BMMCs (32.3 ± 4.7*103 cells versus 11.6 ± 2.5*103 neutrophils, P<0.01, Figure 
4). Blocking neutrophil CXCR2 using a specific mouse α-CXCR2 blocking antibody 
inhibited the mast cell induced neutrophil migration (18.8 ± 2.2*103 neutrophils, 
P<0.05 compared to IgE stimulated mast cells), while the addition of the CXCR4 
receptor antagonist AMD3100 did not affect neutrophil migration (24.8 ± 6.9*103 
neutrophils, P=NS). These data illustrate that mast cells, when activated, can 
indeed directly induce neutrophil recruitment.
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Figure 5. In vivo mast cell mediated neutrophil influx is mediated by CXCR2. Intraperitoneal mast cell 
activation of apoE-/- mice (n=8) with compound 48/80 resulted in a significant influx of CXCR2+ neutrophils 
and this effect was strongly diminished by blocking CXCR2 (A, B). Mast cell activation, measured by CD63 
expression (C), caused a local increase in CXCL1 (D). Monocyte influx was significantly decreased after 
mast cell activation in a CXCR2-independent manner (E). Peritoneal neutrophil activation was significantly 
increased after mast cell activation, which was unaffected by αCXCR2 treatment (F). *P<0.05, **P<0.01, 
***P<0.001 compared to control group.
αCXCR2 inhibits mast cell-mediated neutrophil recruitment in vivo 
We aimed to validate our in vitro findings in an in vivo setting by activating 
peritoneal mast cells while blocking CXCR2 with αCXCR2 (Figure 5A). Similar to the 
previous results in C57BL/6 mice, compound 48/80-mediated mast cell activation 
in apoE-/- mice induced a 4-fold increase in CD11b+Ly6Ghigh neutrophil influx to 
the peritoneum compared to control mice as measured by flow cytometry (Figure 
5B; P<0.05). The recruited neutrophils were primarily CXCR2+ (47%), while the 
amount of CXCR4+ (4%) and CXCR2/CXCR4 double positive (3%) neutrophils was 
limited. Mast cell activation, measured by CD63 expression, was similar in the 
compound 48/80 and αCXCR2 + compound 48/80  treated mice (Figure 5C). In 
line with these results, the peritoneal CXCL1 concentration was indeed increased 
after mast cell activation (11.6 ± 1.4 pg/mL and 13.8 ± 4.8 pg/mL compared 
to 1.8 ± 0.4 pg/mL in PBS treated mice, P<0.001, Figure 5D). As observed in 
the previous influx study, total number of monocytes in the peritoneum was 
reduced after mast cell activation (Figure 5E). Mast cell activation in combination 
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with αCXCR2 resulted in a strong reduction in neutrophil chemotaxis (Figure 5B; 
P<0.05), underlining the importance of mast cell derived CXCL1 in neutrophil 
recruitment. Previously, mast cell derived mediators have been described to 
influence neutrophil effector functions. Interestingly, in our study we observed 
a similar increase in activation of recruited neutrophils after peritoneal mast cell 
stimulation, which was not affected by αCXCR2 treatment (Figure 5F).   
Discussion
The current study is the first to demonstrate a correlation between systemic IgE 
mediated mast cell activation and neutrophil influx into the atherosclerotic plaque. 
Moreover, mast cell activation directly induced neutrophil migration in vitro and 
recruitment in vivo, in particular via the secretion of the chemokine CXCL1. 
The mast cell is currently accepted as a potent contributing cell in the process of 
atherosclerosis. Mast cells can induce plaque destabilization by the release of a 
number of mediators such as chymase and tryptase, which can degrade matrix 
molecules that give rise to plaque stability and by the induction of plaque cell 
apoptosis.5,19,20 Mast cells are also known for their capacity to store and produce 
a variety of cytokines and chemokines. Previously, we have provided evidence 
showing that MCP-1 release after either C5a12 or lysophosphatidic acid-mediated16 
mast cell activation may results in the recruitment of monocytes towards the 
plaque. Acute mast cell activation can also induce upregulation of adhesion 
molecules on endothelial cells, thereby enabling the influx of inflammatory cells 
into the subendothelial space.27 Furthermore, it was previously shown that mast 
cell-derived IL-6 and IFNγ are crucial for the induction of mast cell dependent 
atherosclerotic lesion development6, suggesting that the contribution of mast cell 
derived cytokines and chemokines to atherosclerotic lesion development as such is 
more important than previously thought. In this study, we aimed to determine by 
which mechanism IgE mediated mast cell activation affects leukocyte recruitment 
to the atherosclerotic lesion. Unpublished data from our group have shown that 
in apoE-/- mice, plasma IgE levels rise upon Western-type diet feeding. This 
phenomenon renders the investigation of specific IgE mediated mast cell activation 
difficult, as occupation of the FcεRs on mast cells by endogenous IgE antibodies 
may dampen the specific activation by IgE-DNP injection. To prevent this we used 
apoE-/-μMT mice that lack B cells and thus not produce endogenous IgE, and 
systemically injected these mice with IgE. Besides increased mast cell activation, 
which is thus completely induced by the injected IgE, and increased lesion size, we 
observed a striking increase in neutrophil numbers in the intima, and even more 
pronounced in the perivascular tissue. We then aimed to determine whether these 
effects are mast cell specific by comparing leukocyte influx to the peritoneum 
in mast cell deficient and control mice. Indeed, mast cell activation resulted in 
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exaggerated neutrophil influx to the peritoneum, which was absent in mast cell 
deficient mice. Neutrophils were seen to be primarily CXCR2 and CXCR4 positive, 
suggestive of involvement of the CXCR2 ligand CXCL1 and the CXCR4 ligand 
CXCL12. We then confirmed that mast cells produce and secrete both CXCL1, as 
previously established15,28, and CXCL12, and investigated the contribution of these 
chemokines to neutrophil migration in vitro. Blockage of CXCR2, but not of CXCR4, 
in vitro significantly reduced mast cell induced neutrophil migration, indicating 
that mast cell derived CXCL1 may be more important in neutrophil recruitment 
than mast cell derived CXCL12. Previously, it has been described that systemic 
disruption of the CXCL12/CXCR4 axis aggravates atherosclerosis by expansion of 
neutrophils in the blood and in the plaque.29 Also, functional blockade of CXCR4 
in later stages of atherosclerosis was seen to exacerbate plaque progression, 
accompanied by hyperactivation of circulating neutrophils.30 Taking into account 
these previous findings, and the lack of effects of CXCR4 blockade on neutrophil 
migration in vitro, we consider it unlikely that mast cell derived CXCL12 is a major 
contributor in neutrophil influx to the atherosclerotic plaque. Since blockage of 
CXCR2 did significantly reduce mast cell mediated neutrophil migration in vitro, 
we aimed to confirm this observation in vivo. Again, after peritoneal mast cell 
activation, a massive neutrophil influx was observed, which could be partially 
inhibited by αCXCR2 pretreatment. Based on these data we postulate that mast 
cell derived CXCL1 is a major contributor to neutrophil migration to the site of 
inflammation, which is in line with a previous report demonstrating that mast cell 
and macrophage derived CXCL1 and CXCL2 induce neutrophil recruitment in an 
LPS-induced peritonitis model.31 Furthermore, in the current study, we made use 
of compound 48/80 and IgE mediated mast cell activation, which are well-known 
to cause mast cell degranulation. We showed that both these general mast cell 
activators are capable of inducing neutrophil recruitment.  
In advanced atherosclerosis, we have previously established that mast cells can 
activate endothelial cells, thereby inducing the adhesion of leukocytes to the 
endothelial layer in a CXCR2 and VCAM-1 dependent fashion.5 Direct mast cell 
dependent neutrophil recruitment has been previously associated with diseases 
such as EAE32, skin diseases33 and rheumatoid arthritis34, either via CXCL1 or other 
mechanisms such as the tryptase/heparin complex. We now postulate that also 
in atherosclerosis mast cells may directly induce neutrophil recruitment via the 
CXCL1/CXCR2 axis, thus providing another mechanism by which mast cells can 
fuel the ongoing inflammatory response. This mechanism may also explain the 
massive increase in perivascular neutrophils, which can be caused by activation 
of perivascular mast cells and subsequent neutrophil recruitment via perivascular 
microvessels instead of influx through the endothelium.
In the in vivo study, both increased mast cell activation as well as increased 
neutrophil numbers were observed. It is therefore difficult to distinguish between 
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effects on plaque formation caused by either the mast cell itself or indirectly by the 
infiltrating neutrophils. However, a detrimental role for neutrophils in both early and 
late stage atherosclerosis has been previously described. Hypercholesterolemia 
in apoE-/- mice increases the amount of circulating neutrophils, which correlates 
with early atherosclerotic lesion size.35 The direct presence of neutrophils has 
been readily detected in early fatty streaks and in advanced atherosclerosis they 
accumulate especially in shoulder regions of the plaque.36 In human atherosclerotic 
plaques neutrophils are detected as well, and moreover, increased numbers 
of neutrophils correlated with rupture-prone lesions.37 Markers of so-called 
neutrophil extra-cellular traps are even associated with adverse cardiac events.38 
Furthermore, neutrophils release granules containing large amounts of matrix-
degrading proteases, they produce vast amounts of reactive oxygen species and 
go rapidly into apoptosis.39 Thus, there are a number of mechanisms via which 
neutrophils can contribute to atherosclerotic plaque growth and destabilization. 
In our study, we have provided evidence that stimulation of mast cells resulted 
in increased activation of recruited neutrophils, which may cause additional 
detrimental effects on local inflammation.  
In conclusion, systemic mast cell activation results in neutrophil accumulation within 
the vessel wall, and enhanced atherosclerotic lesion development. Recruitment 
studies revealed a direct role for mast cell derived CXCL1, which attracts CXCR2+ 
neutrophils. These data may thus provide a novel mechanism by which mast 
cells can aggravate the ongoing inflammatory response in atherosclerotic lesion 
development and progression. 
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Supplemental table 1: Primer pairs used for qPCR analysis. The relative gene expression of CXCL1 
and CXCL12 was determined to the average expression of the two housekeeping genes: hypoxanthine 
phosphoribosyltransferase (HPRT) and 60S ribosomal protein L27 (RPL27).
Supplemental data
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Chapter 8
General Discussion and Perspectives
8.1 Introduction
Cardiovascular disease (CVD), which encompasses a group of disorders of the 
heart and vasculature, remains a leading cause of death world-wide. Currently, 
about 17.3 million people die annually as the consequence of CVD and with the 
growing population and increase in life expectancy this number has been estimated 
to grow to more than 23.2 million a year by 2030.1,2 In the majority of these cases 
death is caused by a myocardial infarction or a stroke due to thrombotic blood 
vessel occlusion as a consequence of atherosclerotic plaque rupture or erosion. 
Atherosclerosis is the underlying lipid-induced chronic inflammatory disease, which 
already starts early in life and progresses until clinical symptoms may become 
apparent, often from the age of 60 and onwards. In addition to the individual grief, 
the economic burden on society is enormous, totaling 320 billion a year (in the 
US) due to health expenditures and lost productivity.3  
The main therapeutic strategy is based on lipid lowering by means of statin 
treatment, which are HMG-CoA reductase inhibitors, a rate limiting enzyme in 
cholesterol synthesis. Under current guidelines, patient’s cholesterol levels 
are aimed to be lowered to a considered healthy <70 mg/dL (<1.8 mmol/L), 
however resent trials seem to indicate that even further lowering (for example 
by combination therapy with Ezetimibe) results in additional risk reduction.4 In 
addition to its lipid lowering potential, statins have been shown to exhibit anti-
inflammatory properties, which combined have reduced the relative risk of CVD-
related deaths in patient by 25-30%. Nonetheless, there remains a considerable 
residual risk and the absolute risk reduction, especially in patients with less 
extreme cholesterol levels, is limited. This clearly emphasizes the need for new 
therapeutic modalities based on a more thorough understanding of the disease 
and all its risk factors. 
Besides dyslipidemia and traditional risk factors for cardiovascular disease such 
as smoking, untreated hypertension, physical inactivity and diabetes mellitus, a 
contributing role for psychosocial risk factors, including psychological stress, has 
become evident and inspired research into the biological pathways involved.   
8.2 Psychological stress: an underappreciated risk factor for cardiovascular 
disease
Early work by Rosenman et al. indicated a clear correlation between certain 
behavior and personality types and the risk of developing coronary heart disease.5 
These studies provided the first link adverse between emotional states, which can 
be considered in general as stressful, and disease. Further evidence for a direct 
role for psychological stress in the development of atherosclerosis was provided 
by landmark studies in cynomolgus monkeys by Kaplan et al. demonstrating 
extensive coronary atherosclerosis in stressed animals compared to their 
unstressed controls, even under normocholesterolemic conditions.6 More recently, 
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the association between multiple psychosocial risk factors and the incidence of 
acute myocardial infarction (AMI) was assessed in the large case-control study 
INTERHEART. Especially chronic exposure to for example work-related stress 
correlated with a more than 2-fold greater risk of AMI. 
Chapter 2 of this thesis provides an overview of the major biological systems known 
to be involved in stress-induced exacerbation of cardiovascular disease, including 
the inflammatory response, the autonomic nervous system, neuroendocrine 
and oxidative systems. Both human epidemiological and clinical data as well as 
mechanistic insights obtained from various animal models are discussed. A clear 
distinction is made between chronic and acute stress exposure. While chronic 
stress results in the wear-down and maladaption of the various systems, including 
the immune system, acute stress boosts various responses via the central and 
local release of stress-related hormones and neuropeptides. Additional attention 
is given to the role of early life stress as atherosclerosis development initiates 
already in childhood and adolescence, necessitating earlier intervention strategies.
8.3 Stress-induced plaque vulnerability and atherothrombosis: a key role 
for mast cells?
In Chapter 3 and 4, the immunomodulatory potential of the acute stress response 
in relation to atherosclerotic lesion progression, vulnerability and atherothrombotic 
complications were investigated. Previous research had uncovered a pro-
atherogenic effect of the sympathetic nerve-derived factor substance P, acting 
in part via mast cell activation7, and a strong colocalization between nerve fibers 
and mast cells in the perivascular tissue. This inspired us to investigate the 
more general acute stress response in modulating mast cell activity with regard 
to atherosclerotic plaque vulnerability and atherothrombotic complications in 
Chapter 3. To establish whether acute stress, in this case a 30-120 minute period 
of restraint stress, was capable of activating perivascular mast cells, apoE-/- mice 
were subjected to the stress protocol and their stress response monitored. As 
expected, acute restraint caused a strong rise in plasma corticosteroid levels, 
but also resulted in a significant increase in circulating amount of the pro-
inflammatory cytokine IL-6. Subsequent morphological characterization of various 
(vascular) tissues, demonstrated especially a significant increase in cardiac mast 
cell activation after 120’ of restraint stress exposure. In addition to increased 
atherosclerosis development upon chronic mast cell activation8,9, pro-inflammatory 
cytokine and protease release from mast cells at later stages of the disease was 
shown to decrease atherosclerotic lesion stability. In humans, acute exposure to 
severe stressors, such as the terror of a natural disaster or terrorist attack and the 
intense grief after losing a loved one, is highly linked to increased risk of myocardial 
infarction or stroke. To test the hypothesis, that acute stress-induced mast cell 
activation contributes to this we evaluated the effect of acute stress-induced mast 
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cell activation on atherosclerotic lesion stability. ApoE-/- mice were put on a high 
fat diet for 6 weeks to induce the development of advanced atherosclerotic lesions 
in the aortic root. Next, the mice were subjected to 120’ restraint stress with 
or without prior administration of the mast cell stabilizer cromolyn. Subsequent 
analysis of the collagen content and the incidence of intraplaque hemorrhages 
(IPH) in the atherosclerotic lesions, both hallmarks of a vulnerable plaque in mice, 
demonstrated a significant reduction in collagen in the stressed mice compared 
with non-stressed controls. Furthermore, the incidence and size of the IPH were 
higher in the stressed mice, possibly due to increased leakiness of intraplaque 
neovessels as previously shown for other routes of mast cell activation.7,9 The 
contribution of the mast cell herein was confirmed by the inhibition the stress-
induced effects on systemic inflammation and locally on plaque vulnerability by 
pretreatment with cromolyn. However, the inhibition was only partial, which might 
be explained by the relative poor effectiveness of cromolyn in mice.10 To further 
confirm the mast cell-dependency of the observed pro-atherogenic effects of acute 
stress, a similar experiment was performed in mast cell depleted apoE-/- mice. 
In line with the results obtained by cromolyn pretreatment, mast cell deficiency 
significantly reduced the stress induced increase in circulating levels of IL-6 and 
completely abolished the effects of stress on plaque vulnerability parameters.
The majority of cardiovascular disease-related deaths are caused by the thrombotic 
occlusion of coronary or cerebral arteries, resulting in a myocardial infarction or 
stroke. Rupture or erosion of the fibrous cap, of an advanced and vulnerable 
atherosclerotic lesion exposes the thrombogenic content of the plaque and initiates 
platelet activation and the blood coagulation system. In Chapter 4 the direct 
contribution of the acute stress response on platelet activation, blot clotting and 
thrombus formation was assessed. Although 120’ restraint stress in apoE-/- mice 
resulted in a robust decrease in circulating white blood cells and a redistribution of 
the different leukocyte subpopulations, red blood cell and platelet numbers were 
not changed. Furthermore, platelet activation status, assessed by agonist induced 
expression of the glycoprotein αIIbβ3, was not affected. However, acute stress 
did increase tail bleeding time and somewhat reduced clot retraction capacity, 
both indicative of impaired coagulation. Next, we investigated the direct effect 
on thrombus formation, by means of a FeCl3-induced carotid artery thrombosis 
model. Topical application of FeCl3 in this model results in rapid endothelial 
damage, platelet activation and adherence to the vessel wall and subsequent 
formation of a vessel occluding clot. Interestingly, exposure to acute stress, either 
directly or 24 hours upfront did not affect the time to occlusion of results in any 
obvious differences in the composition of the thrombi. Similar experiments in the 
mast cell deficient apoE-/- mice did not reveal mast cell-dependent effects, except 
an inhibition of the acute-stress induced increase in tail bleeding time. Further 
research is necessary to dissect out the potential mast cell-derived mediators 
160  |  Chapter 8
implicated in this effect.
Combined, the results described in chapter 3 and 4, indicate the acute stress 
response as a potent mast cell activator, resulting in increased inflammation 
plaque destabilization. With regard to atherothrombotic complications and the 
direct effect of acute stress on thrombus formation, no clear results were obtained 
necessitating additional research. Possibly targeting specific mast cell-derived 
mediators, such as heparin could shed light on the observed difference in tail 
bleeding time.
8.4 Neuropeptide Y signaling in atherosclerosis
One of the most abundantly expressed stress-related neuropeptides is 
neuropeptide Y (NPY). After its identification in porcine brain extracts in 198211, 
further research determined the widespread distribution of this 36-amino acid 
peptide both in the central and peripheral nervous system. Peripherally NPY is 
co-stored and co-release with norepinephrine and ATP and potentiates the effects 
of these neurotransmitters. The first biological function identified was its potent 
vasoconstrictive property on cerebral and renal arteries, making NPY a possible 
drug target for the prevention of hypertension. However, additional research 
elucidated strong mitogenic effects of NPY on vascular smooth muscle cells, 
endothelial cells and adipocytes12, and  provided associations between chronic 
stress-induced increases in NPY levels and obesity and metabolic syndrome.13 
The direct involvement of NPY in atherosclerosis was inferred from increased 
disease progression in patients with a gain-of-function mutation in the preproNPY 
gene.14 In Chapter 5 the expression of NPY in stable versus unstable human 
and murine atherosclerotic lesions was investigated. NPY expression in carotid 
endarterectoctomy specimens obtained from the AtheroExpress biobank15 
was significantly higher in unstable compared with stable lesions. In line with 
these results, increased expression was also observed during atherosclerosis 
progression in apoE-/- mice. To establish a direct pro-atherogenic effect of NPY 
and investigate the local effect increased perivascular concentrations of NPY, for 
instance after local release from adventitial nerve fibers, we constructed a NPY-
expressing lentivirus for perivascular application at the site of atherosclerotic 
lesion formation. Rapid atherosclerosis development at an accessible site was 
induced by collar-placement around the carotid arteries as described by von 
der Thusen et al.16 Next the NPY-lentivirus was applied in pluronic gel to ensure 
the local overexpression. In line with previous results, overexpression of NPY 
resulted in a significant increase in lesion size. Interestingly, perivascular mast 
cell activation was also significantly increased, leading us to evaluate NPY-induced 
mast cell activation. In vitro incubation of bone marrow-derived mast cells with 
recombinant NPY indicated a bimodal response, resulting in the release of the 
pro-inflammatory cytokine IL-6 and mast cell-specific protease tryptase by NPY 
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concentrations in the high μM and low nM range. NPY acts both centrally and 
peripherally through its G-protein couple receptors (Y1-Y6). Of these receptors, 
Y1, Y2 and Y5 are most ubiquitously expressed and best characterized. In 
Chapter 6 we obtained the expression profiles of these different receptors during 
atherosclerosis and restenosis in apoE-/- mice. In contrast to NPY itself, which 
was increasingly expressed in both disease models, expression of the Y1 receptor 
was almost completely abolished upon disease initiation. In contrast expression 
of the Y2 and Y5 receptors as well as the peptidase DPPIV, which cleaves NPY in 
NPY3-36 lacking Y1 receptor affinity, was generally higher during atherosclerosis 
progression. Next we assessed the therapeutic potential of systemic Y1, Y2 or Y5 
antagonist treatment in atherosclerosis. LDLr-/- mice put on WTD were injected 
3 times a week with a specific Y1 (BIBO-3304), Y2 (BIIE-0246) or Y5 (CGP-
71683) receptor antagonist for a 6 week period. In contrast to previous results 
obtained in restenosis models in rats and mice in which NPY- or stress-induced 
neointima formation could be inhibited by both local and systemic Y1 receptor 
antagonism, atherosclerotic lesion formation was increased. Especially, Y2 receptor 
antagonism led to a faster disease progression resulting in significantly bigger 
and more advanced lesions, with lower macrophage and vascular smooth muscle 
cell content and increased perivascular mast cell accumulation. Interestingly, pro-
atherogenic changes, upon altered Y1 signaling, including changes in food intake 
and triglyceride metabolism17,18 and increased levels of the pro-inflammatory 
cytokine IL-1219 could be observed in the Y1 and Y5, but not the Y2 receptor 
antagonist treated mice. 
The results from Chapter 3 and 5 more firmly established the important 
contribution of mast cells in atherosclerosis development and progression of 
plaques towards a vulnerable state. Packed with pro-inflammatory mediators 
and uniquely localized to respond quickly to pathogens, but also endogenous 
danger-associated signals and neurogenic stimuli, these innate immune cells 
contribute to the ongoing vascular inflammation and can reduce the integrity of 
the plaque.20 Besides these pro-inflammatory cytokines and proteases, mast cells 
secrete chemokines such as MCP-1 and IL-8, which can modulate the influx of 
other immune cells. In Chapter 7, we investigated the recruitment of leukocytes 
towards the atherosclerotic lesion upon systemic mast cell activation. To control 
for a previously observed increase in circulating levels of IgE in Western type 
diet (WTD) fed apoE-/- mice, we performed the mast cell activation in apoE−/−
μMT mice, which lack endogenous IgE. Interestingly, besides a faster lesion 
development, systemic mast cell activation, by means of antigen-induced FcεR 
crosslinking, during the 8 weeks on WTD resulted in a striking increase in intimal 
en perivascular neutrophil recruitment. To dissect out the mast cell-specificity of 
this effect, peritoneal influx studies in C57Bl/6 and mast cell deficient KitW-sh/W-sh 
were performed. Peritoneal injection of the mast cell activator compound 48/80 
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resulted in a significant increase in, especially the chemokine receptor CXCR2 and 
CXCR4 positive, neutrophils in the control apoE-/- mice but not in the mast cell 
deficient mice. In vitro migration assays, using a transwell system in which isolated 
neutrophils were shown to migrate towards activated mast cell supernatant, 
demonstrated the primary involvement of the CXCR2 receptor on the neutrophil, as 
CXCR2 blockade, but not CXCR4 receptor antagonism could inhibit the migration. 
This was further confirmed in vivo were pretreatment with an anti-CXCR2 receptor 
antibody similarly blocked compound 48/80 induced peritoneal recruitment of 
neutrophils. These data provide an additional mechanism by which these two 
innate immune cells reinforce each other’s responses and thereby aggravate the 
ongoing vascular inflammation leading to accelerated atherosclerosis.
Considerations and perspectives
Cardiovascular diseases in humans develop over decades and clinical symptoms 
generally manifest  from the age of 60 onwards. However, the vascular damage 
and inflammation associated with atherosclerosis initiation already occurs during 
early adolescence, resulting in a complex disease course modulated by many 
different risk factors throughout the lifetime. Psychosocial risk factors, including 
psychological stress, have gained well-deserved attention as important (modifiable) 
risk factors contributing to the metabolic, endocrine and inflammatory processes 
involved in atherosclerosis.
In this thesis, the immunomodulatory properties of the acute stress response and 
the neuronal hormone NPY in the context of atherosclerosis development and 
progression have been investigated. Special attention was given to the contribution 
of the mast cell herein, and modulation of its activity by the stress response. 
Our data provide evidence for a direct contribution of acute stress-induced mast 
cell activation in atherosclerotic plaque destabilization. Also, increased vascular 
expression of the stress-related hormone NPY was shown to correlate with 
disease severity and contribute to atherosclerosis development, at least partly, 
via the induction of perivascular mast cell activation. Combined with the novel 
insights in mast cell-mediated modulation of other immune responses involved 
in atherosclerosis, such as neutrophil recruitment to the plaque, therapeutic 
strategies aimed at mast cell inhibition or stabilization seems a valuable approach 
for the prevention of cardiovascular disease-related deaths. Up to date, few studies 
evaluating the cardiovascular benefits of mast cell stabilization, for example by 
means of anti-allergic drugs, have been performed. The Prevention of REStenosis 
with Tranilast and its Outcomes (PRESTO) trail, assessed the anti-inflammatory 
and anti-proliferative properties of the anti-allergic drug tranilast for the 
prevention of restenosis after percutaneous coronary intervention. Unfortunately, 
in contrast to two smaller previous trials21, no improvement in angiographic or 
clinical restenosis was observed in this multicenter randomized clinical trial.22 
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While tranilast has been shown to inhibit pro-inflammatory mediator release from 
mast cells it also effects proliferation and migration of smooth muscle cells and 
fibroblasts complicating the evaluation of mast cell specific effects. More recently, 
several patents regarding the use of mast cell stabilizers for the prevention and 
treatment of cerebral ischemia23, cardiovascular disease in general24, obesity25 
and in combination with statins for inflammatory disorders26 were filed. These 
patents highlight the potential of mast cell stabilization in a variety of disease. 
However, systemic mast cell inhibition might compromise the protective responses 
of the mast cell as part of the immune system, in for example the skin, lung and 
intestine, against bacterial and parasitic infections. Intervention strategies, aimed 
at modulating mast cell function and activation via disease-specific ligands might 
circumvent this while retaining the desired beneficial effects. One such example 
might be inhibition of mast cell activation by specific complement factors highly 
expressed in vein graft disease.27 With regard to mast cell triggers in the context 
of atherosclerosis development and progression, we identified increased vascular 
NPY expression as a potential mast cell activator, leading to increased disease 
progression. However, our results also indicate the difficulty of modulating NPY 
signaling, as its receptors are expressed both in the central nervous system and 
the periphery acting on various endocrine, metabolic and immunologic responses. 
Also systemic application of for example Y1 receptor antagonists did not influence 
exercise-induced ischemic parameters in patients with coronary artery disease28 
and Y5 receptor antagonism did not augment the weight loss efficacy of two 
anorexiants, orlistat and sibutramine.29 Animal studies, especially with regard to 
restenosis, demonstrated clear beneficial effects of Y1 receptor antagonism and 
one might envision local application of such antagonists by means of drug eluting 
stents. Furthermore, the Y2 receptor was demonstrated to be indispensable 
in mediating stress-induced obesity and metabolic syndrome. Up to date no 
conclusive results demonstrating a beneficial effect of Y2 receptor antagonism 
in humans has been obtained and our data (in mice) indicate that systemic Y2 
receptor antagonism, like previously shown for Y1 receptor antagonism19, may 
actually promote atherosclerotic plaque development via a currently unresolved 
mechanism. Furthermore, improved glycemic control in type 2 diabetes mellitus 
patients treated with the DPPIV inhibitory sitagliptin, which besides the degradation 
of the gastrointestinal hormones GLP-1 and GIP, also modulates NPY signaling and 
has been associated with increased heart failure.30 However, a recent large, multi-
center trial evaluating such detrimental side-effects of sitagliptin in addition to 
usual care, did not show significant differences in hospitalization rates for heart 
failure, acute pancreatitis or pancreatic cancer31, warranting further mechanistic 
insight into NPY signaling and ways of harnessing the therapeutic potential of these 
specific NPY receptor antagonist for the prevention of cardiovascular disease.
As mentioned before, the psychological stress response contributes to 
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cardiovascular and metabolic disease a.o. via the upregulation of neuropeptide Y. 
Furthermore, other major stress hormones, including glucocorticoids, adrenalin 
and noradrenaline have all been implicated in the correlation between risk of 
cardiovascular complications and chronic exposure to psychosocial risk factors, 
such as work-related stress and depression. Several trials have addressed the 
cardiovascular benefit of psychological treatment of depression, including the 
SADHART, ENRICHED and MIND-IT trials32, but unfortunately without clear effects 
on cardiovascular disease. In addition to atherosclerosis progression, plaque 
vulnerability remains a key determinant of atherothrombotic complications. 
Here, we identified a direct link between acute stress exposure and plaque 
destabilization through increased mast cell activation. Combined with acute stress 
induced changes in coagulation, these results warrant further investigation into 
the specific mediators involved and therapeutic potential of modulating both the 
stress response and immune cell activation. Such therapeutic interventions might 
best focus on the prevention of secondary events in patients with confirmed 
vulnerable lesions. 
In conclusion, the stress response, a.o. acting via the synthesis and release of 
various neuropeptides, significantly contributes to atherosclerosis development 
and constitutes a relatively underappreciated risk factor for acute cardiovascular 
syndromes. The results obtained in this thesis provide further evidence for the 
direct influence of the stress response in modulating innate immune responses 
which contribute to atherosclerotic plaque development and destabilization. 
Future (clinical) investigations evaluating and treating mental health combined 
with lipid-lowering and anti-inflammatory strategies may be the necessary next 
step in the prevention of cardiovascular disease.
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Nederlandse samenvatting
Vandaag de dag zijn hart- en vaatziekten de voornaamste doodsoorzaak in 
de Westerse wereld. Onder de algemene term “hart- en vaatziekten” vallen 
aandoeningen als een myocard infarct (hartaanval), perifeer vaatlijden en 
cerebrovasculaire aandoeningen (beroerte). Momenteel sterven jaarlijks wereldwijd 
ruim 17 miljoen mensen aan de gevolgen van hart- en vaatziekten en men schat 
dat met het toenemen van de wereldbevolking en de levensverwachting dit getal 
omstreeks 2030 gegroeid zal zijn naar ruim 23 miljoen doden per jaar. Naast groot 
persoonlijk leed is dit ook een enorme economische last voor de samenleving. 
Een groot gedeelte van deze sterfgevallen is het gevolg van een hartaanval of 
beroerte veroorzaakt door een bloedstolsel, welke ontstaan door een ruptuur van 
een instabiele atherosclerotische plaque. Atherosclerose, ook wel aderverkalking 
genoemd, is het proces dat leidt tot de vorming van atherosclerotische plaques. 
Het is een chronisch ziekteproces waarin na veranderingen in de endotheellaag 
van slagaders, lipiden, cholesterol en cellen van het immuunsysteem zich 
ophopen in de vaatwand. Deze cellen van het aangeboren immuunsysteem, 
de macrofagen, nemen steeds meer gemodificeerde (geoxideerde) lipiden en 
cholesterol op, waardoor ze veranderen in zogenoemde schuimcellen en de initiële 
atherosclerotische plaques, ‘fatty streaks’, vormen. Hoewel deze fatty streaks al in 
jongvolwassenen aangetoond kunnen worden zijn deze meestal asymptomatisch. 
De klinische complicaties zoals een hartinfarct of beroerte vinden meestal pas 
40 à 50 jaar later plaats, een periode waarin de initiële plaques zich verder 
ontwikkeld hebben tot vergevorderde en soms instabiele plaques. Mede door de 
enorme opname van cholesterol en de daardoor geïnduceerde ontstekingsreacties 
gaan macrofagen en andere geïnfiltreerde cellen in de atherosclerotische 
plaque dood, die samen met lipiden een zogeheten necrotische kern vormen. 
Deze thrombogene necrotische kern wordt van het bloed gescheiden door een 
kapsel van spiercellen en fibrotisch materiaal. Pas wanneer dit fibrotisch kapsel 
scheurt en de inhoud van de plaque in contact komt met het bloed, wordt het 
bloedstollingssysteem geactiveerd, wat kan leiden tot een bloedvat-afsluitend 
stolsel met levensbedreigende complicaties. 
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Op dit moment is de belangrijkste therapeutische strategie om het risico op hart- 
en vaatziekten te verminderen het verlagen van bloed cholesterol niveaus door 
middel van statines. Hoewel dit medicijn het relatieve risico met 25-30% verlaagd 
heeft, blijft er een aanzienlijk risico over. Dit geeft aan dat voor een betere 
behandeling nieuwe strategieën nodig zijn, gebaseerd op een meer volledige 
kennis van de ziekte atherosclerose en al haar risicofactoren. Naast hyperlipidemie 
en traditionele risicofactoren voor hart- en vaatziekten als roken, hoge bloeddruk, 
diabetes en geringe lichamelijke beweging, lijken psychosociale risicofactoren, 
waaronder psychische stress, ook een belangrijke bijdrage te leveren aan zowel 
het chronische ziekteproces als de acute complicaties. Hoofdstuk 2 van dit 
proefschrift geeft een overzicht van de biologische systemen die betrokken zijn bij 
de bijdrage van psychische stress op het verhoogde risico op hart- en vaatziekten. 
Naast het immuunsysteem zijn dit het autonome zenuwstelsel, het neuro-
endocriene en het oxidatieve systeem. Zowel epidemiologische en klinische data 
alsmede inzichten in de biologische mechanismen verkregen uit proefdierstudies 
worden besproken, waarin een duidelijk onderscheid gemaakt wordt tussen de 
effecten van acute en chronische stress. Terwijl chronische stress vooral bijdraagt 
aan het cardiovasculaire risico door middel van foutieve aanpassingen aan de 
hiervoor genoemde systemen, kan acute stress een directe aanleiding zijn voor 
het ruptureren van een instabiele atherosclerotische plaque. Omdat atherosclerose 
al in een vroeg stadium aantoonbaar is, wordt hier ook gekeken naar de rol van 
stress in de eerste levensjaren en de gevolgen hiervan met betrekking tot het 
risico op hart- en vaatziekten later in het leven. Het immuunsysteem speelt een 
belangrijke rol bij het ontstaan en de verdere ontwikkeling van atherosclerotische 
plaques. Dit systeem kan ruwweg opgedeeld worden in het aangeboren en 
verworven (adaptieve) immuunsysteem. Cellen van het aangeboren 
immuunsysteem, waaronder de hiervoor genoemde macrofagen, maar ook 
neutrofielen en mestcellen vormen een belangrijke eerste verdediging tegen 
infecties en zorgen voor het inschakelen van het adaptieve immuunsysteem. In 
hoofdstuk 3 zijn de effecten van acute stress op met name het aangeboren 
immuunsysteem in relatie tot atherosclerotische plaque ontwikkeling en 
destabilisatie bestudeerd. Eerder onderzoek heeft aangetoond dat mestcellen, 
aanwezig in het weefsel dat de bloedvaten omringt, in nauw contact staan met het 
perifere zenuwstelsel en dat activatie van de mestcellen door neuropeptiden, 
uitgescheiden door deze zenuwen, kan leiden tot versnelde atherosclerose. Dit 
was voor ons de aanleiding om de effecten van de acute stress reactie op 
mestcelactivatie en atherosclerotische plaquestabiliteit te onderzoeken. Om acute 
stress te induceren bij muizen werd gebruik gemaakt van een acuut stress model, 
waarbij de muizen 120 minuten geïmmobiliseerd werden. Naast de verwachte 
verhoging van stress hormonen zoals corticosteron, bleek ook het pro-
inflammatoire cytokine Interleukine 6 (IL-6) in het bloed en de hoeveelheid 
170  |  Nederlandse Samenvatting
geactiveerde mestcellen in het hart significant hoger te zijn in de stress groep ten 
opzichte van de controle muizen. Omdat in mensen blootstelling aan acute stress, 
zoals tijdens een natuurramp, een terroristische aanval of na het overlijden van 
een partner, sterk geassocieerd is met een verhoogd risico op een hartinfarct of 
beroerte, hebben wij in deze studie gekeken naar de stabiliteit van de 
atherosclerotische plaques in de gestreste en controle muizen. Om ook specifiek 
naar de bijdrage van mestcellen te kijken werd een extra groep met de mestcel 
stabilisator cromolyn behandeld voor de acute stressor. Analyse van de gevormde 
atherosclerotische plaques toonde een verhoogd aantal intraplaque bloedingen en 
verminderde collageen hoeveelheden, beide kenmerken van een instabiele 
plaques, in de stress groep. Voorbehandeling met cromolyn kon deze veranderingen 
deels voorkomen. Om zeker te zijn van complete mestcel remming, is eenzelfde 
experiment uitgevoerd met mestcel deficiënte muizen. Ook hier zagen wij na 
stress geen intraplaque bloedingen, wat duidt op een belangrijke bijdrage van de 
mestcel in acute stress gemedieerde plaquedestabilisatie. Naast de stabiliteit van 
de plaque is ook de thrombogeniciteit van het bloed van belang bij het induceren 
van een infarct na ruptuur van een atherosclerotische plaque. In hoofdstuk 4 is 
gekeken naar het effect van de acute stress respons op bloedplaatjes activatie, 
stollingstijd en bloedstolsel vorming. Hoewel 120 minuten stress geen significant 
effect op plaatjes activatie had, was de bloedstollingstijd na een staartsnede 
langer en stolsel retractie verminderd. De invloed van acute stress op trombose 
vorming werd onderzocht door middel van een ijzerchloride-geïnduceerd trombose 
model, waarbij plaatselijk ijzerchloride (FeCl3) aangebracht wordt op de 
halsslagader en de bloedcirculatie gemeten wordt, totdat het bloedvat afgesloten 
is. Het was interessant dat wij geen duidelijke verschillen zagen in stollingstijd 
tussen de gestreste en de controle muizen. Ook de bijdrage van mestcellen in de 
effecten van acute stress op plaatjesactivatie, stolling en trombosevorming, getest 
door middel van mestcel deficiënte muizen, lijkt gering. Gecombineerd laten de 
resultaten in hoofdstuk 3 en 4 zien dat de acute stress leidt tot mestcel activatie 
in het hartweefsel en dat acute stress bijdraagt aan destabilisatie van vergevorderde 
atherosclerotische plaques. Vervolgonderzoek is nodig om uit te wijzen welke 
factoren uitgescheiden door de mestcel hiervoor verantwoordelijk zijn, om deze 
vervolgens specifiek te kunnen remmen. Een mogelijk voorbeeld hiervan zijn de 
mestcel-specifieke enzymen chymase en tryptase, waarvan bekend is dat zij de 
extracellulaire matrix kunnen afbreken, wat bijdraagt voor plaque destabilisatie. 
Het is van therapeutisch belang om te bepalen hoe mestcellen in de nabijheid van 
de atherosclerotische plaque geactiveerd worden. Dit zou dan als drug target 
kunnen dienen om de ontstekingsreactie en het verder ontwikkelen van de plaque 
te remmen. Naast de klassieke activatieroute, die wordt gekarakteriseerd door 
crosslinking van IgE-antilichamen gebonden aan FcεR receptoren op het oppervlak 
van de mestcel, zijn andere activatoren ontdekt. Verschillende liganden van de 
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Toll-like receptor familie, factoren van het complement systeem (C5a, C3a) en 
neuropeptiden (substance P) zijn in staat perivasculaire mestcellen te activeren 
en zo bij te dragen aan de ontstekingsreactie in de vaatwand. Een van de meest 
voorkomende stress-gerelateerde neuropeptiden in het lichaam is neuropeptide Y 
(NPY). Buiten het centrale zenuwstelsel komt dit peptide voornamelijk samen met 
het hormoon noradrenaline en het signaal molecuul ATP voor en heeft 
vaatverwijdende effecten. Een rol voor NPY in atherosclerose bleek onder andere 
uit een versneld ziekteverloop in personen met een verhoogde NPY activiteit door 
een gain-of-function mutatie in dit gen. In hoofdstuk 5 hebben wij de expressie 
van NPY vergeleken in verschillende stadia van zowel humane als muizen 
atherosclerotische plaques. Er werd een verhoogde expressie van NPY gemeten in 
instabiele humane plaques en vergevorderde muizen laesies. Om het directe 
effect van verhoogde NPY niveaus op de vorming van atherosclerotische plaques 
te onderzoeken is een lentiviraal construct gemaakt, dat na lokale toediening tot 
een overexpressie van NPY leidde nabij de plaats van plaque vorming. In 
overeenstemming met eerdere resultaten zorgde de verhoogde expressie tot 
versnelde plaque vorming ten opzichte van muizen behandeld met een controle 
virus. Opvallend was de verhoogde hoeveelheid geactiveerde mestcellen na NPY 
overexpressie. Dit werd hierna in vitro (in celcultuur) onderzocht door geïsoleerde 
mestcellen te activeren met verschillende concentraties NPY. Zowel bij nanomolaire 
als micromolaire concentraties NPY was er een verhoogde concentratie IL-6 en 
tryptase waarneembaar in het medium, wat duidt op directe mestcel activatie 
door NPY. NPY signalering vindt plaats via verschillende G-eiwit gekoppelde 
receptoren (Y1-Y6), waarvan Y1, Y2, en Y5 het meest tot expressie komen en het 
best gekarakteriseerd zijn. In hoofdstuk 6 is de rol van elk van deze receptoren 
in atherosclerotische plaque vorming onderzocht. Genexpressie analyse van deze 
receptoren gedurende plaque vorming wees op verminderde expressie van Y1 en 
verhoogde of gelijke expressie van Y2, Y5 en het enzym DPPIV, dat NPY1-36 knipt 
tot NPY3-36, zodat het niet meer bindt aan Y1. Om therapeutisch de pro-
atherogene effecten van NPY te remmen zou dus een Y2 of Y5 antagonist mogelijk 
een groter effect hebben. Deze hypothese werd getest door middel van toediening 
van Y1, Y2 or Y5 receptor antagonisten in muizen die atherosclerotische plaques 
ontwikkelen. Na 6 weken behandeling werden de muizen en de plaques 
geanalyseerd op plaque grootte en compositie. Anders dan verwacht waren de 
plaques groter in de receptor antagonist behandelde muizen. Met name de Y2 
receptor antagonist behandeling resulteerde in significant grotere en meer 
instabiele plaques met minder macrofagen en gladde spiercellen en verhoogde 
mestcel hoeveelheden. Y1 en Y5 receptor antagonisme leidde daarentegen tot 
veranderd triglyceride metabolisme en verhoogde productie van de pro-
inflammatoire IL-12 cytokine familie, zonder een duidelijk effect op atherosclerose. 
Op basis van deze data lijkt het toepassen van NPY receptor antagonisten ter 
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bescherming tegen de ontwikkeling van atherosclerose therapeutisch niet 
interessant, en dient er rekening te worden gehouden met dergelijke bijwerkingen 
door het gebruik van deze stoffen tegen het ontstaan van restenose. Naast pro-
inflammatoire cytokines en proteasen scheiden mestcellen na activatie ook 
groeifactoren en chemokines uit. Veranderende concentraties van deze chemokines 
in het bloed en in weefsels vormen vervolgens gradiënten waardoor immuuncellen 
naar bepaalde locaties, bijvoorbeeld de plaque, kunnen migreren. In 
hoofdstuk 7 is daarom onderzocht in hoeverre langdurige mestcelactivatie leidt 
tot actieve rekrutering en accumulatie van witte bloedcellen. Na herhaalde IgE-
gemediëerde mestcelactivatie gedurende de ontwikkeling van atherosclerose in 
muizen vonden we sterk verhoogde hoeveelheden neutrofielen, zowel in de plaque 
als in het perivasculaire weefsel. Om vervolgens te bepalen in hoeverre dit effect 
mestcelafhankelijk was, werden zowel mestcel deficiënte als controle muizen in de 
buikholte geïnjecteerd met een mestcelactivator. Ook hier was voornamelijk de 
rekrutering van neutrofielen zichtbaar, die met name positief waren voor de 
chemokine receptoren CXCR2 of CXCR4. Blokkade van CXCR2 middels een anti-
CXCR2 receptor antilichaam bevestigde de rol van deze receptor en het mestcel 
uitgescheiden ligand CXCL1 in neutrofiel rekrutering na mestcelactivatie. Deze 
experimenten laten een additioneel mechanisme zien waarmee deze twee celtypen 
van het aangeboren immuun systeem elkaars respons versterken en bijdragen 
aan vasculaire ontstekingen en atherosclerose ontwikkeling. Zoals eerder gezegd, 
zijn hart- en vaatziekten momenteel een van de belangrijkste doodsoorzaken en 
omvatten een ziekteproces wat al in jongvolwassenen begint maar pas op latere 
leeftijd voor levensbedreigende complicaties zorgt. Naast risicofactoren zoals 
hyperlipidemie, roken en geringe lichaamsbeweging worden psychosociale 
risicofactoren, als psychische stress, steeds meer erkend als belangrijk, maar ook 
als verander- en behandelbaar. De resultaten beschreven in dit proefschrift 
onderschrijven de bijdrage van stress in atherosclerotische plaqueontwikkeling en 
als risicofactor voor acute cardiovasculaire syndromen zoals een hartinfarct of 
beroerte. Met name de pro-atherogene rol van mestcellen is verder belicht, welke 
geactiveerd door de acute stress respons en door het stress-gerelateerde 
neuropeptide NPY, kan leiden tot atherosclerotische plaquedestabilisatie en 
versnelde plaquevorming. Daarnaast werd een interactie tussen geactiveerde 
mestcellen en neutrofielen ontdekt, welke sterk bijdraagt aan de ontstekingsreactie 
in de door atherosclerose aangetaste vaatwand. Deze resultaten identificeren 
verschillende potentiële therapeutische aangrijpingspunten, welke mogelijk in de 
toekomst toegepast kunnen worden om het residuele risico op hart- en vaatziekten, 
dat overblijft na cholesterol verlaging, te verminderen.
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